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Abstract 
Pregnancy induces maternal metabolic adaptations including mild glucose 
intolerance and weight gain in order to support fetal development and lactation. 
Adipose tissue (AT) function in gestation is featured by reduced insulin sensitivity 
and fat mass accrual which partly accounts for the weight gain in pregnant 
women and adaptation of glucose metabolism. A common metabolic pregnancy 
complication is gestational diabetes mellitus (GDM), a disease characterized by 
impaired glucose tolerance with onset in gestation. However, the relationship 
between AT expandability and glucose metabolism in gestation is not well 
understood. The goal of this thesis was to investigate the adaptations of human 
AT expansion induced by pregnancy, how these changes are reflected in 
pregnancies complicated with GDM and characterize a mouse model to study the 
mechanisms underlying this disease. This dissertation illustrates that pregnancy 
promotes AT expandability by a signaling mechanism between placental 
pregnancy-associated plasma protein-A (PAPP-A) and AT- insulin-like growth 
factor binding protein-5 (IGFBP5). In addition, gravidas with GDM showed 
impaired AT expansion. Studies investigating the relationship between PAPP-A 
and glycemic state demonstrated that low levels of PAPP-A in the 1st trimester 
are highly associated with the development of GDM. Moreover, PAPP-A 
knockout mice exhibit reduced insulin sensitivity and impaired AT growth 
exclusively in gestation. These results expand the knowledge of AT biology in 
v 
 
gestation and have the potential to improve maternal care by proposing PAPP-A 
as an early biomarker and possible therapeutic for GDM. It also introduces a new 
mouse model to study the etiology of gestational diabetes. 
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CHAPTER I: Introduction  
 
Maternal metabolic adaptations during gestation promote fetal 
development  
During pregnancy, metabolic changes in women occur in order to support fetal 
growth and to prepare for lactation. An increase in maternal blood glucose is 
essential since the feto-placental unit utilizes glucose as its main energy source 
(Angueira et al., 2015) (Leturque et al., 1986) (Herrera, 2000).  Maternal adipose 
tissue, skeletal muscle, and liver, which are organs directly involved in glucose 
metabolism, reduce their insulin sensitivity while the beta cells from the pancreas 
increase their insulin production and secretion (Sonagra, Biradar, Dattatreya, & 
Murthy, 2014) (Kuhl, 1991). The reduction of insulin sensitivity in pregnancy has 
been longitudinally measured utilizing the hyperinsulinemic-euglycemic clamp 
technique. Decreased glucose infusion rates (Catalano, Tyzbir, Roman, Amini, & 
Sims, 1991) (Kirwan et al., 2002) and reduced insulin suppression of 
endogenous glucose production in the third trimester (Catalano et al., 1992) 
(Sivan, Chen, Homko, Reece, & Boden, 1997) favors a state of hyperglycemia 
and accounts for the 65% decrease of insulin sensitivity observed in late 
gestation. These metabolic adaptations of maternal peripheral organs are the key 
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events favoring glucose availability for fetal uptake (Barbour et al., 2007) (Musial 
et al., 2016).  
 
Besides increased blood glucose and reduced insulin sensitivity, weight gain is 
also observed in gestation due to an increase in blood volume, fetal mass, and 
maternal fat stores (Larciprete et al., 2003) (Berggren et al., 2017) (Pirani, 
Campbell, & MacGillivray, 1973) (Abrams & Selvin, 1995). The growth in 
maternal fat mass, or adipose tissue accrual, is accompanied by the expansion 
of adipose tissue stores (Kinoshita & Itoh, 2006) (Kopp-Hoolihan, van Loan, 
Wong, & King, 2017). The expansion of adipose tissue is necessary for 
maintaining metabolic homeostasis, since as pregnancy advances, fat utilization 
is the preferred fuel source by maternal peripheral organs (Rebuffe-Scrive et al., 
1985) (Herrera & Ortega-Senovilla, 2010). 
 
The remodeling of energy balance in gestation highlights the role of adipose 
tissue in supporting maternal metabolism. The main function of adipose tissue is 
to store energy from excess calorie intake in the form of triglycerides and release 
them as free fatty acids in response to energy demands (Trayhurn & Beattie, 
2008). The lipid availability from maternal adipose tissue stores is dependent on 
the effects of insulin action according to the stage of pregnancy. In early 
gestation, rapid weight gain and enhanced insulin sensitivity in the adipose tissue 
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results in lipid accumulation and fat mass gain. In late gestation, adipose tissue 
reduces its sensitivity to insulin, favoring lipolysis and lipid mobilization to 
maternal peripheral tissues (Knopp, Saudek, Arky, & O’sullivan, 1973) (Herrera, 
2000) (Lain & Catalano, 2007). The excess release of free fatty acids (Pusukuru 
et al., 2016) (Poveda et al., 2018) and the increase in the mean rate of glycerol 
production (Diderholm, Stridsberg, Ewald, Lindeberg-Nordén, & Gustafsson, 
2005) is likely to contribute to the development of peripheral reduced insulin 
sensitivity and to decrease maternal glucose utilization. The excess glucose is 
then available for fetal uptake. The changes in maternal lipid metabolism feature 
the importance of adipose tissue adaptations to pregnancy.  
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Gestational diabetes mellitus: A common pregnancy complication affecting 
glucose metabolism 
In a normal pregnancy, the reduction of insulin mediated glucose disposal is 
accompanied by an enhancement of insulin secretion to maintain euglycemia 
(Kuhl, 1991). However, maternal maladaptation to changes in glucose 
metabolism can lead to adverse pregnancy outcomes that can affect both mother 
and baby during gestation, immediately post-partum, and later in life (Gaillard, 
Steegers, Franco, Hofman, & Jaddoe, 2015) (The HAPO Study Cooperative 
Research Group, 2008).  
 
In 1915, EP Joslin reported in the Boston Medical and Surgical Journal (now 
New England Journal of Medicine) the presence of glycosuria in pregnant women 
(Joslin, 1915). Interestingly, the report mentions that the glycosuria disappears 
after child birth but it can worsen with following pregnancies and a “severe form 
of diabetes” may result. Since then, scientific studies in the field of maternal 
metabolism have defined the pathologic glucose intolerance with first recognition 
during pregnancy as gestational diabetes mellitus (GDM). The pathogenesis of 
this condition is based on insufficient pancreatic b-cell insulin secretion needed to 
compensate for the reduced insulin sensitivity of peripheral tissues in mid to late 
gestation (Mørkrid et al., 2012), excessive insulin resistance of peripheral tissues 
(Catalano et al., 2002) (Friedman et al., 1999) (Barbour, McCurdy, Hernandez, & 
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Friedman, 2011) (Okuno et al., 1995), or a combination of both (Akbay et al., 
2003) (Fasshauer, Blüher, & Stumvoll, 2014). In general, GDM develops due to 
the impaired ability of peripheral tissues to adapt to glucose metabolism changes 
in pregnancy. 
Prevalence, risks, diagnosis, and prognosis of GDM 
Worldwide, 1 in 7 of live births are affected by GDM (International Diabetes 
Federation, 2017). Until 2016, between 7.6%-8.2% of women have been 
diagnosed with GDM in United States (Casagrande, Linder, & Cowie, 2018) 
(Zhou et al., 2018). The prevalence of GDM is increasing due to new diagnostic 
criteria, the obesogenic epidemic, and sedentary lifestyles. Pre-pregnancy body 
mass index (BMI), maternal age, ethnicity, and a family history of type-2 diabetes 
are risk factors associated with GDM (Noctor & Dunne, 2015).  
 
As part of the standard prenatal care, all pregnant women receive a glucose test 
between 24-28 weeks of gestation to screen for hyperglycemia. Two tests are 
currently accepted for GDM diagnosis. The most used in clinics consists of a two-
step approach: 1-hour 50g oral glucose challenge screening test where abnormal 
results are followed by a 3-hour 100g oral glucose tolerance test (Harper et al., 
2016). Diagnostic values follow the cut-offs described by either the National 
Diabetes Data Group (National Diabetes Data Group, 1979) or Carpenter-
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Coustan criteria (Carpenter & Coustan, 1982) (Table 1.1). However, the cut-offs 
values for both criteria were challenged by the results obtained from the 
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study. The HAPO 
study demonstrated the continuous relationship of maternal glucose levels below 
the established diagnostic cut-off for diabetes with increased birth weight and 
cord-blood serum C-peptide from over 23,000 subjects from nine countries (The 
HAPO Study Cooperative Research Group, 2008). The International Association 
of Diabetes and Pregnancy Groups (IADPSG) utilized the HAPO study as 
initiative to propose an alternative test for GDM, which consists of a one-step 
approach as a 2-hour 75g oral glucose challenge test (International Association 
of Diabetes and Pregnancy Study Groups (IADPSG) Consensus Panel, 2010) 
(Table 1.1). 
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Two-step Approach One-step Approach 
Carpenter                    
and                       
Coustan 
National 
Diabetes Data 
Group 
International Association of 
Diabetes and Pregnancy  
Study Groups 
Screening: 
1hr 50g glucose challenge test  
 
Plasma glucose cut-off values 
(mg/dl) 
No screening test 
≥130 ≥140 
Diagnosis:  
    3hr 100g glucose tolerance test 
 
Plasma glucose cut-off values 
(mg/dl) (two or more abnormal) 
Diagnosis:  
2hr 75g glucose tolerance test  
 
Plasma glucose cut-off values 
(mg/dl) (one or more abnormal) 
Fasting ≥95 ≥105 ≥92 
1hr ≥180 ≥190 ≥180 
2hr ≥155 ≥165 ≥153 
3hr ≥140 ≥145 N/A 
Table 1. 1 Threshold values for screening and diagnosis of GDM according to 
criteria from Carpenter-Coustan, National Diabetes Data Group, and International 
Association of Diabetes Study Groups. 
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The controversy of which test and diagnostic criteria to use when diagnosing 
GDM presents a challenge when it comes to determining the actual incidence 
and standards of care that must be followed in GDM.  
 
The impact of hyperglycemia and GDM on both mother and child has been 
described in a series of clinical and population studies.  Babies born from 
mothers with GDM have a higher incidence of neonatal hyperinsulinemia, 
hypoglycemia, macrosomia and larger fat mass composition than babies born 
from normoglycemic women (Sreelakshmi et al., 2015) (The HAPO Study 
Cooperative Research Group, 2008) (Uebel et al., 2014) (Zhao, Li, & Li, 2014) 
(International Association of Diabetes in Pregnancy Study Group (IADPSG) 
Working Group on Outcome Definitions et al., 2015). In addition, multicenter 
studies have shown a direct relationship between maternal hyperglycemia and 
childhood impaired glucose tolerance and insulin resistance (Scholtens et al., 
2019) (Lowe et al., 2019). A systematic review reported that 50% of the women 
with a history of GDM develop type-2 diabetes five to ten years after the index 
pregnancy (C. Kim, Newton, & Knopp, 2002) and data included in a meta-
analysis showed that women with previous GDM have a seven-fold increase risk 
of type-2 diabetes than women who were normoglycemic during their pregnancy 
(Bellamy, Casas, Hingorani, & Williams, 2009). Global health agencies have 
expressed their urge for understanding the biology of gestational diabetes in 
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order to establish prevention programs and possible therapeutics for this 
condition.  
Pathogenesis of GDM 
The molecular basis of GDM is under investigation; however, it has been 
established that women with GDM have reduced muscle glucose uptake 
(Friedman et al., 1999),  decreased insulin suppression of hepatic glucose 
production (Catalano et al., 1993), and higher serum triglycerides (Koukkou, 
Watts, & Lowy, 1996) than normoglycemic gravidas. Moreover, gestational 
diabetes is characterized by peripheral insulin resistance to glucose disposal 
(Catalano, Huston, Amini, & Kalhan, 1999), low grade inflammation (Wolf et al., 
2004) (Moore-Simas & Corvera, 2014), and dysregulation of adipokines (Tsiotra 
et al., 2018) (Altinova et al., 2007) (Fasshauer et al., 2014). Due to the increase 
in adipose tissue stores and the direct impact of adipose tissue function on 
glucose and lipid metabolism in pregnancy, studies investigating this physiology 
in the context of GDM are needed to elucidate what molecular and cellular 
mechanisms are driving the impaired ability of fat to adapt to gestation. 
Understanding the etiology of GDM will provide possibilities for early diagnosis, 
prevention and even treatment that will break the cycle of the transgenerational 
effects of this metabolic disease. 
10 
 
Adipose tissue expansion and its role in glucose metabolism during 
gestation 
Fat storage location determines maternal insulin sensitivity  
The depot distribution of fat mass is a key determinant of maternal insulin 
sensitivity (Straughen, Trudeau, & Misra, 2013) (Mazaki-Tovi et al., 2015). 
Subcutaneous fat mass deposition presents as fat accumulation beneath the skin 
in the abdominal, subscapular, gluteal and femoral areas and is associated with 
insulin sensitivity (Snel et al., 2012) (McLaughlin, Lamendola, Liu, & Abbasi, 
2011). Visceral adiposity presents fat deposition inside the intra-abdominal 
cavity, in close proximity to the liver and intestines. Due to its close location to 
the liver, visceral fat accumulation increases the availability of  adipose tissue 
hormones and adipokines into the portal circulation, affecting metabolic health by 
altering glucose and lipid metabolism (Kabir et al., 2005) (Frank, de Souza 
Santos, Palmer, & Clegg, 2018). Therefore, the preferential location of fat 
deposition in the subcutaneous depot prevents the ectopic deposition of lipids in 
visceral tissues with consequent development of insulin resistance (Snel et al., 
2012) (M. Zhang, Hu, Zhang, & Zhou, 2015). 
 
Clinical studies have investigated the association of fat distribution and risk of 
gestational diabetes. Two studies reported the relationship between maternal 
11 
 
abdominal adiposity measured via ultrasound at the first trimester of gestation 
and GDM risk assessed by oral glucose test at weeks 24-28 of gestation. The 
results demonstrated that gravidas with a higher content of visceral adipose 
tissue had higher risk of developing GDM than those with lower accumulation of 
visceral fat (Gur et al., 2014) (De Souza, Berger, Retnakaran, Maguire, et al., 
2016). Others have also found a positive relationship between ectopic lipid 
deposition, measured via sonographic features of fatty liver at 11-14 weeks of 
gestation, and the risk for GDM at the time of diagnosis (De Souza, Berger, 
Retnakaran, Vlachou, et al., 2016) (Lee et al., 2019).  The literature available 
agrees in the positive association between visceral adiposity and the 
development of GDM. Since pregnancy is a period of rapid weight gain, maternal 
adipose stores must coordinate their lipid deposition in subcutaneous depots to 
avoid developing metabolic complications later in gestation that can lead to 
hindered glucose metabolism.  
Adipocyte hypertrophy and hyperplasia are associated with gestational insulin 
sensitivity 
Different cell populations reside in adipose tissue including adipocytes, 
macrophages, fibroblasts, endothelial cells, pericytes and mesenchymal stem 
cells. Adipocytes are insulin-sensitive cells that store lipid in the form of 
triglycerides and release lipids as free fatty acids in response to energy needs 
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giving adipose tissue a flexible and rapid adaptation to metabolic demands. 
Adipocytes can grow via two mechanisms: hypertrophy and hyperplasia. 
Hypertrophy occurs when existing adipocytes store lipid by enlargement of their 
lipid droplet, therefore increasing in cellular volume. Hyperplasia, on the other 
hand, consists on the differentiation of adipocyte progenitors into mature 
adipocytes. Therefore, hypertrophy equals to an enlargement in the size of 
existing adipocytes while hyperplasia results in an increase of adipocyte number 
(Arner, 2018).  
 
The relationship between adipocyte size and insulin sensitivity has been studied 
in diverse clinical settings. In an obese cohort, subcutaneous and omental 
(visceral) adipocyte size had a positive correlation with increased plasma insulin 
and triglyceride levels while a negative association with insulin sensitivity (Rydén, 
Andersson, Bergström, & Arner, 2014). Interestingly, subcutaneous adipocyte 
number positively correlated with insulin sensitivity but had a negative 
association with plasma insulin and triglyceride levels (Rydén et al., 2014). In a 
weight loss after bariatric surgery (roux-en-y gastric bypass) study, fat mass and 
subcutaneous adipocyte volume and number were measured before and two 
years after surgery. Results showed that weight loss resulted in reduced fat mass 
and that adipocyte volume was reduced but no changes were observed with 
respect to adipocyte number.  This reduction in adipocyte volume was positively 
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associated with improved insulin sensitivity as determined by hyperinsulinemic-
euglycemic clamp studies (Andersson et al., 2014).  A longitudinal study of 
normal weight and obese pregnant women measured abdominal subcutaneous 
adipocyte volume and number in the first and third trimester of gestation. The 
results showed that normal weight gravidas had increased adipocyte size while 
obese gravidas had an increase in adipocyte number suggesting that obese 
gravidas recruited new adipocytes to store fat.  (Svensson et al., 2016). 
Therefore, the pre-pregnancy BMI and composition of adipose tissue could 
indicate how adipocytes adapt to gestation. Another longitudinal study done in 
normal weight women measured gluteal subcutaneous adipocyte size and 
number at the pre-pregnancy stage followed by early (8-12 weeks) and late (36-
38 weeks) gestation (Resi et al., 2012). Interestingly, this particular 
subcutaneous depot showed adipose tissue growth by both hypertrophy and 
hyperplasia indicating that each fat depot site may present distinct mechanisms 
for adipose tissue expansion.  
 
The connection between insulin resistance and impaired adipocyte growth can 
be explained by the limited expansion capacity of hypertrophic adipocytes. Fat 
cells growing via hypertrophy reach an expansion limit, driving lipid accumulation 
in ectopic sites (visceral organs) and causing low grade chronic inflammation in 
the adipose tissue (Rutkowski, Stern, & Scherer, 2015) (Wajchenberg, 2000) 
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(Verboven et al., 2018). In the visceral fat of obese and type-2 diabetes men, 
hypertrophied adipocytes secrete pro-inflammatory cytokines promoting 
macrophage infiltration and establishing local low-grade inflammation but lean 
individuals do not present these features (Verboven et al., 2018). Together, the 
evidence suggests that the glycemic status during pregnancy is largely due to a 
delicate balance between adipocyte number, volume and the site of fat 
accumulation.  
Angiogenesis is essential for adipose tissue expansion 
Besides changes in adipocyte size and number, the growth of adipose tissue is 
dependent on remodeling of the extracellular matrix and adipose tissue 
angiogenesis. In fact, adipose tissue angiogenesis (extension of the vascular 
network) can be considered as the rate limiting step for adipose tissue expansion 
as vascularization is essential for oxygen supply, nutrient intake, waste removal, 
and establishes the crosstalk between cells and organs through hormonal and 
growth factor exchange (Rupnick et al., 2002) (Cao, 2007) (Nishimura et al., 
2007). Developmental origins of the adipose organ in embryonic stages 
demonstrate that adipocytes arise from vascular networks, since extension of the 
vascular bed is followed by the appearance of lipid containing cells located 
around the capillaries (Hausman & Richardson, 2004) (Han et al., 2011). In the 
adult human and murine adipose tissue, resident mesenchymal stem cells give 
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rise to adipocyte progenitors and are tightly associated with the vascular 
endothelium (R. Gupta et al., 2012) (Tran et al., 2012) (Min et al., 2016). In 
periods of metabolic adaptation, these progenitors are able to differentiate into 
mature adipocytes and store lipid.  
 
Our lab has developed a technique, named the adipose tissue angiogenesis 
assay, where we can grow the capillary network from adipose tissue fragments 
obtained from human and animal fat biopsies and recapitulate in vitro the 
expansion capacity and metabolic state of the adipose tissue sample (Rojas-
Rodriguez et al., 2014). The assay consists on embedding small adipose tissue 
explants (fragments cut into 1mm) in Matrigel and culture them under pro-
angiogenic conditions which promotes the sprouting of capillary networks and 
proliferation of associated adipocyte progenitors. Based on this technique, our 
lab has published high impact work that has demonstrated the therapeutic 
potential of adipose tissue progenitor cells in systemic metabolism and 
highlighted the mechanistic role of adipose tissue expandability in glucose 
metabolism. For example, implantation of differentiated adipose progenitor cells 
(primed adipose stem cells “PADS”) in Matrigel into NOD-scidIL2rgnull (NSG) mice 
decreases fasting glucose and enhances glucose disposal rate when compared 
to mice injected with vehicle only (Min et al., 2016). Furthermore, high fat diet fed 
NSG mice implanted with PADS exhibit improved glucose tolerance and reduced 
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liver steatosis compared with controls injected only with Matrigel (Min et al., 
2016).  
 
The effect on in vivo insulin sensitivity on adipose tissue can be recapitulated in 
vitro via the adipose tissue angiogenesis assay, as adipose tissue explants 
obtained from fat biopsies of ob/ob mice and human subjects treated with the 
insulin sensitizer rosiglitazone have increased capillary sprouting when 
compared to untreated ob/ob mice and subjects in placebo (Gealekman et al., 
2008) (Gealekman et al., 2012). The assay was also performed in human 
adipose tissue explants obtained from subcutaneous and visceral fat biopsies. 
Interestingly, the capacity for adipose to grow via angiogenesis is depot specific 
and favors the angiogenic growth via adipose capillary sprouting of the 
subcutaneous over visceral fat tissue (Gealekman et al., 2011).  
 
Pregnancy, as a weight gain state, requires the expansion of adipose stores. 
Since adipose tissue angiogenesis is one of the initial stages of adipose tissue 
growth, the measurement of this parameter in the gravid state can provide insight 
into the preferential location of fat deposition during gestation and its relationship 
with systemic insulin sensitivity. 
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Adipokines as markers of inflammation and insulin sensitivity in gestation 
As an endocrine organ, adipose tissue secretes hormones and cytokines, termed 
adipokines, which serve as intercellular communication peptides and regulate 
energy homeostasis, systemic glucose homeostasis, lipid metabolism, 
inflammation, adipocyte proliferation and differentiation, angiogenesis, and many 
other physiological events (Ouchi, Parker, Lugus, & Walsh, 2011) (Sun, 
Kusminski, & Scherer, 2011) (Kusminski & Scherer, 2012). The role of 
adipokines in adipose tissue expansion has been mostly described by their 
inflammatory properties in obesity and type-2 diabetes. Hypertrophied adipocytes 
that are metabolically dysfunctional display chronic hypoxia and secrete elevated 
quantities of proinflammatory and reduced amounts of anti-inflammatory 
adipokines (Hosogai et al., 2007). Classically activated macrophages (M1, 
proinflammatory) organize as crown-like structures around hypoxic and 
hypertrophied adipocytes which can lead to adipocyte death. Conversely, 
adipocytes from lean individuals preferentially secrete anti-inflammatory 
adipokines and the majority of the residing macrophages are alternatively 
activated (M2, anti-inflammatory) (Ouchi et al., 2011) (Sethi & Vidal-Puig, 2007).  
 
Pregnancy, by itself, is a state of altered inflammation. The adipose tissue and 
placenta are sources of adipokines with different inflammatory roles, however, 
the common goal is to create a state of mild inflammation and reduced insulin 
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sensitivity to support fetal development (D’Ippolito, Tersigni, Scambia, & Di 
Simone, 2012). The adipokines adiponectin, leptin, and TNFa encompass the 
majority of the research regarding glycemic status, adipose tissue function, and 
mild inflammation during gestation, hence are briefly introduced.  
Adiponectin 
Adiponectin is an anti-inflammatory adipokine which circulating levels decrease 
as pregnancy advances in both human and mice. Murine studies have shown 
that adiponectin beneficially lowers hepatic glucose production and lipid 
accumulation and stimulates fatty acid oxidation in skeletal muscle via signaling 
through the adiponectin receptor in different cell types (Combs, Berg, Obici, 
Scherer, & Rossetti, 2001) (Yamauchi et al., 2001). Clinical studies have 
investigated the association between adiponectin and GDM. A cross-sectional 
study reported that at the time of GDM diagnosis, plasma adiponectin was lower 
in subjects with GDM than normoglycemic, and there was a negative correlation 
between these values and the homeostatic model assessment for insulin 
resistance (HOMA-IR) (Altinova et al., 2007). A retrospective study investigated if 
first trimester serum adiponectin could predict the development of GDM in a high-
risk population as determined by obese BMI, maternal age of >40 years, 
ethnicity, history of polycystic ovarian syndrome (PCOS), family history of type-2 
diabetes, and a previous macrosomic baby. Unadjusted logistic regression 
19 
 
demonstrated that low circulating adiponectin in the first trimester is associated 
with a positive screen for GDM and this interaction remained constant after 
adjusting for BMI, ethnicity and a family history of diabetes (Corcoran et al., 
2018). Regarding tissue specific contribution of adiponectin, studies have shown 
that adiponectin mRNA was downregulated in placenta (J. Chen et al., 2006) and 
subcutaneous (Ranheim et al., 2004) (Ott et al., 2018) and visceral (Ott et al., 
2018) adipose tissue of GDM when compared to normoglycemic gravidas. 
However, one study did not find a significant difference between GDM and 
controls in placenta as well as subcutaneous adipose tissue and skeletal muscle 
(Lappas, Yee, Permezel, & Rice, 2005).  Although tissue specific adiponectin 
studies report contradictory findings in adiponectin gene expression and glycemic 
state in gestation, it is important to consider that the total amount of serum 
adiponectin is a combination of the secreted adipokine from both the placenta 
and adipose tissue. Altogether, the evidence obtained from clinical studies 
suggests the association between low circulating adiponectin and the presence 
of GDM. 
Leptin 
The adipokine leptin is mainly produced by the adipose tissue and acts as an 
appetite suppressor and energy expenditure-inducing hormone via interaction 
with its receptor in the hypothalamus (Ahima et al., 1996) (Domingos et al., 
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2011). In addition, leptin has been shown to suppress insulin secretion from 
pancreatic b-cells (Kieffer, Heller, Leech, Holz, & Habener, 1997). The adipose 
tissue-derived leptin is produced in proportion to fat mass storage (Patif et al., 
1995). The concept of leptin resistance occurs when tissues become 
desensitized to leptin signaling resulting in hyperphagia and obesity (Myers, 
Cowley, & Münzberg, 2008). In women, non-human primates, and mice the 
plasma levels of leptin increase with gestation and rapidly fall after birth, 
highlighting placental contribution to leptin circulating levels (Hardie, Trayhurn, 
Abramovich, & Fowler, 1997) (NF Butte, Hopkinson, & Nicolson, 1997) (M. C. 
Henson et al., 1999) (M. Henson & Casatracane, 1998) (Pérez-Pérez et al., 
2018).  
 
The quantification of leptin in plasma and peripheral tissues has been studied in 
relation to glycemic status and BMI in gestation. At the time of cesarean section, 
circulating leptin was elevated in normoglycemic obese compared to 
normoglycemic non-obese gravidas and in GDM obese compared to GDM non-
obese. Leptin gene expression was higher in visceral adipose tissue of both 
normoglycemic and GDM obese gravidas when compared to normoglycemic 
non-obese controls. No differences where observed regarding leptin expression 
in subcutaneous fat or placenta between cohorts (Tsiotra et al., 2018), 
highlighting the depot-specific effect of obesity on increased leptin expression. 
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Data from this report and others (Kirwan et al., 2002) suggests that leptin levels 
are related to the pre-pregnancy obese state rather than the effect of pregnancy 
on leptin levels. Another longitudinal study measured the levels of fasting plasma 
leptin at week 28 of gestation and 8 weeks after delivery in normal glucose 
tolerance, GDM, and type-1 diabetes women. Interestingly, circulating leptin was 
elevated only in GDM and the values for normal glucose and type-1 cohorts were 
not different. Besides plasma leptin, the marked differences between cohorts was 
postpartum BMI, waist-to-hip ratio, and plasma triglycerides which were all 
elevated in GDM when compared to normoglycemic and type-1 diabetes groups 
(Kautzky-Willer et al., 2001a). Although fat mass was not measured in this study, 
is possible that the hyperleptinemia observed in GDM is due to an excess of 
adipose tissue stores. Overall, studies available so far imply the role of maternal 
obesity in the elevated circulating levels of leptin in gestation, where regional 
differences of fat distribution may regulate leptin production and secretion.    
Tumor necrosis factor a 
The tumor necrosis factor alpha (TNFa) is a proinflammatory adipokine 
expressed by macrophages, monocytes, T-cells, fibroblasts, neutrophils, and 
adipocytes and has been attributed to disrupt insulin signaling in insulin-sensitive 
tissues as well as inhibiting insulin secretion from b-cells (Fasshauer et al., 
2014). Plasma TNFa shows a trend for reduced values in early pregnancy 
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compared to pregravid but it increases in late gestation (Kirwan et al., 2002). An 
inverse association between insulin sensitivity (measured via hyperinsulinemic-
euglycemic clamp) and plasma TNFa was observed in late pregnancy (Kirwan et 
al., 2002). In addition, plasma TNFa measured at 34-36 weeks of gestation 
showed that obese pregnant women with GDM have elevated plasma TNFa 
when compared to lean normoglycemic gravidas (Kirwan et al., 2002). At the 
time of GDM diagnosis, serum TNFa was elevated in subjects with GDM than 
normoglycemic, and there was a positive correlation between these values and 
pre-pregnancy BMI (Altinova et al., 2007).  
 
In vitro studies of term placental and subcutaneous adipose tissue explants 
demonstrated that during hyperglycemic conditions, explants obtained from GDM 
women release more TNFa when compared to normoglycemic gravidas. 
Interestingly, there was no difference between groups in omental fat explants 
(Coughlan, Oliva, Georgiou, Permezel, & Rice, 2001). Another study done in 
basal conditions reported that there was no difference in secreted TNFa when 
measured in placental, subcutaneous fat, and skeletal muscle (pyramidalis) 
explants from normal glucose and GDM cohorts (Lappas, Permezel, & Rice, 
2004). At the cellular level, TNFa impairs activation of insulin signaling and 
glucose uptake in mouse muscle cells (C2C12 myoblast cell line) (del Aguila, 
Claffey, & Kirwan, 1999) and in 3T3L1 adipocytes it reduces GLUT4 expression 
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(Stephens, Lee, & Pilch, 1997) (Ruan, Hacohen, Golub, Parijs, & Lodish, 2002) 
and insulin-stimulated glucose uptake (Anusree, Sindhu, Preetha Rani, & Raghu, 
2018). Therefore, is possible that the effect of TNFa on reduced insulin signaling 
is exacerbated in gestational diabetes, contributing to the peripheral tissue insulin 
resistance observed in gravid women with GDM.   
 
The association of each adipokine with glycemia in pregnancy is dependent on 
the parameter and population measured, the gestational age during assessment, 
and the source of the specimen, as some circulating peptides correlate with the 
development of GDM, however the tissue-specific gene and protein expression 
results vary (Fasshauer et al., 2014). However, clinical studies and meta-analysis 
up to date agree that women with GDM have lower levels of circulating 
adiponectin and increased values of circulating leptin than normoglycemic 
gravidas at the time of sampling (Bao et al., 2015) (Fasshauer et al., 2014) 
(Francis et al., 2019) (Atègbo et al., 2006) (Retnakaran et al., 2004) 
(Soheilykhah, Mojibian, Rahimi-Saghand, Rashidi, & Hadinedoushan, 2011) 
(Kautzky-Willer et al., 2001b) (Doruk, Uğur, Oruç, Demirel, & Yildiz, 2014) 
indicating the role of adipose tissue in glycemic control during pregnancy.  
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Adaptations of insulin and insulin-like growth factor signaling mechanisms 
in the gravid state 
Drivers of insulin resistance 
Historically, placental secretion of “diabetogenic” hormones such as 
progesterone, cortisol, estrogen, human placental lactogen, and human placental 
growth factor have been attributed to the insulin resistance observed in gestation. 
Nevertheless, it does not explain why some women who developed GDM present 
impaired fasting glucose, impaired glucose tolerance, or develop type-2 diabetes 
6-12 weeks after giving birth (Kitzmiller, Dang-Kilduff, & Taslimi, 2007) (Huopio et 
al., 2014). The insulin action in peripheral tissues must then explain the 
difference between normoglycemia and GDM development.  
The molecular mechanisms of insulin resistance studied at the cellular-tissue 
level rather than by associations between molecules and glycemic state can 
deepen the understanding of the etiology of GDM. Unraveling the differences in 
insulin signaling from peripheral tissues of normoglycemic and GDM gravidas 
can serve as the basis for advancements in approaches to manage this 
condition. 
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Molecular mechanisms of insulin action 
In normoglycemia, glucose uptake in adipose tissue and skeletal muscle due to 
insulin action initiates when insulin binds the insulin receptor (IR) at the cell 
membrane. A conformational change and autophosphorylation of the tyrosine 
kinase IR induce phosphorylation of the insulin receptor substrate (IRS-1), which 
leads to an interaction and subsequent activation of phosphoinositide 3-kinase 
(PI3K) producing phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 
activates and localizes protein kinases that initiate a series of phosphorylation 
events that result in the activation of protein kinase B (PKB or AKT). The 
substrate of AKT, AS160, is responsible for translocation of GLUT-4 to the 
plasma membrane. Glucose enters the cell through GLUT-4 and undergoes 
glycolysis. AKT signaling events also regulate cellular proliferation and growth as 
well as metabolic functions including lipid synthesis, gluconeogenesis, and 
glycogen synthesis (Boucher, Kleinridders, & Kahn, 2014) (Tokarz, MacDonald, 
& Klip, 2018). 
 
In pregnancy, the insulin signaling events are altered to favor reduced insulin 
sensitivity, but these changes are more pronounced in GDM. These changes can 
occur by alterations in protein concentration or tyrosine/serine phosphorylation of 
the molecules involved in the insulin signaling pathway. Table 1.2 summarizes 
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the findings from cross sectional studies in pregnant women with respect to the 
analysis of insulin signaling molecules in muscle and adipose tissue. 
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Table 1. 2 Adipose tissue and muscle expression of proteins from insulin/IGF 
signaling pathway in pregnancy and GDM. 
 
Non-pregnant (NP), pregnant (P), lean (LN), obese (OB), normoglycemic (NGT), 
gestational diabetes (GDM). Data from 1(Catalano et al., 2002), 2(Friedman et al., 1999), 
3(Barbour et al., 2011), 4(Okuno et al., 1995), 5(Garvey, Maianu, Hancock, Golichowski, & 
Baron, 1992) 
Signaling 
Molecule 
Function in Signaling 
Pathway 
Adipose Tissue           
(abdominal 
subcutaneous)1,4 
Muscle                                
(rectus abdominus)2,5         
(vastus lateralis)3 
Insulin 
Receptor 
(IR) 
Binding of insulin 
causes auto-
phosphorylation of IR 
tyrosine residues. IR 
phosphorylates the 
tyrosine residues of 
IRS-1 leading to its 
activation. 
No difference in 
expression between 
NP-OB, P-OB-NGT, 
and P-OB-GDM1 
No difference in 
expression between NP-
OB, P-OB-NGT, and P-
OB-GDM2 
Insulin 
Receptor 
Substrate-1              
(IRS-1) 
Recruits the p85a/p110 
subunits of the 
phosphoinositide 3-
kinase (PI3K). 
Decreased in P-OB-
GDM when 
compared to NP-OB 
and P-OB-NGT1 
Expression and tyrosine 
phosphorylation are 
decreased in P-OB-NGT 
and even lower values in 
P-OB-GDM when 
compared to NP-OB2   
                                                                                                                                                                                                                                                                                                 
Expression decreased but 
serine phosphorylation 
increased in P-OB-GDM 
over P-OB-NGT3 
p85a 
Forms a heterodimer 
with p110 to activate 
PIK3. Increased 
amounts of p85a 
subunit can inhibit PI3K 
activation. 
Increased in P-OB-
GDM when 
compared to NP-OB 
and P-OB-NGT1 
Increased in P-OB-NGT 
and even higher values in 
P-OB-GDM when 
compared to NP-OB2 
Glucose-
transporter 
4 (GLUT4) 
Upon activation, 
GLUT4 translocates to 
the cell membrane and 
facilitates diffusion of 
glucose inside the cell. 
Reduced in P-NGT 
and even lower 
quantities in P-GDM 
when compared to 
NP4 
No difference in 
expression between NP-
LN, NP-OB, and P-OB-
GDM5 
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Insulin and IGFs share signaling properties 
The insulin-like growth factor-1 (IGF-1) is a hormone with similar structure and 
signaling properties as insulin (46.2 homology score between insulin and IGF-1 
preproteins). IGF-1 is regulated by nutrition and growth hormone and is  
produced and secreted by liver and other peripheral tissues where it has 
autocrine and paracrine actions (Lewitt, Dent, & Hall, 2014) (Klement & Fink, 
2016). IGF-1 can mimic insulin by stimulating glucose and amino acid uptake and 
inhibition of gluconeogenesis (Clemmons, 2012). IGF-1 has mitogenic properties 
and is involved in adipose tissue growth and glucose metabolism (Hesse et al., 
2018). Besides IGF-1, IGF-2 also shares sequence similarity to insulin. The Igf-2 
gene is maternally imprinted and the role of the gene product has been mostly 
described in fetal development (A. Smith, Choufani, Ferreira, & Weksberg, 2007) 
(White et al., 2017). Circulating IGF-2 increases with age and remains 
unchanged through adulthood, whereas IGF-1 levels decrease after puberty (Yu 
et al., 1999). Both IGF-1 and IGF-2 have been described to regulate cellular 
proliferation and differentiation as well as angiogenesis (Yang et al., 
2018)(Harris, Crocker, Baker, Aplin, & Westwood, 2011) (Chao & D’Amore, 
2008). 
The IGF-1 receptor (IGF-1R) has high homology to the IR. The IGF-1 binds the 
IGF-1 receptor and with lower affinity to the IR. Both ligands can also bind a 
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hybrid of the IR/IGF-1R, however IGF-1 has higher affinity than insulin for this 
heteroreceptor (Taniguchi, Emanuelli, & Kahn, 2006). Additionally, IGF-2 can 
bind its receptor (IGF-2R) as well as the IGF-1R and the IR (Andersen, 
Nørgaard-Pedersen, Brandt, Pettersson, & Slaaby, 2017) (Spicer & Aad, 2007). 
Interaction with the IGF-2R results in IGF-2 degradation or mitogenic signaling 
(Harris et al., 2011). The intracellular signaling events are also shared, involving 
tyrosine phosphorylation and activation of the IRS. The different effects of each 
hormone in vivo is dependent on the developmental stage, the location where it 
is expressed, the quantity of each ligand as well as the amount of each receptor 
at the target cells, and the activation of the signaling events (Werner, Weinstein, 
& Bentov, 2008) (Siddle, 2011) (Boucher et al., 2014). Furthermore, 
dysregulation of insulin action and IGF events could occur before receptor 
binding in target tissues, decreased availability of the cellular receptor, or defects 
in intracellular signal transduction.  
IGFs bioavailability is dependent on IGF-binding proteins  
Stability of IGF is dependent on the binding of an IGF-binding protein (IGFBP) 
that can either inhibit or stimulate the growth promoting effects of the ligand 
(Murphy, 1998). Seven IGFBPs have been identified and their function is to 
sequester IGF to prevent cellular receptor binding (H. Kim, Rosenfeld, & Oh, 
1997) (Infante & Rodríguez, 2018). IGF-IGFBP complex availability is tissue 
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specific, thus the binding preference between ligand and binding protein depends 
on the location of where these molecules are interacting (Oxvig, 2015) (Mohan & 
Baylink, 2002).  
Amongst the described IGFBPs, studies in pregnant and non-pregnant cohorts 
showed circulating IGF-1, IGFBP1, and IGFBP3 are elevated in pregnancy 
compared to the non-pregnant state (Monaghan et al., 2004) (Anderlová et al., 
2018). However, gravidas that develop GDM have higher values for IGF-2 and 
IGFBP3 and lower concentration of IGFBP4 when compared to normoglycemic 
gravidas. In addition, gestation increases the expression of IGF1, IGFBP4, and 
IGFBP5 in subcutaneous adipose tissue (Resi et al., 2012) (Anderlová et al., 
2018). Moreover, a longitudinal study across gestation reported the levels of 
serum IGFBP2 were downregulated whereas values of IGF-1 and IGFBP3 
upregulated during early and mid-gestation in gravidas that developed in GDM 
(Zhu et al., 2016).  
Proteolytic Cleavage of IGFBPs   
IGF release from the IGF-IGFBP complex is dependent on proteolytic cleavage 
of the IGFBP (Figure 1.1). The IGFBPs proteases were first described in the 
serum of pregnant women (Bischof, 1989). One of these proteases, pregnancy-
associated plasma protein-A (PAPP-A) is a placental secreted metalloprotease 
synthesized by syncytiotrophoblasts (Tornehave, Chemnitz, Teisner, Folkersen, 
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& Westergaard, 1984). However, reports have demonstrated its gene expression 
in murine adipose tissue (Hjortebjerg et al., 2018) and protein secretion and 
proteolytic activity is observed in subcutaneous and visceral human adipose 
tissue explants (Gude et al., 2016) indicating a tissue specific function for this 
protease (Oxvig, 2015) (Hjortebjerg et al., 2018). Furthermore, mRNA and 
secreted PAPP-A has been detected in human preadipocytes from omentum, 
mesenteric and subcutaneous fat depot (Davidge-Pitts, Escande, & Conover, 
2014). The major known function of PAPP-A is to increase IGF bioavailability in 
the pericellular environment through cleavage of IGFBP2, IGFBP4, and IGFBP5, 
highlighting the role of this protease in the insulin/IGF signaling pathway 
(Conover, Durham, Zapf, Masiarz, & Kiefer, 1995) (Laursen et al., 2001) (Monget 
et al., 2003). In mice, ablation of Papp-A results in dwarf animals with reduced 
female fertility due to decreased ovulated oocytes and shorter ovulation periods 
but extended longevity (~30% longer than wild-type littermates) (Nyegaard et al., 
2010) (Conover & Bale, 2007).  
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Figure 1. 1 Insulin and IGF share signaling pathways. 
 
(a) Insulin-like growth factors (IGF) are sequestered by IGF binding proteins (IGFBP) in 
the pericellular environment, creating a local bioreservoir of IGFs. (b) IGFBP protease 
localizes in close proximity to the cellular insulin/IGF1 receptor (IR/IGF1R). Cleavage of 
IGFBPs by protease releases IGFs. (c)  Free IGF or insulin bind the IR/IGF1R. (d) Upon 
binding, a conformational change in the IR/IGF1R causes autophosphorylation of tyrosine 
residues, which activates the tyrosine kinase activity that leads to increased tyrosine 
phosphorylation of cellular substrates. The IRS-1 and other docking proteins bind to the 
phosphorylated intracellular substrates, thereby transmitting the signal downstream. (e) 
Insulin stimulates the binding and activation of phosphatidylinositol-3 (PI-3)-kinase, to IRS-
1. PI 3-kinase is composed of an 85 kD regulatory subunit (p85) that is associated with 
the phosphorylated IRS-1 and activates the catalytic 110 kD subunit. The formation of 
PI(3,4,5)P3 is necessary for insulin action on glucose transport. The stimulation of PI 3-
kinase activity is linked to AKT. (f) AKT phosphorylates downstream substrates that are 
involved in the regulation of diverse cellular functions including metabolism, proliferation, 
and growth. Adapted from (Taniguchi et al., 2006) 
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Clinical Relevance of PAPP-A 
Currently, PAPP-A is part of the first trimester maternal screen for fetal 
chromosomal abnormalities, as low levels of circulating PAPP-A early in 
gestation are associated with trisomy 13 (Patau’s syndrome), 18 (Edward’s 
syndrome) and 21 (Down’s syndrome) (Snijders, Spencer, Souter, Nicolaides, & 
Tul, 2003) (Wapner et al., 2003) (Driscoll & Gross, 2008) (Leguy et al., 2014). 
The marked presence of PAPP-A and target IGFBPs in maternal circulation and 
adipose tissue presents an opportunity to study this interaction in relation to 
adipose tissue expandability and glucose metabolism in gestation.  
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Animal models of gestational diabetes mellitus 
Advances in the understanding of the molecular mechanisms driving the 
development of a disease are often dependent on the use of animal models that 
replicate the pathologic conditions as is observed in humans. The difficulty when 
developing animal models for gestational diabetes arise due to the onset of 
pathological hyperglycemia and insulin resistance, which needs to be present 
exclusively during gestation. Therefore, any established models for type-2 
diabetes used in pregnant dams do not accurately describe GDM. An ideal 
animal study would present normoglycemic, insulin sensitive animals in the non-
pregnant state and GDM pathophysiology exclusively in gestation.  
Current animal models include induction of GDM in mice, rats, rabbits, dogs, 
sheep, and swine. Different approaches have been used to induce diabetes in 
pregnancy. Surgical removal of pancreatic mass is usually done before puberty 
and has up to 20% mortality rate (Jawerbaum & White, 2010). However, failed 
insulin secretion is observed in virgin females resembling to what is observed in 
type-1 diabetes. Chemical induction with streptozotocin or alloxan which are toxic 
to pancreatic b-cells, cause hyperglycemia, however the timing of treatment 
(before or during gestation) and the dose used results in either mild or severe 
hyperglycemia depending on the animal and strain (Kiss et al., 2009) (Singh et 
al., 2011) (Chandna et al., 2015) (Trejo-González, Chirino-Galindo, & Palomar-
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Morales, 2015) (Y. Chen et al., 2017). High fat and high sucrose diets have also 
been reported to induce hyperglycemia in gestation although these models do 
not recapitulate the genetic variants of GDM and are more relevant for the effect 
of maternal obesity (Moore et al., 2010) (Coate et al., 2013) (Pereira et al., 2015) 
(Hosni, Abdel-Moneim, Abdel-Reheim, Mohamed, & Helmy, 2017). 
Genetic models have also been employed, and the most representative in 
adipose tissue physiology and impaired gestational glucose metabolism are db/+ 
(heterozygous for mutation in leptin receptor) and Adipo-/- (knockout of 
adiponectin). The db/+ females are normoglycemic and insulin sensitive when 
virgins and develop glucose intolerance, insulin resistance, and obesity when 
pregnant (Ishizuka et al., 1999). In addition, these mice give birth to macrosomic 
pups a feature of neonates born from GDM mothers (Ishizuka et al., 1999) and 
had reduced skeletal muscle insulin-stimulated tyrosine phosphorylation of IRS-1 
receptor (Yamashita et al., 2001). However, experiments carried out with the 
db/+ mice had conflicting results, as some reported glucose intolerance and 
others normoglycemia in gestation where the variables observed included the 
kind of chow diet and strain of controls used (Plows et al., 2017). The Adipo-/- 
pregnant dams are glucose intolerant, have higher plasma free fatty acids and 
triglycerides, and had macrosomic pups compared to wild type pregnant controls. 
Although these animals are not insulin resistant, they have reduced b-cell islets 
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size. The caveat of this animal model is the absence of wild type and Adipo-/- 
virgin controls ran in parallel with the pregnant dams (Qiao et al., 2017).  
Dissecting the role of key molecules and alterations in signaling pathways during 
gestation that result in failed b-cell compensation, peripheral tissue insulin 
resistance, or the combination of these events is the appropriate approach to 
discover the cause and possible treatments for gestational diabetes.  
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Scope of the thesis 
Pregnancy as a weight gain state presents an ideal setting to study the 
physiology of adipose tissue expansion and its association with systemic glucose 
metabolism. Defects in adequate deposition of lipids has been reported in 
various animal models and patients with type-2 diabetes. Numerous prospective 
studies clearly indicate the increased morbidity for type-2 diabetes in pregnant 
women with gestational diabetes (GDM) in comparison with normoglycemic 
(NGT) gravidas. Therefore, there is an urgent need for understanding the biology 
of adipose tissue expansion in gestation and its association with glycemic 
control. The purpose of the work presented in this thesis is to characterize the 
adaptations of adipose tissue growth in late gestation and investigate how 
changes in adipose tissue expansion are associated with maternal glucose 
metabolism. The thesis aims are presented in chapters.  
 
In Chapter 2, I characterized the late-pregnancy changes in abdominal 
subcutaneous and omental adipose tissue expandability of pregnant women with 
normoglycemia and gestational diabetes. The results demonstrated that in 
comparison with NGT gravid subjects, pregnant women with GDM have impaired 
adipose tissue growth characterized by enlarged hypertrophic adipocytes in 
omental fat and reduced vascularization in both adipose depots. In addition, 
adipose tissue whole transcriptomic analysis of NGT non-pregnant and pregnant 
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individuals revealed the upregulated expression of insulin-like growth factor 
binding protein 5 (IGFBP5) in gestation. The levels of IGFBP5 were markedly 
decreased in GDM gravidas. The results from Chapter 2 in conjunction with the 
work published by others highlights the maladaptation of adipose tissue growth in 
gravidas with gestational diabetes.  
 
In order to understand the pathology of impaired adipose tissue expansion in 
GDM it is necessary to acquire new knowledge regarding the biology of fat 
expandability in pregnancy on a normoglycemic state. The results presented in 
Chapter 3 consists of studies done in humans and mice exploring a potential 
signaling mechanism driving adipose tissue expansion in pregnancy and 
protecting against gestational diabetes. First, I analyzed the changes in 
subcutaneous adipose tissue expansion between normoglycemic non-pregnant 
and pregnant subjects in late gestation. The results showed that adipose tissue 
in pregnancy is characterized by adipocyte hypertrophy and hyperplasia and is 
accompanied with structural changes of the microvasculature. Re-analysis of the 
transcriptomic database presented in Chapter 2 by hierarchical clustering and 
differential expression confirmed that the gene IGFBP5 was the most 
upregulated gene due to gestation in both subcutaneous and omental depots. 
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Next, I explored if the IGFBP5/IGF axis in the adipose tissue was associated with 
maternal glucose metabolism. It is known that the pregnancy associated plasma 
protein-A (PAPP-A) cleaves IGFBP5. PAPP-A concentration in the serum 
increases as pregnancy advances. In order to investigate if circulating PAPP-A in 
the first trimester of pregnancy is associated with maternal glycemic state we 
performed a retrospective study. Results showed that low levels of PAPP-A in 
weeks 10-14 of pregnancy are associated with high risk of developing abnormal 
glucose tolerance and GDM later in gestation, suggesting the potential of PAPP-
A as an early biomarker of gestational diabetes. The findings from the 
retrospective study were possible by the collaboration with the OB/GYN 
department and IT-Data Sciences Technology group. 
 
In order to elucidate the mechanistic role of PAPP-A with respect to adipose 
tissue growth, I leveraged a new in vitro technique developed by our lab that 
measures adipose tissue expandability. I was interested in understanding if the 
presence of PAPP-A would promote the expandability of adipose tissue. I found 
that pregnancy enhances adipose tissue growth and that the supplementation of 
recombinant human PAPP-A stimulated the expansion capacity of adipose tissue 
from pregnant women. This suggested that PAPP-A was involved in the 
adaptations of adipose tissue expansion during gestation. 
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Last, I explored if Papp-a knockout mice represent an animal model of impaired 
adipose tissue adaptations as presented in human gestational diabetes. The 
mice studies were done with cohorts of non-pregnant (NP) and pregnant (P) wild-
type (WT) and Papp-a knockout (KO) dams. Analysis of adipose tissue 
architecture demonstrated that the changes related to adipocyte size and number 
distribution in normal WT gestation where absent in the KO. Expression of 
Igfbp2, which is also cleaved by PAPP-A, was upregulated by gestation but no 
differences where observed between genotypes. Metabolic phenotyping 
experiments showed the presence of insulin resistance and fatty liver only in the 
PKO, highlighting the similarity of the PKO with the pathology observed in 
gestational diabetes.  
 
The results from cross-sectional and retrospective studies in addition to the 
animal experiments presented in my thesis feature molecules from the IGF 
signaling pathway, particularly IGFBP5 and PAPP-A as having pivotal roles in the 
adaptation of adipose tissue expandability in gestation and in maternal glucose 
metabolism. Besides my research in gestational diabetes and adipose tissue 
physiology, I collaborated in the design, conducted experiments, and analyzed 
data for other projects studying adipose tissue expandability in vitro. The 
published technique developed for this approach is presented in the Appendix 
section.   
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CHAPTER II: Human adipose tissue expansion in 
pregnancy is impaired in gestational diabetes mellitus 
   
Abstract 
During pregnancy, adipose tissue (AT) must expand to support the growing fetus 
and the future nutritional needs of the offspring. Limited expandability of AT is 
associated with insulin resistance, attributed to ectopic lipid deposition. This 
study aimed to investigate human AT expandability during pregnancy and its role 
in the pathogenesis of gestational diabetes mellitus (GDM). This cross-sectional 
study of omental (OM) and subcutaneous (SQ) AT collected at Caesarean 
delivery included fifteen pregnant women with normal glucose tolerance (NGT), 
six with GDM, and three with type 2 diabetes mellitus. Adipocyte size, capillary 
density, collagen content and capillary growth were measured. Affymetrix arrays 
and real-time PCR studies of gene expression were performed. Mean OM 
adipocyte size was greater in women with GDM than in those with NGT 
(p=0.004). Mean OM and SQ capillary density were lower in GDM compared with 
NGT (p=0.015). Capillary growth did not differ significantly between groups. The 
most differentially expressed AT transcript when comparing non-pregnant and 
pregnant women corresponded to the IGF binding protein (IGFBP)-5, the 
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expression levels of which was found by subsequent quantitative real-time PCR 
to be lower in women with GDM vs women with NGT (p< 0.0001). The relative 
OM adipocyte hypertrophy and decreased OM and SQ capillary density are 
consistent with impaired AT expandability in GDM. The induction of adipose 
tissue IGFBP5 in pregnancy and its decrease in GDM point to the importance of 
the IGF-1 signaling pathway in AT expansion in pregnancy and GDM 
susceptibility.  
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Introduction 
Gestational diabetes mellitus (GDM) affects 240,000 pregnancies in the USA 
each year, a number expected to increase to ~720,000 with changes in 
diagnostic criteria and increased incidence (Sacks et al., 2012) (Getahun, Nath, 
Ananth, Chavez, & Smulian, 2008) (Albrecht et al., 2010). GDM has been 
associated with intergenerational effects on risk of obesity, the metabolic 
syndrome and cardio-metabolic disorders (Moore Simas et al., 2010) (Metzger, 
2007) (Hillier et al., 2007)(Malcolm, 2012). Of women with a history of GDM, 50% 
develop type 2 diabetes within 5 years  (Kjos et al., 1995), and up to one-third of 
women with type 2 diabetes have a history of GDM (Cheung & Byth, 2003). 
Notwithstanding the considerable public health relevance of this disorder, its 
etiology remains unclear.  
 
Appropriate expandability of adipose tissue (AT) is necessary for preventing 
ectopic deposition of lipids and their metabolites in tissues such as muscle, liver 
and pancreas, with consequent development of insulin resistance (Gray & Vidal-
Puig, 2007) (Virtue & Vidal-Puig, 2010) (D. Gupta, Krueger, & Lastra, 2012) 
(Summers, 2006). The need for expandability is seen in mouse models in which 
increased AT mass results in metabolic improvement (JY Kim et al., 2007), and 
in epidemiological studies linking increased subcutaneous (SQ) AT with 
protection from type 2 diabetes risk (McLaughlin et al., 2011). Notably, while SQ 
44 
 
AT expansion is associated with diminished risk, expansion of visceral AT is 
associated with increased risk of metabolic disease (McLaughlin et al., 2011). 
This dichotomy is attributed to the propensity of visceral AT to undergo 
inflammation (Tchernof & Després, 2013), associated with insufficient SQ AT 
expandability (Alligier et al., 2013). During pregnancy, AT must rapidly expand to 
support the needs of the fetus and the future needs of the offspring through 
lactation (Herrera, 2000) (Ryan, Sullivan, & Skyler, 1985). Thus, inherent 
limitations in the ability of AT to expand may be unmasked during pregnancy and 
manifest as GDM and future susceptibility to type 2 diabetes.  
 
It was thought that GDM arises from placental hormones that induce insulin 
resistance, coupled with insufficient insulin secretion. Numerous placental 
hormones can affect insulin sensitivity (Catalano, 2014). However, an association 
between these and insulin sensitivity in late pregnancy, and with GDM, has not 
been consistently discerned (Kirwan et al., 2002). A major factor produced by 
placenta is pregnancy-associated plasma protein-A (PAPP-A), a protease that 
can hydrolyze IGF binding proteins (IGFBPs) 4 and 5 (Laursen et al., 2001). 
IGFBPs bind IGF-1 and/or IGF-2 and control their bioavailability within tissues 
(Beattie, Allan, Lochrie, & Flint, 2006). The high affinity of IGFBPs for IGFs 
precludes their binding to the IGF-1 receptor (Beattie et al., 2006) (Garten, 
Schuster, & Kiess, 2012) . Thus, through the production of PAPP-A, the placenta 
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can exert a major effect on the growth of tissues through hydrolysis of IGFBPs 
and release of bound IGF-1. Obesity can affect the placenta, resulting in 
structural and biochemical alterations (Huang et al., 2014) (Jones & Fox, 1976) 
(Mele, Muralimanoharan, Maloyan, & Myatt, 2014) (O’Tierney-Ginn, Presley, 
Myers, & Catalano, 2015), with potential consequent maternal AT growth.  
 
To explore the role of AT expandability in the etiology of GDM we conducted a 
cross-sectional analysis of AT from pregnant women undergoing elective 
Caesarean deliveries. Our results are consistent with the hypothesis that AT 
expandability is decreased in individuals with GDM. Moreover, global expression 
analyses reveal that IGFBP5 is highly induced in AT during pregnancy and is 
decreased in GDM, suggesting a mechanism for placenta–AT communication 
that may be impaired in GDM.  
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Methods 
Study settings and participants 
All pregnant women with singleton gestations presenting to UMass Memorial 
Health Care (UMMHC) between March 2013 and June 2014 for scheduled 
Caesarean delivery were considered for enrolment. The Institutional Review 
Board of the University of Massachusetts Medical School (UMMS) approved the 
study, and all participants provided informed consent. Exclusion criteria were as 
follows: (1) pre-gestational type 1 diabetes; (2) underweight pre-pregnancy body-
mass index (BMI) (<18.5 kg/m2); (3) multiple gestations; (4) reported use of 
substances, including alcohol and/or illicit drugs and replacement or maintenance 
products, in pregnancy; (5) HIV; (6) hepatitis; (7) age <18 years; (8) autoimmune 
disease and/or chronic steroid use; (9) prenatal care initiation after 13 completed 
weeks gestational age and (10) plans to move out of the area within the study 
period.  
Diabetes status  
Type 2 diabetes was diagnosed based on patient report of medical history and 
confirmatory review of medical records. Individuals were considered to have 
GDM if they did not have pre-gestational type 1 or type 2 diabetes and either met 
American Diabetes Association criteria (a value of ≥7.7 mmol/L (140 mg/dl) 1h 
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after a 50g dextrose load (Thermoscientific, Middletown, VA, USA) screening test 
followed by two or more abnormal values in the 100g 3h glucose tolerance test) 
at routine screening between 24 and 28 weeks of gestation, or had a value >10 
mmol/l (180 mg/dl) on the 1h screening test (Landy, Gómez-Marín, & O’Sullivan, 
1996) (Atilano, Lee-Parritz, Lieberman, Cohen, & Barbieri, 1999).  
Covariates and other relevant data collection  
Clinical and anthropometric data were collected at enrollment. Pre-pregnancy 
BMI was calculated as pre-pregnancy weight (kg)/height2 (m2). Post-pregnancy 
BMI was calculated from the last prenatal weight record minus the weight of the 
baby. Blood glucose was measured 1h after ingestion of a 50g glucose load, a 
test routinely performed for GDM screening in individuals without pre-gestational 
type 2 diabetes. 
Non-pregnant individuals  
Cohorts for Affymetrix arrays and gene expression by real time PCR were from 
non-diabetic individuals undergoing bariatric surgery, as previously described 
(Gealekman et al., 2011) (Table 2.2). Consent for collection of additional samples 
of AT was obtained from non-pregnant individuals undergoing panniculectomy 
surgery who had no history of type 2 diabetes.  
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Adipose tissue collection  
Biological specimens were collected at the time of surgical delivery. After delivery 
of the baby, two segments (1cm × 1cm) of omental (OM) tissue from the midline 
inferior periphery were collected. After the rectus fascia was re-approximated, 
prior to skin closure, two samples (1cm × 1cm) of SQ AT were obtained from 
within the surgical incision usually placed approximately 2cm above the pubic 
bone (Pfannenstiel incision). In the case of repeat Caesarean deliveries, 
subcutaneous AT biopsies were taken from deep within the incision to decrease 
scar tissue sampling.  
Analysis of adipocyte size and collagen staining  
AT samples were fixed in 4% formaldehyde and embedded in paraffin. Tissue 
sections (8μm) were mounted on Superfrost Plus microscope slides (Fisher 
Scientific, Pittsburgh, PA, USA), and stained with hematoxylin and eosin (H&E). 
Investigators acquiring the images were blinded to the origin of the sample. 
Adipocyte size was determined using an automated procedure based on the 
open software platform Fiji (Schindelin et al., 2012) (Figure 2.1) . Collagen was 
detected using picrosirius red staining. For quantification, images were imported 
into Fiji, and converted into 8-bit greyscale images. After background subtraction, 
total intensity was recorded.  
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Analysis of capillary density  
Fragments of AT were fixed in 4% formaldehyde, washed and stained with 
Rhodamine-Lectin UEA-1 (Vector Labs, Burlingame, CA, USA) for 1h at room 
temperature and then mounted between 1.5 mm coverslips sealed with Pro-Long 
Gold Antifade Reagent (Life Technologies, Grand Island, NY, USA). A Zeiss 
(Peabody, MA, USA) Axiovert 100 inverted microscope with a ×10 objective and 
AxioCam HRm camera was used to acquire nine Z-plane image stacks at 10μm 
intervals. The individual collecting the images was unaware of the group they 
corresponded to. Quantification of capillary density was determined after 
background subtraction and projection of the Z-stack maximal intensity  
(Figure 2.2). 
AT capillary growth assay  
AT biopsies were cut into small (1mm3) pieces and embedded in individual wells 
of a 96-multiwell plate as described (Rojas-Rodriguez et al., 2014). After 11 days 
of culture in EBM-2 medium supplemented with EGM-2 MV (BulletKit CC-3202; 
Lonza, Allendale, NJ, USA), images were acquired using a Zeiss Axio Observer 
Z1 equipped with an automated stage and a Clara High Resolution CCD Camera 
(Andor, Concord, MA, USA). Images were taken under ×2.5 magnification as a 
stack composed of five Z planes at 150μm intervals and as a canvas of four 
quadrants per well and then combined into a single three-dimensional image. 
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Subsequent image processing and quantification of capillary growth was 
determined after background subtraction and projection of the Z-stack maximal 
intensity (Figure 2.3).  
Affymetrix arrays  
Total RNA was isolated using TRIzol (Life Technologies). Affymetrix (Santa 
Clara, CA, USA) protocols were followed for the preparation of cRNA, which was 
hybridized to HG-U133v2 Chips. Raw expression data collected from an 
Affymetrix HP GeneArrayScanner was normalised across all data sets using the 
RMA algorithm. Probes in which any condition resulted in raw expression values 
above 1,000 were included in the heat map shown in Figure 2.9a.  
Quantitative real-time PCR  
Total RNA was extracted from AT using the RNeasy Lipid Tissue Mini Kit 
(Qiagen, Valencia, CA, USA). One microgram of total RNA was reverse-
transcribed using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). 
cDNA was used as template for real-time PCR using the iQ SYBR Green 
Supermix kit (Bio-Rad) and the CFX96 Real-Time System (Bio-Rad). Human 
ribosomal protein L4 (RPL4) was used for normalization. To reflect the 
abundance of the different IGFBPs and IGF-1 relative to each other and between 
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groups, all values were normalized to the content of the lowest expressed 
transcript, which was IGFBP1 in the non-pregnant group.  
Statistical analysis  
Clinical study data were collected and managed using REDCap (Research 
Electronic Data Capture). Stata/MP v.13.1 or GraphPad Prism v.6.0 were used 
for analysis as indicated. Multiple measures for each individual were acquired for 
each variable investigated. For adipocyte size data, between five and ten 
sections per each individual were used to acquire between 38 and 117 images. 
For capillary density data three three-dimensional image stacks were acquired 
from three independent sections per each individual. For capillary growth data, 
between seven and 58 observations were made for each individual. For 
picrosirius red staining, three sections per individual were used to acquire 15 
images. Each individual’s data were collapsed to the mean, which was then used 
for group analysis. A sensitivity analysis was performed with both the mean and 
median value for each individual. Sensitivity analysis results were similar to the 
mean; therefore, we present only the mean results. To calculate the maximum 
adipocyte size, the single largest adipocyte in each field was recorded, and the  
mean value calculated for each individual. Categorical variables were described 
using frequency and percentage with Fisher’s exact test used to compare 
groups. Group comparisons for adipocyte size, capillary density and 
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angiogenesis data were made using the Wilcoxon rank sum test (Mann–Whitney 
test in Prism 6.0). Within-subject differences between OM and SQ tissue were 
determined using the Wilcoxon signed-rank test. Histograms of adipocyte size 
distributions for each patient were generated using the same bin sizes, and 
groups of histograms were compared using the Wilcoxon test for histograms 
(Prism 6.0). Statistical analysis of difference between groups in experiments 
involving real-time PCR was done using two-way ANOVA with the Holms–Sidak 
correction for multiple comparisons.  
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Figure 2. 1 Image processing and quantification of adipocyte size.  
(a) Image of AT section stained with hematoxylin and eosin (H&E) (x10 magnification). (b) 
Image is imported to Fiji software and converted to 8-bit grayscale image. (c) 
Enhancement of image contrast (Process/Enhance Contrast/ Saturated pixels: 0.35%; 
normalize). (d) Background subtraction (Process/Subtract Background/Rolling Ball; 
radius=50.0pixels; Light background; Sliding paraboloid). (e) Enhancement of image 
contrast (Process/Enhance Contrast/ Saturated pixels: 10%; Normalize). (f) Binarized 
image (Image/Adjust/ Threshold/Huang; Dark background; Apply). (g) Processing on the 
binary image fills in small holes (Process/Binary/Fill Holes) (h) Resulting image showing 
the outlines of the counted objects (Analyze/Analyze Particles, Size (pixel²=1200-Infinity; 
Circularity=0.10-1.00; Show=Outlines; Display results; Exclude on edges). Note the 
reference numbers for each counted adipocyte, which is associated with the 
corresponding area in the results sheet. 
d 
a b c 
e f 
g h 
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Figure 2. 2 Image processing and quantification of capillary density from whole 
mount adipose tissue. 
(a) Selected Z-planes illustrating raw images of AT samples stained with lectin (x10 
magnification). (b) Image stack is imported into Fiji software and the background is 
subtracted (Process/Subtract Background/Rolling Ball radius=5.0pixels). (c) A maximal 
intensity projection of the Z-stack is generated (Image/Stacks/Z Project/Max Intensity).  (d)  
Greyscale image is converted into a binary image (Process/Binary/Make Binary/ 
Method:Default, Background: Dark). The number of white pixels in the image are recorded 
(Plugins/Feature Extraction/Feature J/Feature J Statistics). 
a 
b 
c d 
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Figure 2. 3 Image processing and quantification of capillary growth from adipose 
tissue explants.  
(a) AT explant imaged under 2.5 magnification as a stack composed of 5 z planes at 
150µm intervals. (b) Same Z-planes after background is subtracted from the stack 
(Process/Subtract Background/Rolling Ball radius=5.0pixels). (c) Maximal intensity 
projection of the Z-stack (Image/Stacks/Z Project/Max Intensity). (d) Binarized image 
(Process/Binary/Make Binary/Method:Default; Background: Dark). The resulting numbers 
of pixels are recorded for each image (Plugins/Feature Extraction/FeatureJ/ FeatureJ 
Statistics). 
a 
b 
c d 
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Results 
Patient characteristics 
Relevant characteristics of the patients used for adipocyte size, capillary density, 
fibrosis and capillary growth assays are summarized in Table 2.1. Because the 
number of individuals in the type 2 diabetes category was small, comparisons 
were made only between the NGT and GDM groups. A trend for higher pre-
pregnancy and post-delivery BMI in individuals with GDM was noted but the 
difference was not statistically significant. While there was a statistically 
significant difference in age between the groups, none of the observed variables 
correlated with this variable. Nevertheless, the small sample size is a limitation of 
this study.  
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Characteristic NGT (n=15) GDM (n=6) 
Type 2 
diabetes 
(n=3) 
p value 
(NGT vs 
GDM) 
BMI  
pre-pregnancy 
(kg/m2) 
27.3 (6.2) 32.2 (6.2) 34.0 (6.6) 0.0895 
BMI at term 
(kg/m2) 30.6 (5.8) 33.8 (5.3) 37.4 (5.9) 0.241 
Age 
(years) 29.7 (4.1) 35.3 (4.6) 32.3 (5.5) 0.0119 
GWG 
(kg) 12.65 (3.9) 9.4 (6.1) 11.0 (4.4) 0.1531 
GWG-baby 
(kg) 9.1 (3.8) 5.8 (5.9) 7.9 (4.4) 0.1292 
Baby weight 
(kg) 3.53 (0.47) 3.68 (0.438) 3.07 (0.166) 0.7826 
Serum glucose 
(mmol/l)a 7.13 (2.29) 9.36 (2.78) N/A 0.0003 
Table 2. 1 Subject characteristics of pregnant cohorts. 
Data are presented as mean (SD). aSerum glucose measured at time of GDM screening. 
GWG, gestational weight gain; GWG-baby, gestational weight gain immediately after 
delivery of baby. 
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Parameter Value 
n 11 
Age (years) 41 (32-54) 
BMI at term (kg/m2) 45.4 (39-55) 
Fasting serum glucose (mg/dl) 92 (75-128) 
Fasting serum insulin (mIU/ml) 9.1 (3-14) 
HOMA-IR 1.4 (0.4-1.9) 
Table 2. 2 Patient characteristics of non-pregnant subjects included in Affymetrix 
analysis. 
Values are means, with range for each parameter shown in parenthesis. Data extracted 
from previously published parameters as described (Gealekman et al., 2011). 
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Adipocyte Size 
Adipocyte size was quantified (Figure 2.4). The mean cell size in OM AT was 
4,163 μm2 (SD 1,380μm2; n=13) in individuals with NGT, 7,482 μm2 (SD 
2,980μm2; n=5) in those with GDM and 6,849 μm2 (SD 1,060 μm2; n=3) in those 
with type 2 diabetes, with a statistically significant difference between the NGT 
and GDM group (p=0.019) (Figure 2.4b). OM AT from women with GDM 
contained an increased number of large adipocytes (as shown by a peak in the 
size distribution histogram above the mean value in Figure 2.4c, arrows). The 
difference in the frequency distribution between NGT and GDM was statistically 
significant (p=0.028). A similar trend was seen in samples from three type 2 
diabetes cases, also plotted but not analyzed due to the small sample size. The 
mean cell size in SQ AT was 7,066μm2 (SD 2,612μm2; n=15) in individuals with 
NGT, 9,045μm2 (SD 2,340μm2; n=5) in those with GDM and 9,102μm2 (SD 
2,503μm2; n=3) in those with type 2 diabetes. The difference between the NGT 
and GDM group was not statistically significant (p=0.178) (Figure 2.4b). A trend 
for larger adipocyte numbers in SQ tissue from individuals with GDM was seen in 
the size distribution histograms (Figure 2.4d), but the difference did not reach 
statistical significance. In women with NGT, adipocytes from OM AT (mean size 
4,178μm2; SD 1,440μm2; n=12) were significantly smaller (p=0.0005) than those 
from SQ AT (mean size 7, 581μm
2
; SD 2,672μm
2
; n=12); this difference was 
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eliminated in GDM (p=0.125) due to the increase in mean OM adipocyte size 
(mean size 7,482μm2; SD 2,980μm2; n=5) (Figure 2.4b). 
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Figure 2. 4 Enlarged adipocytes are observed in OM AT of GDM gravidas. 
(a) Representative images of H&E stained AT sections taken from individuals with NGT, 
GDM or type 2 diabetes (T2DM). Scale bar, 200μm. (b) Mean adipocyte size from OM 
(filled symbols) and SQ (white symbols) AT from women with NGT (blue circles), GDM 
(red squares) and type 2 diabetes (green triangles). (c, d). Size distribution of adipocytes 
from OM (c) or SQ (d) AT. Plots show the means and SEM at each bin size of women 
with NGT (blue circles), GDM (red squares) and type 2 diabetes (green triangles). 
Symbols show the means of each individual and lines represent the means and SEM of 
all individuals. *p<0.05 and ***p<0.001 for indicated comparisons. 
c d 
b a 
NGT 
GDM 
T2DM 
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The increase in mean OM adipocyte size in individuals with GDM could not be 
explained by an increase in BMI (Figure 2.5a) or gestational weight gain (Figure 
2.5b) but was highly correlated with serum glucose levels (Figure 2.5c), as was the 
maximal OM adipocyte size (Figure 2.5d). This finding is consistent with those of 
previous studies in non-pregnant individuals in which large adipocytes are 
associated with dyslipidemia as well as glucose and insulin abnormalities 
(Hoffstedt et al., 2010) (Veilleux, Caron-Jobin, Noël, Laberge, & Tchernof, 2011), 
revealing a similarity between a central AT feature in GDM and type 2 diabetes.  
  
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 5 OM adipocyte size has a positive correlation with serum glucose in 
pregnant women. 
(a-d) Linear regression analyses: BMI vs mean OM adipocyte size (r
2
=0.038; p=0.433) 
(a); gestational weight gain (GWG) vs mean OM adipocyte size (r
2
=0.149; p=0.651) (b); 
mean OM adipocyte size vs serum glucose (r
2
=0.505; p=0.0009) (c) and maximal OM 
adipocyte size vs serum glucose (r
2
=0.568; p=0.0003) (d). White circles, NGT; black 
circles, GDM.  
a b 
d 
d 
d c 
GDM 
NGT 
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Capillary density 
In parallel with the growth of adipocytes, the capillary network of AT must expand 
to sustain adipocyte function (Bouloumié, 2002) (Hausman & Richardson, 2004). 
Moreover, the vasculature of AT is a developmental niche for adipocyte 
precursors (Tran et al., 2012) and adequate angiogenesis may be a prerequisite 
for adipocyte hyperplasia. Capillary density was measured in lectin-stained whole 
mounts (Figure 2.6). The mean area of lectin staining (as % of total area) in OM 
AT was 21.3% (SD 5.0%; n=11) in individuals with NGT, 13.2% (SD 4.8%; n=5) 
in those with GDM and 16.6% (SD 4.5%; n=3) in those with type 2 diabetes, with 
a statistically significance difference between the NGT and GDM group (p=0.013) 
(Figure 2.6b). The mean area of lectin staining in SQ AT was 20.3% (SD 5.0%; 
n=18) in individuals with NGTs, 13.6% (SD 3.9%; n=5) in those with GDM and 
16.5% (SD 2.2%; n=3) in those with type 2 diabetes, with a statistically significant 
difference between the NGT and GDM group (p=0.039) (Figure 2.6b). 
Differences in capillary density could not be attributed to changes in adipocyte 
size, as the product of capillary density and adipocyte size remained significantly 
different (Figure 2.6c).  
  
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 6 Capillary density of OM and abdominal SQ AT is reduced in GDM 
gravidas. 
(a) Representative images of capillary density in rhodamine-lectin UEA-1-stained AT 
taken from individuals with NGT, GDM or type 2 diabetes (T2DM). Scale bar, 200μm. (b, 
c) Capillary density, shown as % of area (b) and as % of area × mean adipocyte size (c), 
in OM (filled symbols) and SQ (white symbols) AT taken from individuals with NGT 
(circles), GDM (squares), and type 2 diabetes (triangles). Symbols show the means for 
each individual and lines represent the mean and SEM of all individuals. *p<0.05 for 
indicated comparisons.  
c b 
a 
NGT 
GDM 
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Collagen content 
To explore other alterations in AT associated with metabolic disease, such as 
fibrosis (Divoux et al., 2010), we analyzed fixed sectioned tissue for collagen 
content using picrosirius red (Figure 2.7). No significant differences were 
detected between groups, possibly due to the lower BMI and early onset of 
metabolic disease in this population compared with previously studied bariatric 
surgery populations (Divoux et al., 2010) (Henegar et al., 2008).  
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Figure 2. 7 Collagen content in OM and abdominal SQ AT is not different between 
NGT and GDM gravidas. 
(a) Representative examples of AT sections stained with picrosirius red. Scale bar, 
200μm. (b) Intensity of picrosirius red staining. OM (filled symbols) and SQ (white 
symbols) AT taken from individuals with NGT (circles), GDM (squares), and type 2 
diabetes (triangles). Symbols show the means for each individual and lines represent the 
mean and SEM of all individuals. 
b 
a 
NGT 
GDM 
T2DM 
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Adipose tissue angiogenesis 
To gain insight into the causes that may underlie the observed changes in 
capillary density seen in GDM we measured the capacity of AT to form capillaries 
ex vivo (Figure 2.8). This assay measures the competence of endothelial cells 
and cells associated with the vasculature to grow under ideal angiogenic 
conditions where growth factors are optimally supplied in the growth medium. 
Thus, it can help distinguish between the effects of environmental factors (e.g. 
decreased levels of growth factors) and those of other inherent properties of the 
tissue (e.g. decreased number of progenitor cells). The mean growth density 
(number of pixels) for SQ and OM AT from individuals with NGT was 5.32×107 
(SD 2.43×107; n=12) and 3.34×107 (SD 2.34×107; n=13), respectively, with a 
statistically significant difference (p=0.033), consistent with our previous 
observations in non-pregnant obese individuals (Gealekman et al., 2011). 
However, no significant difference (p=0.882) was detected in OM AT when 
comparing individuals with NGT (3.34×107; SD 2.34×107; n=13) and those with 
GDM (2.94×107; SD 2.19×107; n=5) (Figure 2.8b). Also, no significant difference 
(p=0.349) was detected when comparing SQ AT explants from individuals with 
NGT (5.32×107; SD 2.43×107; n=12) with those from individuals with GDM 
(4.40×107; SD 2.09×107; n=6). The lower mean angiogenic potential seen in 
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tissues from two individuals with type 2 diabetes must be confirmed with a larger 
sample size.  
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Figure 2. 8 NGT gravidas demonstrate depot-specific differences in AT angiogenic 
potential. 
(a) Representative examples of capillary growth in AT (x2.5 magnification). (b) Capillary 
growth area density. OM (filled symbols) and SQ (white symbols) AT taken from 
individuals with NGT (circles), GDM (squares), and type 2 diabetes (triangles). Symbols 
show the means for each individual and lines represent the mean and SEM of all 
individuals. *p<0.05 for indicated comparisons.  
a 
b NGT 
GDM 
T2DM 
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Gene expression analysis 
To explore the mechanisms involved in AT growth in pregnancy, we compared 
previously acquired  Affymetrix gene arrays of SQ and OM AT from 11 non-
pregnant, non-diabetic women undergoing bariatric surgery (Gealekman et al., 
2011) (Table 2.2), with similar arrays of pregnant women with NGT (n=3 
individuals; BMI 20.4, 19.6 and 19.5 kg/m2). Numerous differences in gene 
expression were seen between OM and SQ AT depots, and between pregnant 
and non-pregnant groups (Figure 2.9a). The most differentially expressed gene 
when comparing AT from non-pregnant and pregnant women, for both OM and 
SQ AT, was IGFBP5. Further analysis of Affymetrix data revealed higher levels 
of IGFBP5 in the OM AT than in the SQ AT of non-pregnant women, with no 
correlation with BMI (Figure 2.9b). No changes in expression of IGFBP5 have 
been observed in SQ AT arrays from individuals with a BMI range of 16.7–50.2 
kg/m2 and normal or impaired glucose tolerance (Keller et al., 2011) (data set 
record GDS3961), supporting the notion that the induction seen in our study was 
due to pregnancy. The most significantly altered genes (p<0.0001) were used to 
identify pathways significantly associated with pregnancy. Kyoto Encyclopedia of 
Genes and Genomes (KEGG) identified the ‘protein processing in the 
endoplasmic reticulum’ and ‘protein export’ pathways as being enriched in 
differentially expressed genes (Table 2.3).  
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Figure 2. 9 Pregnancy induces changes in OM and abdominal SQ AT gene 
expression. 
(a) Heat map of 22,000 genes, and specific expression values for IGFBP5 in AT from non-
pregnant and pregnant women with NGT. Values for IGFBP5 (relative signal intensity) are 
shown. (b) Relationship between BMI and IGFBP5 levels in SQ (black triangles) and OM 
(white circles) AT from individuals used for the Affymetrix array. Adjusted p value 
****p<0.0001 for indicated comparison.  
a 
 
b SQ 
OM 
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Table 2. 3 KEGG pathways enriched in AT of pregnant women. 
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To verify the arrays, we conducted real-time PCR analysis of SQ AT from 
additional cohorts of non-pregnant women undergoing panniculectomy surgery 
(mean BMI 29.6 kg/m2; SEM 1.2 kg/m2; n=3), pregnant women with NGT (mean 
BMI 19.7 kg/m2; SEM 0.1 kg/m2; n=3) and pregnant women with GDM (mean 
BMI 34 kg/m2; SEM 4.6 kg/m2, n=3) (Figure 2.10). These results confirmed the 
marked induction of IGFBP5 by pregnancy seen in Affymetrix arrays and 
revealed a significant decrease in IGFBP5 and IGF-1 expression in tissue from 
individuals with GDM (Figure 2.10a). While this difference also coincided with a 
significant difference in BMI among the groups, the lack of correlation between 
IGFBP5 expression and BMI in the individuals used for Affymetrix gene chip 
analysis (Figure 2.9b), and between IGFBP5 expression and the BMI of non-
pregnant individuals and those with GDM (r2=0.28, p=0.278), suggests that the 
observed differences in IGFBP5 expression between individuals with NGT and 
GDM is independent of BMI. In addition to differences in IGFBP5, differences in 
the expression of IGF-1, IGFBP3, IGFBP4 and IGFBP6 were seen (Figure 
2.10a), revealing alterations in the IGF-1 signaling axis in AT in response to 
pregnancy and GDM. Moreover, the decrease in IGFBP5 and IGF-1 expression 
seen in GDM was not paralleled by changes in other key angiogenic factor 
genes, such as VEGFA and FGF2, nor by significant inflammatory alterations as 
inferred by unchanged gene expression of the macrophage marker CD-68 
(Figure 2.10b).  
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Figure 2. 10 Alterations in gene expression are observed in AT of GDM gravidas. 
(a) Real-time PCR analysis of SQ AT from non-pregnant women with NGT (white bars), 
pregnant women with NGT (black bars) and pregnant women with GDM (grey bars). 
Values are normalized to the lowest expressed transcript in the NGT group, which was 
IGFBP1. (b) Real-time PCR analysis of SQ AT from pregnant women with NGT (black 
bars) and pregnant women with GDM (grey bars). Values are normalized to the lowest 
expressed transcript in the NGT group, which was FGF2. Adjusted p values: *p<0.05, 
**p<0.01 and ****p<0.0001 for indicated comparisons.  
a 
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Non-pregnant 
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Discussion 
Adipocyte size is an indicator of the mode of AT expansion, which can occur 
through two distinct processes: adipocyte hypertrophy, where each adipocyte 
increases in size to contain a larger lipid droplet, and hyperplasia, where more 
adipocytes form through differentiation of precursor cells (Hoffstedt et al., 2010) 
(Tchoukalova et al., 2014). AT hyperplasia (small adipocytes) is significantly 
associated with better glucose, insulin and lipid profiles (Hoffstedt et al., 2010) 
(Veilleux et al., 2011). In contrast, large adipocytes are associated with 
dyslipidemia, glucose and insulin abnormalities (Hoffstedt et al., 2010) (Veilleux 
et al., 2011), are insulin resistant (JI Kim et al., 2015) and are prone to necrosis 
and inflammation. Hyperplasia may be more effective at increasing total AT mass 
and storage capacity, thus preventing deposition of deleterious lipid species in 
other organs and ensuing insulin resistance. Consistent with this possibility are 
data from obese mouse models in which AT containing small adipocytes leads to 
improved glucose homeostasis (JY Kim et al., 2007) (Lu, Li, Zou, & Cao, 2014). 
The relative hypertrophy of adipocytes in women with GDM, together with their 
trend to a lower gestational weight gain (Table 2.1), suggests a decreased 
capacity for hyperplastic adipocyte growth and AT expansion, with consequent 
negative effects on glucose and insulin homeostasis. Adipocyte progenitors are 
tightly associated with the AT capillary network (Han et al., 2011) (Tang et al., 
2008). Thus, the decreased capillary density seen in individuals with GDM could 
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underlie diminished pre-adipocyte proliferation and hyperplastic growth, with con- 
sequent hypertrophy of existing adipocytes. Insufficient vascular growth in the AT 
of individuals with GDM could also contribute to insulin resistance through 
hypoxia (Gealekman et al., 2011) (Spencer et al., 2011). Expression levels of the 
gene encoding angiopoietin-like 4 (ANGPTL-4), which is sensitive to hypoxia (Xin 
et al., 2013), were found to be elevated in GDM (Figure 2.10b), possibly 
indicating insufficient oxygenation. Other mechanisms could include failure of 
nutrient exchange or failure to deliver secreted hormones (adipokines) into the 
circulation.  
Previous studies from our group identified IGFBP4 as a potential key factor in AT 
expansion in response to a high-fat diet in mice (Gealekman et al., 2014). The 
marked upregulation of IGFBP5 seen in AT from pregnant women supports a 
similar role for the IGF-1 signaling pathway in adult AT expansion. IGFBP5 binds 
IGF-1 and IGF-2 with high affinity and has been shown in cell and animal models 
to inhibit signaling by sequestering these growth factors (Beattie et al., 2006). 
However, IGFBP5 also binds to the extracellular matrix of tissues, and can 
thereby serve as a local reservoir of IGF-1 (Beattie et al., 2006). The concurrent 
expression of IGFBP5 in AT and secretion of PAPP-A by the placenta suggests a 
mechanism whereby the local concentration of IGF-1 is increased in AT through 
interaction with IGFBP5 and release in response to PAPP-A secretion, thereby 
coordinating placental function with maternal AT expansion (Figure 2.11). 
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Abnormalities in this mechanism could potentially lead to impaired AT expansion 
and to lipotoxicity and metabolic disruption manifesting as GDM. This hypothesis 
is consistent with previous studies in which type 2 diabetes has been associated 
with abnormalities in SQ AT levels of the IGF-1 receptor and IGFBP3 (Yamada et 
al., 2010). While our current study is limited by sample size and by differences in 
age and BMI between groups, the large magnitude of the results presented 
support a new model to explore the mechanism of AT expansion in pregnancy 
and its role in the etiology of GDM.  
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Figure 2. 11 Potential role of IGFBP5 in AT expansion during gestation. 
(a) In non-pregnant women, IGFBPs sequester IGF-1 and IGF-2. Proteolysis of IGFBPs 
releases the growth factors, which act on AT vasculature and maintain tissue 
homeostasis. (b) In pregnancy, the induction of IGFBP5 increases the amount of 
sequestered IGF-1. The pregnancy-specific protease PAPP-A degrades IGFBP5 to 
release IGFs, promoting angiogenesis, pre-adipocyte proliferation and hyperplastic 
expansion. 
 
 
 
a 
b 
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CHAPTER III: PAPP-A mediated adipose tissue 
remodeling mitigates insulin resistance and protects 
against gestational diabetes in mice and humans 
   
Abstract 
Pregnancy is a unique physiological state in which the body must adapt to rapidly 
changing maternal and fetal nutritional needs. A known feature of pregnancy is the 
reduction of maternal insulin sensitivity allowing for appropriately enhanced 
glucose availability to the fetus. However, excessive insulin resistance results in 
maternal glucose intolerance and gestational diabetes mellitus (GDM), increasing 
the risk for pregnancy complications and predisposing both mothers and offspring 
to future metabolic disease. Here we report a previously unrecognized signaling 
pathway that plays a key role in mitigating insulin resistance in pregnancy. We 
show that in both mice and humans, pregnancy promotes adaptations in adipose 
tissue reflected by altered adipocyte size, vascularization and expansion capacity. 
We find that these adaptations are dependent on the pregnancy-associated 
plasma protein-A (PAPP-A), a metalloprotease secreted by human placenta that 
cleaves insulin-like growth factor binding proteins (IGFBP) 2, 4 and 5, and thus 
modulates insulin-like growth factor (IGF) bioavailability. We find levels of 
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circulating PAPP-A in humans are inversely correlated with glycemia and with the 
odds of developing GDM, and recombinant PAPP-A stimulates human adipose 
tissue expandability in vitro. Moreover, mice lacking PAPP-A display pregnancy-
induced insulin resistance, hepatic steatosis and impaired adipose tissue, thereby 
recapitulating the pathophysiology of human GDM. These data identify PAPP-A as 
a critical factor in the regulation of maternal adipose tissue physiology and 
systemic glucose homeostasis, with potential for therapeutic use.  
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Introduction 
Gestational diabetes mellitus (GDM) is one of the most common complications of 
pregnancy, affecting 240,000 U.S. pregnancies yearly, a number expected to 
increase to ~720,000 with potential changes in diagnostic criteria (Gariani et al., 
2019). GDM is associated with increased risk of obesity, metabolic syndrome 
and other cardiometabolic disorders in the offspring (Patel et al., 2012) (Wicklow 
et al., 2018) (Farahvar, Walfisch, & Sheiner, 2019) (Kampmann et al., 2018). 
Furthermore, as many as 50% of women with a GDM develop type-2 diabetes 
mellitus (T2DM) within 5 years (Kjos et al., 1995), and GDM elevates lifetime risk 
of T2DM 7-fold (Bellamy et al., 2009) (Kwak et al., 2013). Understanding the 
etiology of GDM is crucial for developing appropriate preventive and therapeutic 
strategies.  
 
The precise mechanisms underlying the development of GDM are not clear. 
Pregnancy is a state of rapid metabolic adaptation required to meet the 
nutritional needs of both mother and growing fetus, as well as anticipate those of 
the offspring which are met through maternal lactation. An increase in total 
adipose mass is characteristic of normal pregnancy (Eriksson, Löf, Olausson, & 
Forsum, 2010) (Kopp-Hoolihan et al., 2017) (Forsum, Sadurskis, & Wager, 1989) 
(Larciprete et al., 2003), with about 30% of recommended weight gain composed 
of fat mass. The mechanism underlying normal adipose tissue growth in 
83 
 
pregnancy, and its role in partitioning energy resources amongst mother, fetus, 
and offspring through lactation, has yet to be fully defined (Resi et al., 2012). 
Indeed, one of the major metabolic adaptations to pregnancy is a maternal 
decrease in insulin sensitivity, which is thought to facilitate glucose availability to 
the fetus. In non-pregnant subjects, adipose tissue plays a central role in 
regulating insulin sensitivity (Carobbio, Pellegrinelli, & Vidal-Puig, 2017), and 
there is increasing evidence that alterations in adipose tissue, including 
excessive visceral expansion (Shinar, Berger, De Souza, & Ray, 2019), changes 
in adipocyte size (Svensson et al., 2016) (Rojas-Rodriguez et al., 2015) and 
physiological inflammation (Resi et al., 2012) contribute to insulin resistance in 
human pregnancy and to GDM risk.  
 
The insulin-like growth factor (IGF) -1 and -2 signaling axis plays a central role in 
tissue growth through their interactions with the insulin and IGF-1 receptors 
(Roberts & Leroith, 1988). IGFs circulate at high levels relative to other peptide 
growth factors and their mitogenic activities are modulated via their tight 
association with one of seven different IGF binding proteins, IGFBPs 1-7 (Holly, 
2004) (Haruki Nishizawa et al., 2008). The IGF/IGFBP system has been 
implicated in regulating adipose tissue growth (Garten et al., 2012) (Hoeflich et 
al., 1999) (Maridas, DeMambro, Le, Mohan, & Rosen, 2017) and may play a 
special role in adipose tissue adaptation in pregnancy, as levels of subcutaneous 
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and omental IGFBP4 and IGFBP5 are increased in human pregnancy (Resi et 
al., 2012) (Rojas-Rodriguez et al., 2015). IGFBPs increase local availability of 
IGFs by preventing their clearance, but also impair productive binding with their 
receptors. Receptor binding of IGFs and induction of mitogenic signaling is 
dependent on the proteolytic degradation of IGFBPs.  
 
The pregnancy-associated plasma protein A, PAPP-A, has been shown to 
account for the vast majority of proteolytic activity for IGFBP4 in serum from 
pregnant women (Byun et al., 2001) (Overgaard et al., 2000), and is a critical 
factor for early development in mice (Conover et al., 2004). While the vast 
majority of total and proteolytically active circulating PAPP-A in humans is 
derived from the uterus (Bischof, 1984), a significant amount is expressed in 
other tissues, including adipose tissue (Conover, Bale, Frye, & Schaff, 2019). In 
mice, Papp-a is expressed at high levels independent of pregnancy (Qin et al., 
2002), but it has an important developmental role during gestation, as its ablation 
results in proportional dwarfism which is rescued by Igf-2 expression (Bale & 
Conover, 2005). In addition to its role in development, Papp-a has important 
roles in adult animals, as evidenced by alterations in neointimal development and 
increased longevity in mice with Papp-a ablation in adulthood (Conover, Bale, & 
Powell, 2013) (Bale, West, & Conover, 2017). The concomitant induction of 
IGFBPs in adipose tissue and high levels of circulating PAPP-A in human 
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pregnancy suggested the possibility that the IGF-IGFBP-PAPP-A axis would play 
a role in the adaptation of adipose tissue to pregnancy, and in consequent 
modulation of metabolic homeostasis. In this paper, we leverage in vitro model 
systems to quantify human adipose tissue expandability, retrospective population 
data and mouse knockout studies to further investigate this hypothesis.  
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Methods 
Study cohorts 
For Affymetrix analysis, cohorts were as described previously (Gealekman et al., 
2011) (Table 2.2). For analysis of adipose tissue features, all normoglycemic 
pregnant women with singleton gestations scheduled for cesarean section, and 
non-pregnant normoglycemic women without hypertension presenting to 
University of Massachusetts Memorial Health Care (UMMHC) between June 
2015 and November 2016 were considered for enrollment. The Institutional 
Review Board (IRB) from the University of Massachusetts Medical School 
(UMMS) approved the study, and all participants were provided and signed 
informed consent. Diabetes status in the pregnant cohort was classified 
according to the Carpenter-Coustan criteria. The exclusion criteria included, type-
1 and type-2 diabetes mellitus, underweight BMI (<18.5kg/m2, pre-gestational 
BMI in Preg cohort), use of illicit substances including replacement products, 
HIV/AIDS, hepatitis B or C, autoimmune disease, chronic steroid use, age <18 
and >45 years, and plans to move out of the area during study period. Exclusions 
specific to pregnant cohort included multiple gestations, initiated prenatal care 
after 13 completed gestational weeks, alcohol use, and previous diagnosis of 
T2DM.  
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To determine the relationship between serum PAPP-A and glycemic status, 
defined as normal glucose tolerance (NGT), abnormal glucose tolerance (AGT) 
and gestational diabetes mellitus (GDM), retrospective analyses of the electronic 
health records of all pregnant women with singleton gestations who delivered at 
UMMHC from June 2009 to March 2015 and had PAPP-A results were 
performed. The IRB of the UMMS approved the study. Gravidas were classified 
according to the Carpenter-Coustan criteria; NGT is defined as gravidas without 
pre-gestational diabetes and with passing value on routine 50g glucola screening 
(≤140mg/dl) or ≤1 abnormal value (fasting≥95, 1hr≥180, 2hr≥155, 3hr≥140mg/dl) 
on 100g 3hr glucose tolerance test (GTT); AGT included gravidas without pre-
gestational diabetes and with failed value on routine 50g glucola screening 
(>140mg/dl), independent on the value of 100g 3hr GTT; GDM included gravidas 
without pre-gestational diabetes and with failed value on routine 50g glucola 
screening (>140mg/dl), and ≥2 abnormal values (fasting≥95, 1hr≥180, 2hr≥155, 
3hr≥140mg/dl) on 100g 3hr GTT. Women with pre-gestational type 1 or type 2 
diabetes, multiple gestation, and chronic hypertension were excluded from this 
study. Additionally, women who were missing critical data (e.g. prepregnancy 
height and weight, evidence of GDM screen) or had missing or unknown relevant 
demographics of interest (e.g. smoking status, maternal age, parity, 
race/ethnicity) were also excluded. Finally, for women with more than one 
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pregnancy during the study period, one pregnancy was selected at random for 
inclusion in analysis.  Our final analytic sample included 6,361 women.  
For analysis of the correlation between PAPP-A and serum glucose, all records 
containing PAPP-A and glucose values from routine 10-14-week aneuploidy and 
24-28-week GDM screens (50g glucose 1h test), respectively, were extracted 
using Epic EHR v. 2018. In order to allow comparison of serum PAPP-A across 
different gestational ages, PAPP-A data was also presented as multiples of the 
median (MoM). PAPP-A MoM was calculated using the gestational mean for our 
center adjusting for maternal weight, ethnicity, and smoking status. Data from 
subjects complying with the inclusion/exclusion criteria defined above were used 
for regression analysis. This sample reflects the population of Central 
Massachusetts.  
Human adipose tissue collection 
For the pregnant cohort, specimen collection was done at the time of cesarean  
section after delivery of the baby. Prior to skin closure, two samples (1 cm × 1 
cm) of subcutaneous (SQ) adipose tissue (AT) were obtained from within the 
surgical incision usually placed approximately 2 cm above the pubic bone 
(Pfannenstiel incision). In the case of repeat Caesarean delivery, SQ AT biopsies 
were taken from deep within the incision to decrease scar tissue sampling. For 
the non-pregnant cohort, specimen collection was done at the Clinical Trials Unit 
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of UMMS during a scheduled site visit. SQ AT needle biopsies were obtained 
from anterior abdominal wall just lateral and inferior to the umbilicus, both away 
from blood vessels and scars. For acquiring the AT specimens, a 60ml BD 
syringe with 14-gauge needle filled with 30ml of normal saline was used. 
Approximately, 1g of AT was collected.  
Affymetrix arrays  
For transcriptomic analysis, total RNA was extracted using the RNeasy Lipid 
Tissue Mini kit (Qiagen, Valencia, CA, USA). The GeneChip Human Genome 
U133A 2.0 Array was employed for analysis of cRNA, which was obtained 
following manufacturer supplied protocols (Affymetrix, Santa Clara, CA, USA). 
Raw expression data collected from an Affymetrix HP GeneArrayScanner was 
normalized across all data sets using the RMA algorithm. Differential expression 
was performed using Limma as implemented in DEBrowser (Kucukural, 
Yukselen, Ozata, Moore, & Garber, 2019). Hierarchical clustering was done 
using Morpheus (https://software.broadinstitute.org/morpheus/). For pathway 
enrichment, the list of differentially expressed genes was uploaded to ToppGene 
(J. Chen, Bardes, Aronow, & Jegga, 2009) via the ToppFun uploader. ToppFun 
default parameters were used to generate pathway lists, which were considered 
to be significantly enriched if the p-adjusted value was less than 0.05.  
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Analysis of adipocyte size 
Samples were fixed in 4% formaldehyde and embedded in paraffin. Eight- 
micrometer sections were mounted on Gold Seal microscope slides (Fisher 
Scientific, Pittsburgh, PA, USA), and stained with hematoxylin and eosin (H&E). 
Investigators acquiring the images were blinded to the origin of the sample.  
Brightfield images were acquired using a 5X (for human studies) or 10X (for 
mouse studies) objective on a Zeiss Axiovert 35 microscope and a Zeiss 
AxioCam ICc1 digital camera. Adipocyte size was determined using an 
automated procedure based on the open software platform Fiji (Schindelin et al., 
2012) (as described in Figure 2.1)  
Analysis of microvasculature 
Samples were fixed in 4% formaldehyde and rinsed in phosphate-buffered saline 
(PBS). Samples were cut in 1mm fragments and stained with rhodamine-labeled 
Ulex Europaeus Agglutinin I (UEA-1) (Vector Labs, Burlingame, CA, USA) for 1h 
at room temperature and then mounted on Gold Seal microscope slides, sealed 
with Pro-Long Gold Antifade Mountant (Life Technologies, Grand Island, NY, 
USA) and covered with 1.5 mm coverslips. Images were taken under 5X 
magnification in a Zeiss Axiovert 200M microscope equipped with Zeiss AxioCam 
HRm digital camera. Quantification of capillary connectivity was done using an 
algorithm for connected regions implemented in Image J 
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(http://homepages.inf.ed.ac.uk/s9808248/imagej/find-connected-regions/). 
Images of UEA-1 stained explants were converted into 8 bit and background 
corrected prior to applying the algorithm. Results quantifying the number and 
mean size of regions in each image were recorded. All image acquisition and 
analysis were done by operators blinded to the origin of the samples.  
In vitro adipose tissue expandability assay 
The in vitro expandability assay (adipose tissue angiogenesis) was done as 
described previously (Rojas-Rodriguez et al., 2015). Briefly, AT samples were cut 
into 1mm3 pieces and embedded in Matrigel (Corning, Bedford, MA, USA) using 
single wells of a 96-well template plate. AT explants were cultured under 
proangiogenic conditions for 11 days using EGM-2MV media (Lonza, Allendale, 
NJ, USA). Imaging was done at day 7 and day 11 after embedding using a Zeiss 
Axio Observer Z1 equipped with an automated stage and a Clara High 
Resolution CCD Camera (Andor, Concord, MA, USA). Images were taken under 
×2.5 magnification as a stack composed of five Z planes at 150μm intervals and 
as a canvas of four quadrants per well and then combined into a single three-
dimensional image. Image processing for capillary sprouting quantification 
included background subtraction, maximal intensity projection of the Z-stack and 
binarization (Figure 2.3). For analysis of effects of PAPP-A in vitro, recombinant 
human PAPP-A (R&D Systems, Minneapolis, MN, USA) was added as described 
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in each figure legend (Figure 3.9).  All image acquisition and analysis were done 
by operators blinded to the origin of the samples.  
Animal husbandry and pregnancy 
All procedures were approved by UMMS Institutional Animal Care and Use 
Committee. The experimental animals used in this study were homozygous 
Papp-a (+/+) (wild type, WT) and Papp-a (-/-) (knockout, KO) littermates obtained 
from crosses of heterozygous Papp-a (+/- ) mice (Conover et al., 2004). All mice 
were fed normal chow diet (22% protein and 5% fat, Isopro 3000) ad-libitum and 
housed under controlled temperature and 12-hour light/dark cycle conditions. For 
all experiments, 10-12 week old mice were used. For the pregnancy 
experiments, homozygous WT or KO animal trios consisting of 1 male and 2 
females were housed together. Presence of vaginal plug was considered as day 
1 of gestation. After visualization of plug, females were separated from males. All 
experiments with pregnant animals were carried out at day 16 of gestation.   
Metabolic phenotyping of Papp-a mice 
Whole body composition assessment of fat and lean mass was done in 
conscious mice utilizing 1H-MRS technology (Echo Medical Systems, Houston, 
TX, USA). For the glucose tolerance test, pregnant dams and non-pregnant 
controls were fasted for 6 hours (8:00am-2:00pm). Small blood samples (~5ul) 
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were obtained from tail vein at 0, 15, 30, 45, 60, 90, and 120 min after 
intraperitoneal (IP) injection of glucose (2g/kg dose from 20% w/v glucose 
solution, Sigma, St Louis, MO, USA). Blood glucose was measured using One 
Touch Ultra 2 glucose meter (Lifescan, Milpitas, CA, USA). For the insulin 
tolerance tests, pregnant dams and non-pregnant controls were fasted for 4.5 
hours (8:00am- 12:30pm). Small blood samples (~5ul) were obtained from tail 
vein at 0, 15, 30, 45, 60, and 90min after IP injection of insulin (0.65u/kg dose, 
Novolin R, Novo Nordisk, Bagsværd, Denmark). Blood glucose was measured 
using One Touch Ultra 2 glucose meter (Lifescan). For insulin secretion 
measurements, pregnant dams and non-pregnant controls were fasted for 6 
hours (8:00am- 2:00pm). Blood samples (~50ul) obtained from tail vein at 0 and 
45 min after IP injection of glucose (2g/kg dose from 20% w/v glucose solution, 
Sigma) were collected in capillary tubes and transferred to EDTA coated 
microtubes. Plasma was obtained by centrifugation at 2000g for 10min at 4°C. 
Insulin concentrations were determined in each sample by a commercial 
ultrasensitive ELISA (Alpco, Salem, NH, USA). Hyperinsulinemic-euglycemic 
clamps were conducted in the National Mouse Metabolic Phenotyping Center at 
UMASS according to established methods (J Kim, 2009).  
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Mouse tissue collection 
Collection of inguinal, axillar, parametrial distal and proximal to uterine horn, 
periovarian, retroperitoneal, mesenteric, interscapular brown adipose tissue and 
liver was performed using sterile microsurgery instruments. The weight of all 
depots and tissues was recorded using an analytical balance, and tissues were 
then flash frozen for further analysis.  
Mouse mammary gland whole-mount staining 
For visualization of the three-dimensional structure of mammary gland 
development in pregnant mice, mammary gland tissue along the inguinal and 
axillar fat pad was excised. Whole-mount staining was done with carmine alum, a 
nuclear stain that allows the detection of epithelial structures embedded in the 
adipose tissue of the mammary fat pads (Plante, Stewart, & Laird, 2011). The 
protocol consisted on fixing the excised tissue in Carnoy's fixative (100% EtOH, 
chloroform, glacial acetic acid; 6:3:1) overnight at 4°C, followed by a wash in 
70% ethanol and rehydration steps. Then, whole mounts samples were stained 
overnight with carmine alum at room temperature. Excess staining was removed 
by a serial of dehydrating ethanol baths and clearing in xylene overnight. Last, 
mammary glands were immersed in methyl salicylate prior to examination. 
Images of the mammary gland were taken with a digital camera attached to a 
Nikon SMZ800 stereomicroscope. 
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Quantitative real-time PCR  
Total RNA was isolated from AT utilizing the Lipid Tissue Mini Kit (Qiagen). One 
microgram of total RNA was reverse-transcribed using iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA, USA). cDNA was used as template for real-time PCR 
using the iQ SYBR Green Supermix kit (Bio-Rad) and the CFX96 Real-Time 
System (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was 
used for normalization of each sample. Values were expressed as the fold 
difference of the lowest value in each data set.  
Triglyceride analysis 
Liver samples were homogenized in 5% Nonidet P40. Homogenates were 
heated at 80-100°C for 2 min and cooled to room temperature (RT) on ice. This 
step was repeated and then followed by centrifugation (12000g, 10min, RT). The 
supernatant was used to measure triglyceride content following the protocol from 
L-type triglyceride M assay (Fujifilm Dako Diagnostics, Richmond, VA, USA).  
Statistical analysis 
Statistical analysis was performed using the following tests as implemented in 
GraphPad Prism v.8.0, and specific tests are described in each figure legend. 
Difference of histograms was calculated using the Wilcoxon matched pairs test 
as implemented in GraphPad Prism 8, and individual p values for differences at 
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each size range calculated using multiplicity adjusted (Sidak) student t-tests. 
Statistical significance between groups was estimated using ordinary one-way 
ANOVA corrected for multiple comparisons using the Sidak test. For contingency 
analyses, statistical significance between comparisons to the highest quartile 
was done using Fisher’s exact test. Statistical significance of the difference 
between control and treated explants was calculated using paired student t-tests. 
Statistical significance of the difference between doses at each timepoint was 
calculated using repeated measures two-way ANOVA. Statistical significance of 
the differences between fat depot, genotype and pregnant state for each gene 
were calculated using three-way ANOVA corrected for multiple comparisons 
using the Tukey test.  
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Results 
Patient characteristics 
Relevant characteristics of the patients used for adipocyte size, 
microvasculature, and in vitro adipose tissue expandability assays are 
summarized in Table 3.1.  There was not a statistically significant difference in 
age, BMI, or smoking status between the non-pregnant and pregnant cohorts. 
Although there was not a significant difference in race between groups, most of 
the subjects in both cohorts were white. 
Cohorts characteristics for the subjects included in the retrospective analysis of 
serum PAPP-A and diabetes status are included in Table 3.2. There was a 
statistically significant difference between age, BMI, and parity between groups. 
Notably, there was diversity in the races included in the study but the majority of 
the women were white. No difference between smoking status was observed 
between cohorts.  
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Table 3. 1 Patient characteristics of cohorts included in adipose tissue analysis. 
Data are presented as mean and percent of the subjects included in the study. 
 
Characteristic Total (n=25) 
Non-pregnant 
(n=12) 
Pregnant 
(n=13) p value N % N % N % 
Age (Mean, SD) 31.5 5.6 31.7 7.1 31.2 4.1 0.978 
BMI (pre-pregnancy 
or at biopsy) 
  
   Normal range 5 20.0% 1 8.3% 4 30.8% 
0.267    Overweight 9 36.0% 6 50.0% 3 23.1% 
   Obese 11 44.0% 5 41.7% 6 46.2% 
Race   
   White 21 84.0% 11 91.7% 10 76.9% 
0.48 
   Asian 1 4.0% 0 0.0% 1 7.7% 
   Black or African     
   American 2 8.0% 0 0.0% 2 15.4% 
   Other race 1 4.0% 1 8.3% 0 0.0% 
     Hispanic, Latino,    
     or Spanish origin 
  
     No, not of   
     Hispanic, Latino,    
     or Spanish origin 
20 80.0% 9 75.0% 11 84.6% 
0.071      Yes, Puerto Rican 2 8.0% 0 0.0% 2 15.4% 
     Yes, another  
     Hispanic, Latino or  
     Spanish origin  
3 12.0% 3 25.0% 0 0.0% 
Ever smoked   
   No 16 64.0% 8 66.7% 8 61.5% 0.999    Yes 9 36.0% 4 33.3% 5 38.5% 
Current smoker   
   No 23 92.0% 11 91.7% 12 92.3% 
0.999 
   Yes 2 8.0% 1 8.3% 1 7.7% 
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Table 3. 2 Population characteristics of subjects included in retrospective analysis 
of serum PAPP-A and glycemic state. 
Data are presented as mean and percent of the subjects included in the study. 
 
 
 
Characteristic 
Total 
(n=6361) 
GDM status 
p 
value 
NGT 
(n=5,703) AGT (n=298) GDM (n=360) 
n or 
mean % 
n or 
mean % 
n or 
mean % 
n or 
mean % 
Age (Mean) 29.8 5.7 29.5 5.7 31.8 4.9 32.4 4.9 <0.001 
Gestational 
age (Mean) 12.5 0.6 12.5 0.6 12.5 0.7 12.5 0.5 0.652 
BMI Categories    
< 18.5 198 3.1% 186 3.3% 6 2.0% 6 1.7% 
<0.001 18.5 to < 25.0 3,042 47.8% 2,823 49.5% 117 39.3% 102 28.3% 25.0 to < 30.0 1,757 27.6% 1,574 27.6% 83 27.9% 100 27.8% 
>= 30.0 1,364 21.4% 1,120 19.6% 92 30.9% 152 42.2% 
Race   
Asian 527 8.4% 416 7.4% 50 17.1% 61 17.2% 
<0.001 
Black 473 7.5% 418 7.4% 17 5.8% 38 10.7% 
Caucasian/white 4,049 64.2% 3,692 65.3% 181 61.8% 176 49.6% 
Hispanic/Latino 577 9.2% 520 9.2% 21 7.2% 36 10.1% 
Other 680 10.8% 612 10.8% 24 8.2% 44 12.4% 
Cigarette 
smoker   
No 5,724 93.3% 5,122 93.1% 276 94.5% 326 95.0% 
0.133 Smoker 411 6.7% 378 6.9% 16 5.5% 17 5.0% 
Parity   
Nulliparous 2,763 43.4% 2,519 44.2% 107 35.9% 137 38.1% 
0.002 
Multiparous 3,598 56.6% 3,184 55.8% 191 64.1% 223 61.9% 
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Adaptations of adipose tissue during pregnancy in humans 
To characterize the changes that occur in adipose tissue during pregnancy, we 
compared total gene expression of subcutaneous (SQ) and omental (OM) 
adipose tissue obtained during cesarean section from normoglycemic pregnant 
subjects with those of non-diabetic, non-pregnant subjects obtained during 
gastric bypass surgery as described previously (Rojas-Rodriguez et al., 2015) 
(Gealekman et al., 2011) (Table 2.1 and Table 2.2) . We reanalyzed this data set 
using hierarchical clustering of the 1200 genes displaying the highest median 
absolute deviation among the four groups. This analysis resulted in four distinct 
clusters, segregated by both depot and pregnancy state (Figure 3.1a). Among 
the genes defining these clusters were a set that was highly enriched in 
pregnancy in both subcutaneous and omental depots (Figure 3.1a, bracket). To 
identify the specific genes and pathways modified by pregnancy in both depots, 
we performed differential expression analysis (Figure 3.1b,c). IGFBP5 was the 
most upregulated gene, increasing by more than 60-fold and 20-fold in 
subcutaneous and omental adipose depots, respectively (Figure 3.1b,c). Notably, 
pathway enrichment analysis identified a central regulatory arm of the IGF 
signaling axis, the growth hormone receptor signaling pathway, among other 
significantly enriched pathways related to metal binding, IL-6 signaling, and heat 
stress response. (Figure 3.1d).  
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Figure 3. 1 Analysis of adipose tissue global gene expression changes highlights a 
particular transcriptomic signature associated with pregnancy. 
(a) Hierarchical clustering of genes expressed in subcutaneous (SQ) or omental (OM) 
adipose tissue of non-pregnant or pregnant women. (b,c) Volcano plots of genes 
modulated by pregnancy in both depots, as expressed in each depot; IGFBP genes 
detected are highlighted. (d) KEGG enrichment analysis of genes modulated by 
pregnancy in both depots.  
 
a b c 
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To distinguish adipose tissue responses specific to pregnancy relatively 
independent of BMI, we obtained a separate cohort of samples by needle biopsy 
of SQ adipose tissue from weight matched non-pregnant women (Table 3.1). The 
changes in adipocyte size and number are presented in Figure 3.2. The mean 
adipocyte size was significantly altered by pregnancy and it was the major 
change between cohorts (Figure 3.2b). This difference is attributable to adipocyte 
hypertrophy (Figure 3.2c), with a negligible decrease in the number of small 
adipocytes, suggesting compensatory hyperplasia during pregnancy.  
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Figure 3. 2 Adipocyte size changes are observed in human pregnancy. 
(a) Representative H&E stains of SQ adipose tissue sections from a non-pregnant (above) 
and a pregnant (below) subject with similar BMIs (26). (b,c) Mean adipocyte size (b) and 
frequency size distributions (c) from H&E stains of adipose tissue sections. Adipocytes 
were measured in 5-10 slides from each subject, and the mean and SEM of each subject 
depicted in the plots. Difference of histograms was calculated using the Wilcoxon matched 
pairs test as implemented in GraphPad Prism 8, and individual P values for differences at 
each size range calculated using multiplicity adjusted (Sidak) student t-tests.  
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As adipose tissue is densely vascularized and adipocyte progenitors are 
localized along the adipose tissue vasculature, we examined whether pregnancy 
would induce changes in the microvasculature by staining tissue fragments with 
lectin. This staining yielded qualitative changes in the microvasculature, with 
decreased homogeneity of vessel diameter and discontinuity and tortuosity of 
vessel structure in pregnant subject biopsies (Figure 3.3a). To quantify these 
observations, we applied an imaging algorithm to measure connectivity between 
regions. The microvasculature from pregnant women was less connected 
compared to that of non-pregnant women, as determined by a decrease in region 
size per image and an increased in total regions per image (Figure 3.3b-d). 
These results reveal that human adipose tissue adapts to pregnancy with a 
robust increase in expression of IGF signaling pathway genes, specifically 
IGFBP5, and with hypertrophy, hyperplasia and changes in microvasculature 
dynamics.  
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Figure 3. 3 Human gestation is accompanied by alterations in the microvasculature 
architecture of adipose tissue. 
(a) Whole mount lectin staining of adipose tissue from a non-pregnant (above) and a 
pregnant (below) subject with similar BMIs (30). Arrows in magnified area indicate 
discontinuity, and arrowheads lectin positive cells separated from vessel structures seen 
in images from pregnant subjects. (b) Continuous regions detected in the image using 
Image J connected regions algorithm. (c) Maximal region size and (d) number of regions 
measured in 5-10 whole mount images from each subject, and the mean and SEM of each 
subject depicted in the plots. Statistical significance of the difference between pregnant 
and non-pregnant was calculated using student t-tests.  
  
a b 
c d 
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PAPP-A levels are directly associated with glycemic control in human pregnancy 
If the IGFBP/IGF axis in adipose tissue is important for the regulation of glucose 
homeostasis during pregnancy, we reasoned that circulating levels of PAPP-A, 
which increases in proportion to placental growth and specifically cleaves 
IGFBPs 2, 4 and 5, would be associated with glycemia and/or disrupted glucose 
metabolism. Levels of circulating PAPP-A were significantly lower in serum 
samples of pregnant subjects with abnormal glucose tolerance (AGT) and GDM 
compared to those with normal glucose tolerance (NGT) (Table 3.2 and Figure 
3.4 a). We separated all PAPP-A serum values in the population into quartiles 
(Figure 3.4b) and calculated the odds of AGT and GDM occurring in each PAPP-
A quartile. Compared to the highest quartile of PAPP-A the odds of AGT (Figure 
3.5a) and GDM (Figure 3.5b) significantly increased as the value of PAPP-A 
decreased.  
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Figure 3. 4 First trimester serum PAPP-A levels are decreased in AGT and GDM 
gravidas. 
(a) Violin plots of PAPP-A levels at 10-14 weeks of gestation in women categorized as 
normal glucose tolerance (NGT, n=5601), abnormal glucose tolerance (AGT, n=284), and 
gestational diabetes (GDM, n=345) at week 24-28 of gestation. Statistical significance was 
estimated using ordinary one-way ANOVA corrected for multiple comparisons using the 
Sidak test. Median and quartile values are indicated. b. Range of PAPP-A values 
comprising each quartile.  
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Figure 3. 5 Low first trimester serum PAPP-A is associated with the presence of 
abnormal glucose tolerance and gestational diabetes later in gestation.  
(a,b) Odds ratio and 95% CI for AGT (a) or GDM (b). Statistical significance between 
comparisons to the highest quartile was done using Fisher’s exact test.  
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PAPP-A results are routinely expressed as multiples of the median (MOM) in 
order to compare values across different gestational ages, as well as factors 
strongly associated with increased diabetes risk in non-pregnant populations- 
BMI, ethnicity and smoking status. Despite these adjustments we find that the 
odds of GDM significantly increased as the quartile of serum PAPP-A MOM 
decreased (Figure 3.6) compared to the highest quartile, indicating that PAPP-A 
MOM is related to the odds of developing gestational diabetes independent of 
other factors related to diabetes in general.  
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Figure 3. 6 Low first trimester PAPP-A MoM is associated with the development of 
gestational diabetes later in gestation. 
Odds ratio and 95% CI of GDM at different quartiles of PAPP-A MOM. Statistical 
significance between comparisons to the highest quartile was done using Fisher’s exact 
test.  
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To test PAPP-A association with systemic glucose metabolism independent of 
other factors, we compared serum PAPP-A MOM with blood glucose values after 
1h of a 50g dextrose load in subjects diagnosed with normal glucose tolerance. 
We observed a linear, inverse relationship between PAPP-A MOM values and 
glucose levels (Figure 3.7).  
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Figure 3. 7 PAPP-A MoM has a negative correlation with 1 hr glucose values of 
normoglycemic pregnant women. 
Linear regression between PAPP-A MOM and 1-hr glucose values at week 24-28 of 
gestation (n=862).  
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Human adipose tissue expandability is increased in pregnancy and stimulated by 
PAPP-A  
To directly explore whether PAPP-A cleavage of IGFBPs could mediate our 
observed pregnancy-induced adaptations of adipose tissue, we used an in vitro 
system that measures adipose tissue expandability. When small fragments of 
human adipose tissue are implanted in MatriGel and cultured in EGM2-MV 
medium, endothelial and mesenchymal progenitor cells emerge and proliferate, 
gradually covering a larger area around the explant. The area of the capillary 
growth covered by the sprouting cells is a surrogate measure of adipose tissue 
expandability, varying as a function of depot of origin and physiological state of 
the donor (Gealekman et al., 2011). We found that explants from subcutaneous 
adipose tissue from pregnant women display greater expandability compared to 
those from non-pregnant women (Figure 3.8), consistent with evidence of 
increased hyperplasia (Figure 3.2). Moreover, subcutaneous adipose tissue 
explants from pregnant women cultured in the presence of recombinant human 
PAPP-A displayed significantly greater growth area compared to vehicle control 
(Figure 3.9a). The effect of recombinant PAPP-A was dose dependent and 
increased over time in culture (Figure 3.9b). These results demonstrate that 
PAPP-A can directly stimulate adipose tissue expandability and are consistent 
with a direct effect in mediating the adaptations of adipose tissue in pregnancy.  
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Figure 3. 8 In vitro adipose tissue expandability is enhanced in pregnant women. 
(a) Representative images of sprouts emerging from adipose tissue explants obtained 
from normoglycemic non-pregnant or pregnant women. Images were taken at 7 and 11 
days of culture. (b) Quantification of sprouting area from AT explants at the indicated 
timepoints. Between 10-30 explants were embedded for each subject, and each symbol 
represents the mean sprouting area of all explants per subject. Plotted are the means and 
SEM of non-pregnant and pregnant subjects. Statistical significance of differences 
between groups was quantified using unpaired, two-tailed student t-tests.  
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Figure 3. 9 PAPP-A stimulates in vitro adipose tissue expandability in pregnant 
women. 
(a) Explants from four pregnant women (n=5-10 explants per subject) were 
cultured in the presence of recombinant human PAPP-A (rhPAPP-A, 600ng/ml) or 
vehicle control. Statistical significance of the difference between control and 
treated explants was calculated using paired student t-tests. (b) Mean and SEM of 
the sprouting area of 5-10 explants from 4 separate subjects treated with vehicle 
control or in the presence of the indicated concentration of recombinant human 
PAPP-A (rhPAPP-A) for the times shown. Statistical significance of the difference 
between doses at each timepoint was calculated using repeated measures two-
way ANOVA.  
 
 
 
a b 
116 
 
Papp-a deletion in mice prevents pregnancy-associated adipose tissue 
remodeling  
To directly test the role of PAPP-A in remodeling adipose tissue during 
pregnancy in vivo, we studied mice in which the Papp-a gene was ablated (KO). 
These mice have been characterized as proportional dwarfs, being viable and 
fertile but exhibiting only 60% of wild-type (WT) size (Conover et al., 2004). 
Pregnancy induced a similar proportional increase in body weight in WT 
littermate controls and KO mice (Figure 3.10a) which was attributable to an 
increase in lean body mass with no significant change in fat mass (Figure 
3.10b,c) consistent with studies of pregnancy in C57BL6 mice (Qiao et al., 2019). 
As a percent of total (lean + fat mass), lean and fat mass are affected by 
pregnancy to a similar extent between WT and KO mice (Figure 3.11).  
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Figure 3. 10 Pregnancy increases body weight and lean mass in WT and Papp-a KO 
mice. 
(a) Body weight, (b) total lean mass, and (c) total fat mass from non-pregnant or pregnant 
wild-type (NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). 
Statistical significance was assessed using ordinary one-way ANOVA corrected with the 
Sidak test for multiple comparisons.  
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Figure 3. 11 Pregnancy decreases fat mass percent in WT and Papp-a KO mice. 
(a) Lean mass and (b) fat mass percent from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fat and lean mass 
percent were calculated by normalizing to lean + fat mass. Statistical significance was 
assessed using ordinary one-way ANOVA corrected with the Sidak test for multiple 
comparisons.  
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To examine pregnancy-induced adipose tissue adaptations and the role of Papp-
a, we dissected and analyzed all discernable depots in WT and KO pregnant and 
non-pregnant mice, following the guidelines published by S. Cinti (Cinti, 2015) 
(Figure 3.12). 
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Figure 3. 12 Anatomical localization of the adipose organ. 
Representative figure of the anatomical localization for the fat pads analyzed (adapted 
from (Cinti, 2015)).  
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The largest depot was the parametrial, which was comprised of a proximal and 
distal sections relative to the uterine horn. In WT mice, pregnancy caused a 
decrease in the mass of all depots with the exception of axillary and interscapular 
brown adipose tissue (iBAT) depots. However, with the exception of the inguinal 
depot, we did not see pregnancy-induced changes in depot mass in the KO mice 
(Figure 3.13).  
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Figure 3. 13 Changes in fat pad mass due to pregnancy are absent in Papp-a KO. 
Mass of individual fat depots expressed as % body weight. Statistical significance of 
differences in gene expression between non-pregnant and pregnant state within each 
depot was measured using multiplicity (Holm-Sidak) adjusted t-tests.  
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Histochemical analysis of each fat pad (Figure 3.14) revealed significant changes 
in the distribution of fat cell sizes induced by pregnancy in the parametrial, 
inguinal, periovarian, retroperitoneal and mesenteric depots. With the exception 
of the parametrial-distal depot, these depots exhibited a decrease in adipocyte 
size, and an accumulation of small-sized adipocytes, suggesting hyperplastic 
growth in the mentioned fat pads. These changes in adipocyte size distribution 
did not occur in fat depots from Papp-a KO mice demonstrating that pregnancy-
induced remodeling of fat depots is dependent on Papp-a.  
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Figure 3. 14 Pregnancy-induced variations in adipocyte size and number are not 
observed in Papp-a KO. 
Frequency distribution of adipocyte sizes measured in H&E stained sections (~10 images 
per depot) from 6 mice per group. Data shown is from the fat pads with the most difference 
between non-pregnant and pregnant mice. For each of the indicated fat pads, statistical 
significance of differences in frequency at each bin between non-pregnant and pregnant 
state was measured using multiplicity (Holm-Sidak) adjusted t-tests.  
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During the examination of H&E inguinal and axillar adipose tissue sections, we 
noticed an interesting feature regarding the presence of alveoli in the pregnant 
mice (Figure 3.15, 3.16), as the inguinal mammary glands are embedded along 
the inguinal fat pad and the thoracic mammary glands are located in close 
proximity to the axillar fat pad. The pregnant KO had reduced alveolar 
development in the inguinal (Figure 3.15) and their presence was almost absent 
in the axillar pad (Figure 3.16) as observed by both H&E staining of adipose 
tissue sections (Figure 3.15a, 3.16a)  and whole-mount carmine-alum staining of 
inguinal and axillar fat pads (Figure 3.15b, 3.16b). These results, in addition to 
the absence of adipocyte size and number changes demonstrate that the 
adaptations of adipose tissue to gestation are regulated by Papp-a.  
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Figure 3. 15 The development of inguinal mammary glands in response to 
pregnancy is reduced in Papp-a KO. 
(a) Inguinal adipose tissue sections stained with H&E from non-pregnant or pregnant wild-
type (NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Images 
were taken under 10X magnification. Red arrows indicate the alveoli embedded within the 
inguinal fat pad. In addition, note the difference in adipocyte size between NPWT and 
PWT, which is not noticeable between NPKO and PKO. (b) Inguinal whole-mount carmine 
alum staining of non-pregnant or pregnant wild-type (NPWT, PWT) or non-pregnant or 
pregnant Papp-a KO mice (NPKO, PKO). Black arrowheads indicate areas of the epithelial 
ductal system. The development of mammary ducts in response to pregnancy is reduced 
in the PKO. Scale bar 0.5 cm. 
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Figure 3. 16 The development of mammary glands proximal to the axillar fat pad in 
response to pregnancy is absent in Papp-a KO. 
(a) Axillar adipose tissue sections stained with H&E from non-pregnant or pregnant wild-
type (NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Images 
were taken under 10X magnification. Red arrows indicate the alveoli embedded within the 
inguinal fat pad. (b) Axillar whole-mount carmine alum staining from non-pregnant or 
pregnant wild-type (NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, 
PKO). LN, lymph node. Black arrowheads indicate areas of the epithelial ductal system. 
The development of mammary ducts in response to pregnancy is absent in the PKO. Scale 
bar 0.5 cm. 
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To investigate if the absence of Papp-a would impair adipose tissue 
expandability in gestation, we performed the in vitro expandability assay with 
explants of inguinal fat pad (Figure 3.17). Similar to the observed adipocyte 
hyperplasia, pregnancy induced the growth of capillary sprouts in the inguinal 
adipose explants of WT mice. In the KO, pregnancy did not stimulate adipose 
tissue expandability.  These results further support the evidence that Papp-a is 
involved in the adaptations of adipose tissue growth in gestation.   
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Figure 3. 17 Adipose tissue expandability is impaired in pregnant Papp-a KO. 
(a) Representative images of sprouts emerging from adipose tissue explants obtained 
from non-pregnant or pregnant wild-type (NPWT, PWT) or non-pregnant or pregnant 
Papp-a KO mice (NPKO, PKO). Images were taken at 11 days of culture. (b) 
Quantification of sprouting area from AT explants. Between 20-30 explants were 
embedded for each mouse, and each symbol represents the mean sprouting area of all 
explants per group. Plotted are the means and SEM of non-pregnant and pregnant WT 
and KO mice (n=3 per group). Statistical significance was assessed using ordinary one-
way ANOVA corrected with the Sidak test for multiple comparisons.  
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To explore the mechanisms by which Papp-a is required for adipose tissue 
remodeling, we measured the expression of genes in the IGF signaling pathway 
in fat depots from pregnant and non-pregnant WT and Papp-a KO mice (Figures 
3.18-3.23). Depot, genotype and pregnancy-dependent changes were analyzed 
by three-way ANOVA. While all genes analyzed varied significantly by depot, 
only Igf-2 (Figure 3.19), Igfbp2 (Figure 3.20) and Igfbp4 (Figure 3.21) significantly 
changed in pregnancy, and Papp-a trended towards a significant increase in the 
mesenteric depot in pregnancy (Figure 3.18). Igfbp2 was the gene most strongly 
upregulated by pregnancy, mostly in the inguinal and axillary depots. The only 
gene significantly affected by the absence of Papp-a was Igf-2, which was 
upregulated in both inguinal and axillary depots to a greater extent in Papp-a KO 
than in WT mice.  
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Figure 3. 18 Papp-a expression differs between fat pads of wild-type mice.  
Real-time qPCR for Papp-a in fat depots from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fold expression 
values were calculated by normalization to the lowest expression value in the dataset. 
Graphs show mean and SEM of n=3 mice per group assayed in triplicate. Statistical 
significance of the differences between fat depot, genotype and pregnant state for each 
gene were calculated using three-way ANOVA corrected for multiple comparisons using 
the Tukey test. Statistical significance of differences in gene expression between states 
within individual depots were measured using multiplicity adjusted t-tests.  
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Figure 3. 19 Igf-2 expression reveals compensation for Papp-a deletion in specific 
adipose depots of pregnant Papp-a KO. 
Real-time qPCR for Igf-2 in fat depots from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fold expression 
values were calculated by normalization to the lowest expression value in the dataset. 
Graphs show mean and SEM of n=3 mice per group assayed in triplicate. Statistical 
significance of the differences between fat depot, genotype and pregnant state for each 
gene were calculated using three-way ANOVA corrected for multiple comparisons using 
the Tukey test. Statistical significance of differences in gene expression between states 
within individual depots were measured using multiplicity adjusted t-tests.  
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Figure 3. 20 Igfbp2 expression is enhanced by pregnancy and differs between 
adipose depots in wild-type and Papp-a KO. 
Real-time qPCR for Igfbp2 in fat depots from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fold expression 
values were calculated by normalization to the lowest expression value in the dataset. 
Graphs show mean and SEM of n=3 mice per group assayed in triplicate. Statistical 
significance of the differences between fat depot, genotype and pregnant state for each 
gene were calculated using three-way ANOVA corrected for multiple comparisons using 
the Tukey test. Statistical significance of differences in gene expression between states 
within individual depots were measured using multiplicity adjusted t-tests.  
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Figure 3. 21 Igfbp4 expression varies between fat depots and pregnant state in 
wild-type and Papp-a KO.  
Real-time qPCR for Igfbp4 in fat depots from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fold expression 
values were calculated by normalization to the lowest expression value in the dataset. 
Graphs show mean and SEM of n=3 mice per group assayed in triplicate. Statistical 
significance of the differences between fat depot, genotype and pregnant state for each 
gene were calculated using three-way ANOVA corrected for multiple comparisons using 
the Tukey test.  
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Figure 3. 22 Igfbp5 expression is different in each fat pad of wild-type and Papp-a 
KO. 
Real-time qPCR for Igfbp5 in fat depots from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fold expression 
values were calculated by normalization to the lowest expression value in the dataset. 
Graphs show mean and SEM of n=3 mice per group assayed in triplicate. Statistical 
significance of the differences between fat depot, genotype and pregnant state for each 
gene were calculated using three-way ANOVA corrected for multiple comparisons using 
the Tukey test.  
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Figure 3. 23 Igf-1 expression is different in each fat pad of wild-type and Papp-a 
KO. 
Real-time qPCR for Igf-1 in fat depots from non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Fold expression 
values were calculated by normalization to the lowest expression value in the dataset. 
Graphs show mean and SEM of n=3 mice per group assayed in triplicate. Statistical 
significance of the differences between fat depot, genotype and pregnant state for each 
gene were calculated using three-way ANOVA corrected for multiple comparisons using 
the Tukey test.  
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Papp-a deletion results in gestational insulin resistance  
We then studied the metabolic consequences of the abnormalities in adipose 
tissue remodeling induced by Papp-a loss. Fasting blood glucose was lower in 
the pregnant state in both WT and KO mice, but was slightly higher in non-
pregnant KO compared to WT mice (Figure 3.24). This was accompanied by 
trends towards higher basal insulin values in response to pregnancy, and also 
higher basal insulin values in KO mice compared to WT, although the data did 
not reach statistical significance (Figure 3.25).  
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Figure 3. 24 Pregnancy reduces fasting glucose in both wild-type and Papp-a KO. 
Blood glucose after a 6hr fast of 10-12-week old non-pregnant or pregnant wild-type 
(NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Statistical 
significance was assessed using ordinary one-way ANOVA corrected with the Sidak test 
for multiple comparisons.  
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Figure 3. 25 Fasting insulin is not altered by pregnancy in wild-type and Papp-a KO. 
Plasma insulin after a 4.5hr fast of 10-12-week old non-pregnant or pregnant wild-type 
(NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). Statistical 
significance was assessed using ordinary one-way ANOVA corrected with the Sidak test 
for multiple comparisons. 
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To directly measure insulin sensitivity, we conducted insulin tolerance tests. 
These revealed a trend towards increased insulin resistance induced by 
pregnancy in WT mice, and this effect was much more pronounced in KO mice 
(Figure 3.26). Greater insulin secretion following glucose injection was seen in 
pregnant compared to the non-pregnant mice, however there were no differences 
due to Papp-a deletion (Figure 3.27). These results indicate that loss of Papp-a 
results in pregnancy-induced insulin resistance, without effects on b-cell insulin 
secretion.  
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Figure 3. 26 Pregnant Papp-a KO exhibit reduced insulin sensitivity. 
Percent of basal glucose from 10-12-week old non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO) during an insulin 
tolerance test (0.65 units of insulin/kg body weight) after 4.5 hr fast. Statistical significance 
between groups was assessed using repeated measures one-way ANOVA corrected for 
multiple comparisons using the Holm-Sidak test, and statistical significance of differences 
at each time point measured using multiplicity adjusted t-tests.  
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Figure 3. 27 Glucose stimulated insulin secretion is enhanced in pregnant dams. 
Plasma insulin after administration of glucose (2g/kg body weight) in 10-12-week old 
non-pregnant or pregnant wild-type (NPWT, PWT) or non-pregnant or pregnant Papp-a 
KO mice (NPKO, PKO) following a 6hr fast. Statistical significance was assessed using 
ordinary one-way ANOVA corrected with the Sidak test for multiple comparisons.  
 
 
 
 
NPWT, n=7
PWT, n=6
NPKO, n=8
PKO, n=8
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To examine whether insulin resistance could be accompanied by changes in the 
liver, we analyzed triglyceride content and histological appearance (Figure 3.28). 
Liver weight increased significantly in response to pregnancy in both WT and KO 
mice, but livers from KO pregnant mice were larger than those from WT pregnant 
mice (Figure 3.28a). This increased weight could be attributed to an increase in 
triglyceride levels (Figure 3.28b), which was reflected by the presence of large 
lipid droplets (Figure 3.28c) and was only observed in pregnant KO mice. Thus, 
the insulin resistance induced by pregnancy in Papp-a KO mice was 
accompanied by fatty liver.  
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Figure 3. 28 Pregnant Papp-a KO have increased hepatic triglyceride content. 
Liver mass (a) and triglyceride (b) content from 10-12-week old non-pregnant or pregnant 
wild-type (NPWT, PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO). (c) 
Representative images of H&E liver sections taken under 10X magnification. Insets 
contain magnified sections of each image. Statistical significance was assessed using 
ordinary one-way ANOVA corrected with the Sidak test for multiple comparisons.  
  
a b 
c 
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Unexpectedly, the insulin resistance and fatty liver phenotype on the pregnant KO 
mice was not reflected by impaired glucose tolerance. Indeed, the absence of 
Papp-a was accompanied by improved glucose tolerance in both non-pregnant 
and pregnant states (Figure 3.29). To determine potential mechanisms of 
enhanced glucose disposal in the KO mice, we conducted hyperinsulinemic-
euglycemic clamps (Figure 3.30). KO mice required higher glucose infusion rates 
and displayed enhanced whole-body glucose turnover. This was accompanied by 
enhanced skeletal muscle glucose uptake (Figure 3.30, right panel) and increased 
whole body glycolysis. We also observed a trend towards higher hepatic glucose 
production, consistent with insulin resistance. 
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Figure 3. 29 Papp-a KO dams exhibit improved glucose tolerance. 
Percent of basal glucose from 10-12-week old non-pregnant or pregnant wild-type (NPWT, 
PWT) or non-pregnant or pregnant Papp-a KO mice (NPKO, PKO) during a glucose 
tolerance test (2g glucose/kg body weight) after 6hr fast. Statistical significance between 
groups was assessed using repeated measures one-way ANOVA corrected for multiple 
comparisons using the Holm-Sidak test, and statistical significance of differences at each 
time point measured using multiplicity adjusted t-tests.  
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Figure 3. 30 Papp-a KO display enhanced glucose disposal under the 
hyperinsulinemic-euglycemic clamp. 
Glucose values (left y-axis, mg/Kg/min) and muscle glucose uptake (right y-axis, 
nmol/g/min) during hyperinsulinemic-euglycemic clamps for each parameter measured (x 
axis). Bars indicate mean and SEM. Statistical significance of the differences for each 
parameter were calculated using unpaired Student’s t-tests.  
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Discussion  
The results presented in this paper demonstrate that both mouse and human 
pregnancy induces adipose tissue adaptations important for the regulation of 
insulin sensitivity. Our findings implicate PAPP-A as a key signaling molecule in 
this remodeling of adipose tissue. Acting on IGFBPs, this protease establishes a 
pregnancy-specific signaling axis in adipose tissue that can couple fetal growth to 
maternal fuel homoeostasis.  
 
PAPP-A was initially described as one of three proteins produced by the human 
endometrium that increase dramatically after decidualization and pregnancy (R. 
Smith, Bischof, Hughes, & Klopper, 1979) (Bischof, 1979). Of these only PAPP-A 
increases progressively from very early (6-10 weeks) gestation to term (Bischof, 
1989). The development of sensitive assays for PAPP-A early on revealed 
significant correlations with pregnancy abnormalities (Barnea, 1986) (Griffin, 
1983) (Sutcliffe et al., 1982). A single low value for PAPP-A was highly 
significantly correlated with Down syndrome pregnancies (Brambati et al., 1993) 
(Wald et al., 1992), leading to its adoption for screening chromosomal 
abnormalities in early pregnancy, although the mechanisms behind these low 
values are unclear. Cloning of the PAPP-A gene led to its identification as a Zn+ 
binding metalloprotease (Kristensen, Oxvig, Sand, Hundahl Moeller, & Sottrup-
Jensen, 1994), and functional studies to its subsequent identification as the 
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single protease responsible for cleavage of IGFBP4 (Conover, Oxvig, Overgaard, 
Christiansen, & Giudice, 1999) and capable of cleavage of IGFBP5 (Laursen et 
al., 2001). The key role of PAPP-A in IGFBP proteolysis and IGF signaling is 
evidenced by its effects on embryonic development; in humans, PAPP-A levels in 
early pregnancy correlate with fetal size at term (Pedersen, Sørensen, & Ruge, 
1995) (Baer, Lyell, Norton, Currier, & Jelliffe-Pawlowski, 2016) (Giudice et al., 
2015), and in mice ablation of Papp-a results in proportional dwarfism (Conover 
et al., 2004). In addition to its role in fetal development, total and proteolytic 
human PAPP-A levels progressively rise in serum throughout pregnancy (Gyrup, 
Christiansen, & Oxvig, 2007), suggesting a longitudinal mediation of maternal 
peripheral tissue adaptations to fetal growth. This view is supported by the 
inverse linear correlation between circulating PAPP-A and serum glucose shown 
in our study. Moreover, it suggests that the observed correlations between low 
PAPP-A levels and pregnancy abnormalities might be attributable to inadequate 
regulation of IGF signaling in maternal peripheral tissues, required for adaptation 
to the growing demands of the fetus.  
 
In the case of diabetes, a correlation between low level first trimester PAPP-A 
and GDM risk has been reported in some (Beneventi et al., 2011) (Lovati et al., 
2013) (Petry et al., 2017), though not in all studies (Husslein & Lausegger, 2012) 
(Savvidou, Syngelaki, Muhaisen, Emelyanenko, & Nicolaides, 2012). In our 
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retrospective study of over 6000 women, we found a strong positive correlation 
between development of GDM and second, third and fourth quartile first-trimester 
PAPP-A levels, compared to the highest quartile. Importantly, it has been 
recognized that levels of circulating PAPP-A at the three trimesters of pregnancy 
are affected by diverse maternal factors and medical history (Wright, Silva, 
Papadopoulos, Wright, & Nicolaides, 2015), including weight, age, smoking, race 
and diabetes status. Because these factors lower the sensitivity and accuracy of 
single measure PAPP-A levels for aneuploidy screening, algorithms used by 
clinical laboratories to report PAPP-A MOM correct for these factors.  
 
Nevertheless, in our study we find that PAPP-A MOM levels in the lowest quartile 
are still associated with increased odds of development of GDM, supporting the 
hypothesis PAPP-A levels are an independent risk factor for the development of 
gestational metabolic disease. Mechanistically, our results support a model in 
which low levels of PAPP-A result in impaired proteolysis of adipose tissue 
IGFBPs, which are upregulated in adipose depots during pregnancy. In turn, IGF 
signaling decreases, impairing pregnancy-induced adipose tissue remodeling 
(Rojas-Rodriguez et al., 2015). This mechanistic view is supported by our finding 
of direct stimulation of human adipose tissue expandability by PAPP-A in vitro 
(Figure 3.9) reflecting in vivo physiology (Gealekman et al., 2014) (Pellegrinelli et 
al., 2018) (Gealekman et al., 2012), as well as our findings of impaired adipose 
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tissue remodeling and pregnancy-specific insulin resistance in Papp-a knockout 
mice.  
 
Despite displaying 86% conservation between human and mouse at the amino 
acid level and sharing catalytic features, Papp-a is not highly produced in the 
placenta during pregnancy in mice (Qin et al., 2002), therefore pregnancy-
specific regulation in this species may occur through its expression and function 
in peripheral tissues. The effects of Papp-a on murine adipose tissue can be 
mediated through cleavage of Igfbp2, as this binding protein was specifically 
upregulated by pregnancy, and is a known substrate of Papp-a (61, 62) (Gérard, 
Delpuech, Oxvig, Overgaard, & Monget, 2004) (Monget et al., 2003). The direct 
role of Papp-a in remodeling adipose depots is also supported by the finding that 
depots displaying lesser impairments exhibit a larger compensatory 
overexpression of Igf-2, consistent with observations that increased Igf-2 
mitigates the effects of Papp-a deficiency (Bale & Conover, 2005). In human 
adipose tissue, the largest pregnancy-induced change in a single gene is the 
enhanced expression of IGFBP5, accompanied by >10-fold elevation in 
circulating PAPP-A net proteolytic activity (Gyrup et al., 2007). Thus, while the 
specific IGF binding proteins and the source of PAPP-A may differ between mice 
and humans, the mechanism whereby the PAPP-A/IGF axis enables adipose 
tissue adaptation to pregnancy is conserved between these species.  
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The pregnancy-specific adaptations we observed in mice include a trend towards 
decreasing total fat pad mass, the appearance of small adipocytes, consistent 
with increased fat mobilization and adipose tissue growth by hyperplasia, and the 
enhanced expansion capacity of adipose explants. The molecular mechanisms 
that remodel adipose tissue during pregnancy appear to be variations on 
mechanisms already known to play a major role in adipose tissue development. 
In non-pregnant humans, the IGF signaling pathway is known to play a major role 
in the regulation of adipose tissue expandability (Garten et al., 2012) (Maridas et 
al., 2017) (Gealekman et al., 2014) (Hjortebjerg et al., 2018) (Rajkumar, Krsek, 
Dheen, & Murphy, 1996) (Silha, Gui, & Murphy, 2002). In mice, expression of 
Igfbp4 is regulated by age and obesity, and it can directly modulate adipose 
tissue expandability in vitro (Gealekman et al., 2014).  
 
Adipose tissue expandability is increasingly recognized to play a central role in 
the regulation of insulin sensitivity through secretion of cytokines and preventing 
lipotoxicity (Carobbio et al., 2017). Failure of adipose tissue to suppress lipolysis 
or insufficient adipose tissue storage capacity leads to increased lipid delivery to 
the liver and enhanced gluconeogenesis and hepato-steatosis (Kabir et al., 2005) 
(Reilly et al., 2015). Interestingly, we find that non-pregnant Papp-a KO mice 
display a trend to increased hepatic glucose production, although enhanced 
glucose utilization prevents glucose intolerance. This enhanced glucose 
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utilization, which is unusual in the context of insulin resistance, is reflected in 
hyperinsulinemic clamps by increased glucose uptake in skeletal muscle and 
may result from an increased muscle oxidative metabolism previously reported in 
aged Papp-a KO mice (Conover, Bale, & Nair, 2016). Moreover, a striking 
phenotype is seen in response to pregnancy, where Papp-a KO mice display 
much greater insulin resistance evidenced by insulin tolerance tests 
accompanied by fatty liver, consistent with impaired adipose tissue function.  
 
Our model from this presented data does carry limitations. We cannot be certain 
that circulating PAPP-A derived from the placenta is mediating subcutaneous 
human adipose tissue IGFBP5 cleavage. Although the vast majority of circulating 
PAPP-A in human pregnancy is derived from the uterus (Bersinger & Klopper, 
1984), other tissue also expresses a significant amount (Gude et al., 2016). 
Further studies assessing adipose tissue adaptations during the course of 
pregnancy and their correlation with subcutaneous adipose tissue PAPP-A gene 
expression and circulating levels of total and active PAPP-A over time may help 
answer this question. Another approach studying tissue-specific ablation in mice 
may determine whether circulating Papp-a can affect remodeling in adipose 
tissue-specific KO mice and the extent to which each tissue contributes to the 
metabolic adaptations to pregnancy. In addition, the finding of reduced alveolar 
development needs to be explored further as in humans it has been described 
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that women with glucose intolerance during pregnancy (either gestational, type 1, 
or type 2 diabetes) have greater odds of low milk supply during the lactation 
period (Riddle & Nommsen-Rivers, 2016). Therefore, is possible that the role of 
PAPP-A in adipose tissue remodeling also impacts mammary gland adaptations 
to pregnancy in both human and mice. Nevertheless, our current findings identify, 
for the first time, the important PAPP-A dependent effects of pregnancy on 
adipose tissue remodeling in human and mice critical for maternal metabolic 
homeostasis.  
 
Gestational diabetes is a growing medical concern, with increasingly recognized 
long-term health consequences for mothers and their offspring (Farahvar et al., 
2019) (C. Zhang et al., 2019). Our finding that PAPP-A insufficiency may drive 
GDM development opens the possibility of therapeutic use of this protease. 
Through gathering a better understanding of PAPP-A/IGF signaling, initiating a 
targeted investigation of PAPP-A expression regulation, and directly studying the 
action of PAPP-A as a biologic, we will determine its potential as a therapeutic 
option in mitigating GDM and its transgenerational pathologies.  
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CHAPTER IV: Discussion  
 
Overview 
Research in metabolism emphasize the endocrine role of adipose tissue in 
glucose homeostasis. 
In periods of excess calorie intake, the adipose tissue expands in response to 
insulin signaling by storing glucose as triglycerides. Glucose uptake and storage 
by the adipose tissue and other insulin sensitive tissues prevents hyperglycemia 
and the stored triglycerides can be released as free fatty acids at times of energy 
need (Choe, Huh, Hwang, Kim, & Kim, 2016).  The rapid adaptations of adipose 
tissue expandability led by changes on insulin sensitivity in pregnancy features 
the metabolic role of adipose tissue as a regulator of energy sources between 
maternal tissues and the feto-placental unit (N Butte, 2000) (Lain & Catalano, 
2007).  
 
Adipose tissue metabolism in gestation can be described in two phases. The first 
half of pregnancy is characterized by fat mass accrual accompanied by adipose 
tissue growth, which is facilitated by enhanced insulin sensitivity. The second half 
of gestation is highlighted by lipid mobilization from adipose tissue stores due to 
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reduced insulin sensitivity. This metabolic adaptation to gestation favors glucose 
uptake by fetal tissues while maternal tissues rely on lipid as energy source 
(King, 2000) (Wiznitzer et al., 2009).  
The maintenance of glucose homeostasis in periods of adipose tissue growth is 
dependent on the site and composition of fat mass. 
The main site for lipid storage is in the subcutaneous adipose tissue, however, 
once it reaches an expansion limit, the deposition of lipids gets shifted to ectopic 
sites leading to an insulin resistance state (Virtue & Vidal-Puig, 2010). Reports 
from various studies across populations from different ethnicities coincide that 
visceral adiposity is associated with the development and the presence of insulin 
resistance and type-2 diabetes (Gastaldelli et al., 2002) (Anjana et al., 2004) 
(Usui et al., 2010) (Neeland et al., 2012) (Nordström, Hadrévi, Olsson, Franks, & 
Nordström, 2016). Furthermore, individuals with fat accumulation in the 
subcutaneous depot have improved insulin profiles and lower risk of metabolic 
disease than those with preferential visceral fat accumulation (Porter et al., 2009) 
(McLaughlin et al., 2011).  
 
In addition to fat localization, the mechanisms of adipocyte growth have been 
implicated in the maintenance of systemic insulin sensitivity. Hyperplastic growth 
via differentiation of adipocyte progenitors aids in the maintenance of insulin 
157 
 
sensitivity, contrary to hypertrophic adipocytes leading to inflammation and 
insulin resistance (Isakson, Hammarstedt, Gustafson, & Smith, 2009) (Lönn, 
Mehlig, Bengtsson, & Lissner, 2010) . Adipocyte growth is accompanied by 
extension of the vasculature, therefore adipose tissue angiogenesis is also a key 
determinant of insulin sensitivity (Corvera & Gealekman, 2014). 
Importance of studying adipose tissue expansion in gestation  
The association between visceral fat deposition and type-2 diabetes in non-
pregnant individuals have prompted the studies on the effect of visceral adiposity 
in glucose metabolism on gravid women particularly due to the state of rapid 
weight gain that pregnancy imposes. Most of the work for depot-specific fat mass 
content assessment along gestation has been done utilizing non-invasive 
approaches. Others have biopsied and analyzed the composition of 
subcutaneous adipose tissue longitudinally across gestation. In depth study of 
the adaptations of adipose tissue expansion and its effect on insulin state 
requires the analysis of both subcutaneous and visceral fat depots in order to 
elucidate what molecular mechanisms are driving the growth of adipose tissue 
and how they are altered in gestational diabetes. Evidence obtained from these 
studies can then be applied for the development of animal models that can lead 
the discovery of potential molecules with preventive and therapeutic roles for 
gestational diabetes. 
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Major results of the thesis 
Cross-sectional studies: Morphological and gene expression changes in adipose 
tissue due to gestation and glycemic state in pregnancy 
In this thesis work, I performed two independent cross-sectional studies for the 
characterization of the morphological changes in adipose tissue expansion due 
to gestation and how these effects are altered in pregnancies with GDM. The 
adipocyte size and number distribution, vascularization level via capillary density 
and capacity for adipose tissue growth of subcutaneous adipose tissue where 
determined for normoglycemic non-pregnant and pregnant women. These 
parameters were also measured in a paired analysis of subcutaneous and 
omental adipose tissue of normoglycemic and gestational diabetes gravid 
women. Altogether, the results presented in this thesis demonstrate that 
pregnancy induces adipose tissue expansion via adipocyte hypertrophy and 
hyperplasia and extension of the vascular network in the subcutaneous adipose 
tissue. The presence of GDM resulted in a distinctive pattern of inadequate 
adipose tissue expansion. Namely, omental fat depots contained hypertrophied 
adipocytes and both the subcutaneous and omental adipose tissue had reduced 
vascularization. 
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Moreover, adipose tissue gene expression analysis from Affymetrix array and 
real-time PCR indicate the upregulation of IGFBP5 expression due to pregnancy 
and the reduced expression levels of this gene in GDM.  
Retrospective study: First trimester circulating PAPP-A and the association with 
maternal glycemic state at the time of screening for gestational diabetes 
PAPP-A is a metalloprotease secreted by the placenta which circulating levels 
increase as pregnancy advances and has been shown to cleave IGFBP2, 
IGFBP4, and IGFBP5. Due to the observations of IGFBP5 expression changes in 
adipose tissue with maternal glycemic state, I was interested in investigating the 
relationship between PAPP-A and the development of glucose intolerance in 
gestation. Analysis of a retrospective study in gravid women delivering at 
UMMHC showed that pregnant women with low levels of circulating PAPP-A at 
weeks 10-14 of gestation had higher odds for developing abnormal glucose 
tolerance or GDM later in pregnancy.   
PAPP-A effects on human adipose tissue expandability in pregnancy   
Based on the results from this thesis, a normoglycemic pregnancy is 
characterized by high levels of circulating PAPP-A, enhanced adipose tissue 
expansion and upregulation of adipose tissue IGFBP5. Since IGFBP5 is a 
substrate for PAPP-A, I explored if PAPP-A stimulates the expansion capacity of 
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adipose tissue in vitro. Indeed, the presence of recombinant human PAPP-A 
enhances the expansion capacity of adipose tissue explants from pregnant 
women. 
Characterization of the impact of Papp-a deletion on glycemic state and adipose 
tissue expandability in murine pregnancy   
The findings of inadequate adipose tissue expandability and low levels of PAPP-
A in pregnant women with GDM prompted me to investigate a possible mouse 
model for this disease. To fulfill this end, I utilized a whole-body Papp-a knockout 
mouse line and performed metabolic phenotyping as well as analysis of adipose 
tissue histology and gene expression of the molecules involved in IGF signaling 
in wild-type and Papp-a knockout non-pregnant and pregnant dams. Overall, the 
results demonstrate that Papp-a knockout pregnant dams have reduced insulin 
sensitivity and fatty liver when compared to Papp-a knockout non-pregnant and 
wild-type pregnant controls. Also, the changes in adipocyte size and number 
observed due to pregnancy in wild-type animals were absent in Papp-a 
knockouts. Last, only Igfbp2 expression was increased by pregnancy with no 
difference in relative abundance between wild-type and knockout pregnant dams. 
 
In general, the work presented in this thesis characterized the morphological 
changes of adipose tissue expansion in gestation and how these adaptations are 
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altered in GDM. The proposed molecular mechanism between placental PAPP-A 
and adipose tissue IGFBP-5 feature the role of adipose tissue expandability in 
maintaining maternal glucose metabolism and highlights the use of PAPP-A as 
an early biomarker and therapeutic for gestational diabetes. In addition, a mouse 
model of Papp-a knockout is proposed for the study of gestational diabetes.  
  
162 
 
Major conclusions and implications of the work 
 Gravid women with GDM have impaired adipose tissue expansion  
In chapter 2, I demonstrated that pregnant women with GDM have impaired 
adipose tissue expansion. The increased amounts of enlarged adipocytes 
observed in the omental fat suggest that GDM women tend to store lipid via 
hypertrophy in a visceral site, which is one of the features that can lead to insulin 
resistance and altered lipid profiles. On the contrary, normoglycemic gravid 
women have in their omental fat depot a higher number of small adipocytes, 
which is characteristic of hyperplasia and associated with insulin sensitivity.  
 
The effect of hypertrophic adipocytes on metabolism has been described in both 
human and mice where enlarged fat cells have increased rates of lipolysis, 
secrete pro-inflammatory adipokines and have reduced insulin sensitivity with 
decreased GLUT-4 trafficking than smaller adipocytes (JI Kim et al., 2015) 
(Verboven et al., 2018). In a paired analysis of subcutaneous and omental 
adipose tissue from lean and obese non-pregnant women, isolated adipocytes 
where categorized as hypertrophic or hyperplastic according to their size and 
number and associated with the lipid profiles for each subject (Veilleux et al., 
2011). Women with omental hypertrophic adipocytes had deleterious lipid profiles 
than subjects with omental adipocyte hyperplasia while no differences in lipid 
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profiles were observed among individuals with hyperplastic or hypertrophic 
subcutaneous adipocytes. Logistic regression analysis estimated that a 10% 
enlargement of omental adipocytes increased the risk for hypertriglyceridemia by 
more than 4-fold, and this association was not observed for subcutaneous 
adipocyte size. Therefore, the size of omental adipocytes can be associated with 
the state of lipid metabolism.  
 
The differences in adipocyte size between fat depots has also been studied by 
others in different stages of pregnancy. Rebuffé-Scrive et al collected 
subcutaneous abdominal and femoral adipose biopsies of non-pregnant, early 
gestation (8-11 weeks gestational age), and lactating women (Rebuffe-Scrive et 
al., 1985). Femoral fat cells were larger than abdominal in all groups and, 
interestingly, adipocytes in both subcutaneous regions were larger in lactating 
women compared to the other cohorts. In addition, basal lipolysis rates were 
increased in lactating women with a pronounced effect in the femoral region 
indicating a depot-specific response to lipid metabolism in response to lactation. 
Similar to the approach utilized in my thesis research, Huda and colleagues 
analyzed isolated omental and subcutaneous adipocytes from fat biopsies of 
healthy pregnant women at the time of cesarean section. Their report 
demonstrated that omental adipocytes had smaller diameter and were less 
lipolytic than subcutaneous adipocytes, supporting my observations of depot-
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specific differences in adipocyte size (Huda et al., 2014). Therefore, each stage 
of pregnancy will present a unique metabolic adaptation reflected, in part, by fat 
depot-specific changes in adipocyte size regulating lipid storage and 
mobilization. 
 
In normoglycemic gravidas, the subcutaneous and omental fat where highly 
vascularized. The subcutaneous had increased expansion capacity (measured 
via angiogenic potential) than the omental depot indicating that both depots are 
capable of healthy expansion, however the subcutaneous had an enhanced 
capacity for growth. The reduced vascularization observed in both the omental 
and subcutaneous fat of GDM women is characteristic of dysfunctional adipose 
tissue growth. The biology of fat expansion consists on an initial acute hypoxic 
state that induces signaling events resulting in mild inflammation which promotes 
remodeling of the extracellular matrix and extension of the vascular network via 
angiogenesis (Resi et al., 2012) (Wernstedt Asterholm et al., 2014) (Attie & 
Scherer, 2009) (Crewe, An, & Scherer, 2017). Unhealthy adipose tissue 
expansion creates a state of chronic hypoxia resulting in a condition of 
unresolved inflammation leading to fibrosis and impaired angiogenesis 
(Michailidou et al., 2012) (Lin, Chun, & Kang, 2016) (Crewe et al., 2017). The 
importance of vascularization specific to the expanding adipose tissue relies not 
only in oxygenation, nutrient supply and growth factor/hormone exchange, but 
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also on the mesenchymal stem cell progenitors residing in the vascular 
endothelium of adipose tissue that proliferate and differentiate into mature 
adipocytes driving the hyperplastic fat growth (Tran et al., 2012) (Min et al., 
2016). Studies done in mice with adipose tissue overexpression of the vascular-
endothelial growth factor (VEGF), a potent activator of angiogenesis, 
demonstrated that animals fed a high-fat diet had formation of functional vessels 
and were protected from diet-induced glucose intolerance and insulin resistance 
(Elias et al., 2012). Also, when C57BL/6J and ob/ob mice are treated with the 
insulin sensitizer rosiglitazone, these animals have an adipose tissue pro-
angiogenic effect that increases the capillary network when compared to 
untreated controls (Gealekman et al., 2008) suggesting the relationship between 
adipose tissue microvasculature and insulin sensitivity.  
 
In humans, subcutaneous adipose tissue changes in basal and the early phase 
of weight gain induced by overfeeding results in an increase of capillary density 
and upregulation of genes involved in angiogenesis indicating that the initial 
stages of adipose tissue expansion begin with extension of the vascular network 
(Alligier et al., 2012). Therefore, based on the results obtained from the GDM 
women included in this thesis I conclude that the adipose tissue of GDM gravidas 
failed in adapting to the changes that maintain a healthy adipose expansion. It is 
possible that the impact of reduced vascularization is more prominent in the 
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omental depot due to the presence of hypertrophic adipocytes that could drive a 
state of chronic-low grade inflammation and lead to insulin resistance.  
 
To my knowledge, this is the first study that examined the morphological changes 
of adipocyte growth along with differences in both angiogenesis and vascular 
network of subcutaneous and omental adipose tissue in normoglycemic and 
GDM gravidas at the end of gestation. However, there are some caveats 
regarding the experimental approach and design of the study. The technique for 
measuring adipose tissue vascularization relies on a whole-mount lectin staining 
of a small fat fragment. Ideally, the measurements of capillary density are 
analyzed relative to the adipocyte number and surface area. A more accurate 
measure for fat vascularization could be done by co-staining adipose tissue 
fragments with lectin and perilipin, which will also give more insight into the 
architectural differences of adipose tissue between normoglycemic and GDM 
gravidas. Regarding adipocyte size and number, I can only estimate the changes 
in adipocyte morphology since I don’t have the measurement of the depot and 
therefore cannot adjust for adipose organ size. An alternative approach can be to 
weight the fat biopsy, isolate the adipocytes from the stromovascular fraction, 
measure adipocyte diameter and volume from 100-300 cells and adjust for the 
weight of the adipose tissue biopsy. It will still be an approximation; however 
more precise than the method I utilized. The measures of capillary density and 
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adipocyte size are usually adjusted by BMI. However, in pregnancy, BMI is not 
an accurate measurement due to the increase in total body water and the 
difficulty for distinguishing between maternal and fetal mass. There are methods 
that have been used to detect differences in regional fat in gestation including 
ultrasound and anthropometry. However, ultrasound does not estimate total body 
composition and anthropometry has its limitations in late pregnancy stages. So 
again, this is another technical limitation of the study.	
	
The small sample size included in the cohorts does not provide enough evidence 
that the abnormal morphological changes observed in the GDM group are 
representative of the disease in the population. Following this line, an appropriate 
comparison with pregnant women that had pre-existing type-2 diabetes was not 
possible, since only three subjects were included in the study and the adipose 
biopsy obtained from them was relatively small. In addition, the cohorts were 
overweight or obese prior to becoming pregnant, so the predisposition to an 
obese state could underlie an additional metabolic stress that was observed in 
the adipose tissue morphology and was accounted primarily to the glycemic state 
of the gravid woman. Additional experiments to support the work in this chapter 
will include a larger cohort of normal, overweight, and obese pre-pregnancy BMI 
of normoglycemic, GDM, and type-2 diabetes. The data obtained will indicate if 
the changes in adipose tissue architecture are due to a pre-existing obese state 
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and differentiate the morphological characteristics between GDM and type-2 
diabetes. Last, the cellular mechanisms driving insulin resistance in the adipose 
tissue of pregnant women need to be explored and characterized in the different 
glycemic states in order to determine what are the molecular drivers specific to 
the adipose tissue promoting the development of gestational diabetes. 	
Pregnancy induces the upregulation of IGFBP5 expression in the adipose tissue 
Chapter 2 and 3 include different analysis techniques of Affymetrix gene arrays 
from abdominal subcutaneous and omental adipose tissue of normoglycemic 
non-pregnant and pregnant women. The most differentially upregulated gene 
was IGFBP5 in both depots of pregnant women compared to non-pregnant 
controls. The upregulation of IGFBP5 and other genes of the insulin/IGF 
signaling pathway was also observed in gluteal subcutaneous adipose tissue at 
late gestation compared to pregravid in a normoglycemic cohort (Resi et al., 
2012). The reduced expression of IGFBP5 and IGF1 in our GDM cohort indicates 
that there is a deficiency in the adaptations of subcutaneous adipose tissue 
remodeling induced by pregnancy via the IGF signaling pathway. Based on these 
results, I can conclude that pregnancy enhances the expression of IGFBP5 in the 
subcutaneous adipose tissue regions which has been shown to expand in 
response to pregnancy (Resi et al., 2012). The caveats for this conclusion 
include the small cohort of gravidas and that I only measured gene expression. 
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Validation of the upregulation of adipose tissue IGFBP5 should be done in larger 
cohorts with normal, overweight and obese BMI pregnant women and confirmed 
with the presence of higher concentration of bioactive IGFBP5 peptides in 
adipose tissue of pregnant compared to non-pregnant women. However, these 
experiments along with the morphological measurements described in the 
previous section, will require larger amounts of adipose tissue samples which is 
not always possible to obtain.  
Adipocyte hypertrophy and hyperplasia are accompanied with extension of the 
vascular network during adipose tissue remodeling in late gestation  
In chapter 3, I explored the changes in adipose tissue morphology that occur in 
response to a normal pregnancy given that the adaptations of adipose tissue to 
gestation are altered due to glycemic state. Histological analysis using non-
pregnant biopsies as controls showed that pregnancy induces an enlargement of 
existing adipocytes in the abdominal subcutaneous fat depot and no differences 
in the number of small adipocytes, suggesting compensatory hyperplasia and 
hypertrophy in the expansion of adipose tissue at late gestation. In addition to 
changes in adipocyte size and number, remodeling of the adipose tissue 
microvasculature and increased expansion capacity determined from the in vitro 
expandability assay is also observed in late pregnancy. As mentioned before, 
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extension of the vascular network is critical for the proliferation of progenitors and 
adipocyte differentiation. 
   
The morphological changes in adipocyte size and number obtained from my 
results were also observed in late gestation compared to pregravid in the 
longitudinal study mentioned previously (Resi et al., 2012), although just in 
gluteal subcutaneous samples. However, another group reported an increase in 
adipocyte diameter and volume in abdominal subcutaneous fat biopsies between 
the first and third trimester of normal weight gravid women, but no changes in 
adipocyte number (Svensson et al., 2016). There was a different approach used 
to determine fat cell size and number between these studies. In my experiments, 
similar to Resi and colleagues, I analyzed adipocyte distribution from adipose 
tissue sections. Svensson digested the adipose tissue with collagenase and 
determined the size from isolated adipocytes. Although measuring isolated 
adipocyte volume seems more relevant to the actual size, analysis of multiple 
adipose tissue sections gives more resolution of the size and number distribution 
in the sample.  
 
In conclusion, the adaptations of adipose tissue remodeling in late gestation are 
a dynamic process that includes adipocyte growth via hypertrophy and 
hyperplasia as well as extension of the vascular network. The limitations for this 
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section in chapter 3 are specific to the approaches for measuring capillary 
density and fat cell size (as discussed previously in pages 166-167) and the time 
of sample collection. Since fat mas accrual starts in the first trimester, I propose a 
longitudinal study where adipose biopsies are collected from the abdominal 
(lateral) and gluteo-femoral depot in the pregravid state, followed by first, second 
and third trimester. Inclusion of both subcutaneous depots is necessary since 
most of the fat mass gain localizes subcutaneously in the abdominal trunk and 
femoral region. Adaptations of adipose tissue to pregnancy not only includes 
changes in adipocyte size and number but also angiogenesis. The inflammatory 
component of the expanding adipose tissue and remodeling of the extracellular 
matrix are also key elements influencing the metabolic health of the expanding 
adipose tissue and should be measured along gestation. Furthermore, the 
adipokine secretion should be investigated due to their leading roles in 
adipogenesis and insulin sensitivity as well as inflammatory agents driving the 
low-grade immune response in the initial stages of adipose tissue growth. 
First trimester PAPP-A is associated with the development of gestational 
diabetes 
The reduced expression of IGFBP5 in GDM led me to examine if PAPP-A, as a 
protease for IGFBP5 (Laursen et al., 2001), is also related to glycemic state in 
pregnancy. PAPP-A can be detected after 28 days of implantation in maternal 
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circulation and is part of the first maternal screen for fetal chromosomal 
abnormalities (Wapner et al., 2003). Early detection of maternal abnormal 
glucose metabolism is important since lifestyle interventions can ameliorate the 
metabolic burden that glucose intolerance has in both mother and child. Thus, 
the retrospective study presented in Chapter 3 examined if low levels of PAPP-A 
between weeks 10-14 of gestation were associated with abnormal glucose 
metabolism at the time of screening for gestational diabetes. The results from the 
large cohort showed that gravid women with low concentrations of circulating 
PAPP-A early in gestation have higher odds for developing abnormal glucose 
tolerance and gestational diabetes. This finding was constant even after 
adjusting for gestational age (PAPP-A MoM), as PAPP-A concentration steadily 
increases from week 6-13 of pregnancy (Bischof, DuBerg, Herrmann, & 
Sizonenko, 1981) and other variables associated with diabetes (BMI, ethnicity, 
smoking status). Wright and colleagues also investigated if there was a  
relationship between circulating PAPP-A and glycemic state in gestation (Wright 
et al., 2015). They conducted a prospective study and found that low levels of 
PAPP-A were observed in pregnant women with pre-existing type-2 diabetes, 
with a greatest decrease in patients that needed insulin therapy. The results from 
the retrospective study included in this thesis and the evidence from other clinical 
reports suggest PAPP-A as a mediator in glycemic control specifically during 
pregnancy. 
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Other studies in the field further support my conclusion as there is evidence of a 
positive association between low first trimester PAPP-A MoM and glucose 
intolerance, although cohorts in these studies were smaller (Kulaksizoglu et al., 
2013) (Petry et al., 2017). Wells and colleagues showed that PAPP-A MoM 
decreased with the severity of diabetes when analyzing subjects that developed  
GDM, were diagnosed with diabetes early in gestation, or had pre-existing type-2 
diabetes (Wells et al., 2015). Maternal age, BMI and sex of the baby were not 
confounders of this relationship, only parity. In comparison with this report, a 
large prospective observational study in London (n=31,225) showed that early 
pregnancy (11-13 weeks) PAPP-A MoM was lower in women who developed 
GDM and further decreased in gravidas that further needed insulin treatment 
(Syngelaki, Kotecha, Pastides, Wright, & Nicolaides, 2015). Contrarily, other 
groups have described that there is no relationship between first trimester PAPP-
A MoM and the presence of GDM. However, these results were obtained from  
small cohorts (Kavak, Basgul, Elter, Uygur, & Gokaslan, 2006) (Husslein & 
Lausegger, 2012) or only found a relationship between low PAPP-A early in 
gestation with pregnant women that had pre-existing type-2 diabetes (Savvidou 
et al., 2012). It is important to note that extremely high PAPP-A is not associated 
with adverse maternal outcomes (Aitken et al., 2003).  
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Based on the results from our study which include a reasonable cohort size, I can 
conclude that low PAPP-A in the first trimester can predict the development of 
gestational diabetes. The limitations of this conclusion are based on the cohort of 
our study which was mainly Caucasian and the majority of the GDM cases were 
obese. In addition, our retrospective study was done utilizing the two-step 
approach and the Carpenter and Coustan criteria for the diagnosis of abnormal 
glucose tolerance and GDM, which is the routine method at the clinics that were 
enrolled in this study. Since the continuous relationship of maternal glucose 
levels below the established diagnostic cut-off for diabetes with averse 
pregnancy outcomes has been characterized (The HAPO Study Cooperative 
Research Group, 2008) (Scholtens et al., 2019) (Lowe et al., 2019), I consider 
that implementing the one-step approach for diagnosis, as is suggested by the 
International Association of Diabetes in Pregnancy Study Groups, will result in an 
even stronger association between the low levels of PAPP-A in the first trimester 
and the development of gestational diabetes.   
PAPP-A stimulates adipose tissue expandability in vitro  
The results of my thesis demonstrate that a healthy, normoglycemic pregnancy is 
distinguished by increased levels of circulating PAPP-A, adipose tissue- IGFBP5 
upregulation, along with enhanced adipose tissue expandability. These findings 
prompted me to investigate how the molecules involved in the IGF signaling 
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pathway regulate adipose tissue expansion in pregnancy. IGFBP5 serves as a 
bioreservoir of IGF in the pericellular environment. Cleavage of IGFBP5 is 
needed for the release of IGF (Allard & Duan, 2018). Free IGF is then available 
for binding to its receptor and activation of the intracellular events regulating 
metabolism and growth (Forbes, McCarthy, & Norton, 2012). Since PAPP-A is an 
IGFBP5 protease, I investigated if PAPP-A promoted adipose tissue growth in 
vitro. The presence of recombinant human PAPP-A stimulated the angiogenic 
growth of adipose tissue explants from pregnant women, suggesting its role in 
one of the early stages of adipose tissue expansion.  
 
PAPP-A activity has been reported as the protease of IGFBP2, IGFBP4 and 
IGFBP5 (Gyrup & Oxvig, 2007). Besides the placenta, other tissues express 
PAPP-A including subcutaneous and visceral adipose tissue although these 
measurements were done in human preadipocytes from non-pregnant individuals 
(Hou, Clemmons, & Smeekens, 2005) and in mice (Harstad & Conover, 2014). 
IGFBP4 proteolysis by PAPP-A was detected in the conditioned media of 
epicardial preadipocytes (Conover et al., 2019) and in visceral adipose tissue 
explants of human subjects (Davidge-Pitts et al., 2014), indicating adipose-
derived synthesis of the protease and the capacity for PAPP-A to cleave IGFBPs 
in the adipose tissue microenvironment. I cannot rule out the possibility that in 
the adipose tissue of pregnant women PAPP-A is also cleaving IGFBP2 and 
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IGFBP4 to a lesser extent and considering that these are experiments with 
human samples, I cannot control the native presence of other IGFBPs that are 
also substrates of PAPP-A.  
 
Our lab has done the adipose tissue angiogenesis assay utilizing subcutaneous 
human explants in the presence of IGFBP4. The results showed that addition of 
IGFBP4 decreased the formation of capillary sprouting, possibly since IGF was 
being sequestered by the binding protein (Gealekman et al., 2014). Thus, in the 
case of pregnancy, the upregulation of IGFBP5 could indicate an increase of 
IGFBP5 protein in the adipose tissue microenvironment and further sequestering 
of IGFs and increasing its local bioavailability. According to the results obtained 
from the in vitro assay, I can conclude that the cleavage by PAPPA is 
coordinating the initial stages of adipose tissue expandability in late gestation 
possibly through IGFBP5 proteolysis.  
 
In the literature it has been reported that PAPP-A can cleave IGFBP5 in the 
absence of IGF1 (Laursen et al., 2001) and that IGFBP5 can function as a 
growth factor independent of IGF1 in intestinal smooth muscle cells (Kuemmerle 
& Zhou, 2002) and in osteoblasts derived from IGF1 null mice (Miyakoshi et al., 
2001). Therefore, there are diverse roles for IGFBP5 in the IGF signaling 
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pathway that unfortunately I am not able to isolate in the approach I am using to 
measure in vitro human adipose tissue expandability.  
 
Besides PAPP-A, ADAM12 (Shi, Xu, Loechel, Wewer, & Murphy, 2000) and 
PAPP-A2 (Kramer, Lamale-Smith, & Winn, 2016) are metalloproteases that 
cleave IGFBBP5 and are also secreted by the placenta. From these two 
proteases, ADAM 12 has been described to be expressed by mouse white and 
brown fat and in human lipomas (Kawaguchi et al., 2003).  ADAM 12 was 
identified as an inducer of alterations in the extracellular matrix favoring the 
morphological change of preadipocytes in the process of differentiation to mature 
adipocytes, indicating a direct role of metalloproteases in adipose tissue 
remodeling during adipogenesis (Kawaguchi et al., 2003). Since the role of 
ADAM12 in adipose tissue growth has been described, I can test if PAPP-A is 
the pregnancy-specific protease stimulating a direct effect in adipose tissue 
expansion via IGFBP5. Additional insight for my conclusion can be obtained with 
an experiment where adipose tissue explants from pregnant women are cultured 
in the presence of recombinant PAPP-A or ADAM12 and measure the capacity of 
adipose tissue expandability in vitro while testing if the conditioned media has the 
cleaved fragments of IGFBP5. Concurrently, I can measure if PAPP-A presence 
enhances receptor activation by probing for the phosphorylated version of the 
insulin and IGF receptor.  
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Pregnant Papp-a knockout mice exhibit insulin resistance and impaired adipose 
tissue growth in gestation.    
In the last part of chapter 3, I studied the possibility of utilizing Papp-a knockout 
mice as an animal model for GDM due to the association of PAPP-A with 
maternal glycemic state and adipose tissue expandability. The metabolic 
phenotyping and analysis of adipose tissue histology resulted in three main 
findings that are comparable with gestational diabetes in humans. Pregnant 
knockout mice are unable to undergo the morphological changes in adipose 
tissue that occur in pregnant wild-type dams, they exhibit insulin resistance, and 
have an excessive hepatic lipid accumulation.  
 
In a normal pregnancy, as was reported with the wild-type controls, there were 
distinct changes in adipocyte size and number that were mainly noted by an 
increase in the number of small adipocytes in both subcutaneous and visceral fat 
pads indicating the proliferation and differentiation of adipocyte progenitors. This 
is supported by the enhanced expansion capacity of inguinal adipose tissue 
explants in wild-type pregnant dams. The role of Papp-a in murine adipose tissue 
remodeling in gestation was evident as in the knockouts there were no changes 
in adipocyte distribution between non-pregnant and pregnant mice.  
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The severe insulin resistance and hepatic lipid content in the pregnant Papp-a 
knockout was also demonstrated in pregnant Pparg2 (Peroxisome proliferator-
activated receptor gamma isoform-2) knockout mice (Vivas et al., 2016). PPARg2 
is a transcription factor predominantly present in the adipose tissue that regulates 
adipogenesis and insulin sensitivity (Werman et al., 1997) (Medina-Gomez et al., 
2005). The Pparg2 KO had decreased expression of lipid metabolism genes in 
subcutaneous adipose tissue and contained increased inflammation in the 
parametrial fat pad (Vivas et al., 2016). It is possible that the phenotypic 
similarities between Papp-a KO and Pparg2 KO are mediated by the impaired 
adaptation of adipose tissue to the metabolic demands of gestation.  
 
I also observed that pregnant Papp-a KO mice had excess triglyceride 
accumulation in their livers, characteristic of an insulin resistant state (Perry, 
Samuel, Petersen, & Shulman, 2014). This liver fat accumulation has a strong 
resemblance to that observed in GDM (Lee et al., 2019) (Mehmood et al., 2018) 
(Foghsgaard et al., 2017). Outside of pregnancy, fatty livers have also been 
observed in rats with growth hormone (GH) deficiency (Kuramoto et al., 2010). 
These rats have increased triglyceride content in their livers and non-alcoholic 
steatohepatitis, which was rescued with Igf-1 supplementation (H Nishizawa et 
al., 2012). Is possible that the local sequestering of Igf-1 by Igfbps and absence 
of proteolysis by Papp-a diminishes Igf-1 availability and is contributing to the 
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fatty liver in the pregnant Papp-a knockout. To test the mentioned hypothesis, I 
would have to quantify the amount of free Igf-1 and Igfbp-Igf-1 complex in liver 
samples of wild-type and Papp-a knockout pregnant dams. These experiments 
will provide relevant information regarding the pregnancy-specific effects of the 
IGF system on hepatic lipid metabolism. 
One interesting result observed in the Papp-a knockouts was that they exhibited 
a fast glucose clearance, an effect not affected by pregnancy. I was not able to 
perform the hyperinsulinemic-euglycemic clamp on the pregnant Papp-a 
knockouts due to their small size and difficulty for the arterial catheterization. 
However, the increased insulin-stimulated muscle glucose uptake in the non-
pregnant Papp-a knockouts could explain the feature of enhanced glucose 
tolerance.  
The results presented from the pregnant Papp-a knockout dams demonstrate 
that Papp-a is fundamental in the adaptations of adipose tissue physiology and 
insulin sensitivity to gestation. A suitable experiment to support this conclusion is 
the analysis of the insulin/IGF signaling pathway molecules in the basal and 
insulin stimulated state of liver, muscle and adipose tissue to confirm the insulin 
resistance phenotype observed in the pregnant Papp-a knockout mice.  
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Future directions  
Investigate the alterations of insulin/IGF signaling and other features of adipose 
tissue expandability in normoglycemic and GDM pregnant women  
A priority in the field of maternal metabolism is to unravel the molecular 
mechanisms that are causing GDM. The phenotype of impaired adipose tissue in 
GDM offers an ideal setting to study how alterations in adipose tissue 
metabolism contribute to the development of glucose intolerance in gestation. 
Insight into this physiology can be obtained by conducting a longitudinal study. 
The time of assessment will include pre-pregnancy, early, mid, and late gestation 
where a hyperinsulinemic-euglycemic clamp will be done in addition to needle 
biopsies of subcutaneous adipose in the basal and insulin-stimulated state. Since 
the percentage of women that will develop GDM is lower than those that will 
remain normoglycemic during gestation (~4.8% GDM prevalence in 
Massachusetts (Deputy, Kim, Conrey, & Bullard, 2018)) the prospective subjects 
recruited for the GDM cohort will be screened for high risk factors of this disease. 
The experimental approach will include measurements of whole and cleaved 
IGFBP5 as well as activation of the molecules involved in the insulin/IGF 
signaling pathway in the fat samples. In addition, the process of mild 
inflammation can be assessed by determining the presence of pro- and anti-
inflammatory cytokines and activation state (M1/M2) of adipose tissue residing 
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macrophages. Last, the remodeling of the extracellular matrix in the expanding 
adipose tissue and its relationship with insulin sensitivity can be determined from 
the collected fat biopsies by analyzing the changes along gestation of 
extracellular matrix components and receptors.  
Characterize the crosstalk between placental PAPP-A and adipose tissue 
IGFBP5 in human pregnancy 
A subset of the subjects from the longitudinal study can then be included in an 
investigation to test the model of placental PAPP-A and adipose tissue IGFBP5 
crosstalk presented in this thesis. At the time of cesarean section, samples of 
subcutaneous and omental adipose tissue and placenta are collected. Fat 
explants are embedded in Matrigel, following the protocol of the in vitro adipose 
tissue expandability assay. Placental explants are kept in culture. Then, the 
conditioned media from the placenta will be used to treat the adipose tissue 
explants and measure if it enhances capillary growth. To confirm the PAPP-A 
proteolytic cleavage of IGFBP5, intact and the peptide fragments of IGFBP5 will 
be determined from the adipose tissue explants treated with the placental 
conditioned media.  
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Determine if PAPP-A is associated with adverse neonatal outcomes  
GDM increases the risk of neonatal adiposity, highlighting the effect of maternal 
glucose intolerance in offspring metabolism. The positive association between 
low levels of PAPP-A and metabolic risk can be further explored in relationship to 
adverse neonatal outcomes. Hence, I propose a prospective investigation to 
study the association between the circulating levels of maternal PAPP-A in the 
first trimester of gestation and neonatal adiposity. The cohort of the study 
consists of a multiethnic population of singleton gestations. Serum plasma for 
PAPP-A quantification will be collected between weeks 11-14 of gestation and 
values will be adjusted for gestational age (PAPP-A MoM). Neonatal adiposity 
will be measured between 1-3 days after birth using the PEAPOD system, an 
infant-sized air-displacement plethysmograph. PEAPOD has been shown to 
provide accurate and reliable assessments of infant body composition (Ellis et 
al., 2007) (Deierlein, Thornton, Hull, Paley, & Gallagher, 2012). An association 
between low PAPP-A MoM and increased neonatal adiposity could indicate how 
early exposure of maternal phenotypes alter offspring metabolism to an extent 
that the effect is maintained postnatally.  
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Explore if the maternal maladaptations to gestation observed in the Papp-a 
knockouts are tissue-specific 
Besides impaired adipose tissue expansion, the whole-body knockout of Papp-a 
results in the presence of insulin resistance and fatty liver. The regulation of 
IGFBPs proteolysis and subsequent IGF signaling is more locally regulated, 
indicating the possibility of tissue specific adaptations to gestation. Generating an 
adipose tissue specific Papp-a knockout strain will explore if the systemic insulin 
resistance and increased liver triglyceride accumulation observed in the pregnant 
Papp-a knockouts occur specifically due to the effects of impaired adipose tissue 
growth and ectopic lipid accumulation. It is possible that the insulin resistance 
and fatty liver phenotype is still present with the tissue specific deletion. This 
effect could indicate that the specific disruption of the IGF/insulin signaling 
pathway in the adipose tissue is responsible for the maternal maladaptation to 
gestation characteristic of the Papp-a knockout mice. 
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Concluding remarks 
The maternal metabolic adaptations to gestation are based on increasing blood 
glucose, reducing insulin sensitivity in peripheral organs, and weight gain. The 
increase in weight is partly attributed to expanding adipose tissue stores which 
encompasses a series of depot-specific cellular and molecular events that 
regulate maternal glucose metabolism. The placenta, as an endocrine organ, 
secretes proteins that also regulate glucose metabolism via interaction with 
metabolic tissues. My thesis employed different translational approaches that 
characterized the cellular and molecular mechanisms modulating glycemic state 
in gestation. 
The results presented in this thesis include cross-sectional studies demonstrating 
the adaptations of adipose tissue expansion in gestation and how alterations in 
this physiology could lead to the development of gestational diabetes. In a 
retrospective study included in this work, I showed the association between a 
placental protease, PAPP-A, and the development of gestational diabetes. By 
developing a novel in vitro technique to recapitulate adipose tissue expandability, 
I showed the stimulatory effect of PAPP-A on adipose tissue growth in 
pregnancy. The adaptations of adipose tissue expandability are possibly 
mediated by interaction of placental PAPP-A and adipose tissue IGFBP5, which 
is highly induced in the fat of pregnant women (Figure 4.1). The effect of PAPP-A 
186 
 
on adipose tissue expansion in gestation was further explored in Papp-a 
knockout pregnant mice and the results of the animal experiments highlight the 
role of Papp-a in mediating insulin sensitivity and the adaptations of adipose 
tissue to pregnancy. 
I hope my work on the metabolic adaptations of adipose tissue and glucose 
metabolism in pregnancy provide insight and motivate future studies investigating 
the molecular basis of gestational diabetes. Specifically, research exploring the 
potential role of PAPP-A as an early biomarker and therapeutic for gestational 
diabetes. 
 
 
 
 
 
 
 
 
187 
 
 
Figure 4. 1 Model for crosstalk between placental PAPP-A and adipose tissue 
IGFBP-5 in gestation. 
(a) During pregnancy, the placenta produces PAPP-A which is secreted into the maternal 
circulation. (b) In response to pregnancy, maternal adipose tissue increases the 
production of IGFBP5 in its local microenvironment. (c) PAPP-A reaches the adipose 
tissue and cleaves IGFBP5, causing the release of IGF-1. (d) IGF-1 is free to bind the IGF 
receptor and promote the intracellular signaling pathways driving adipose tissue 
expansion via angiogenesis. 
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Appendix: Adipose Tissue Angiogenesis Assay 
 
Abstract 
Changes in adipose tissue mass must be accompanied by parallel changes in 
microcirculation. Investigating the mechanisms that regulate adipose tissue 
angiogenesis could lead to better understanding of adipose tissue function and 
reveal new potential therapeutic strategies. Angiogenesis is defined as the 
formation of new capillaries from existing microvessels. This process can be 
recapitulated in vitro, by incubation of tissue in extracellular matrix components in 
the presence of pro-angiogenic factors. Here, we describe a method to study 
angiogenesis from adipose tissue fragments obtained from mouse and human 
tissue. This assay can be used to define effects of diverse factors added in vitro, 
as well as the role of endogenously produced factors on angiogenesis. We also 
describe approaches to quantify angiogenic potential for the purpose of enabling 
comparisons between subjects, thus providing information on the role of 
physiological conditions of the donor on adipose tissue angiogenic potential.  
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Introduction 
The adipose tissue of mammals has evolved as a preferred storage site for 
excess calories in the form of triacylglycerol, and also as a critically important 
endocrine organ, which controls whole body metabolic homeostasis. One of the 
unique features of adipose tissue is its ability to massively expand in response to 
chronic positive energy balance, and to decrease in size under conditions in 
which stored calories are mobilized for use in other organs. Adipose tissue 
expansion results from an increase in adipocyte size, as well as from the 
differentiation of precursors into new adipocytes. As is the case for any tissue, 
changes in adipose tissue mass must be accompanied by parallel changes in 
microcirculation (Cho et al., 2007) (Christiaens & Lijnen, 2010) (Crandall, 
Hausman, & Kral, 1997). Adequate vascularization is required to deliver nutrients 
and oxygen to all cells in the tissue, to remove waste products, and to allow the 
tissue to functionally interact with the rest of the organism through the sensing 
and production of hormones and growth factors. In the case of adipose tissue, 
inadequate microcirculation could impair appropriate triglyceride storage by 
preventing access to circulating lipoproteins under fed conditions; it could also 
prevent adequate fuel delivery to other organs during fasting. Recent data 
suggest that adipose tissue microcirculatory alterations occur in type 2 diabetes, 
raising the possibility that impaired vascular development may be pathogenic in 
this disease (Hodson, Humphreys, Karpe, & Frayn, 2013) (Hosogai et al., 2007) 
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(Michailidou et al., 2012) (Pasarica et al., 2009) (Rausch, Weisberg, Vardhana, & 
Tortoriello, 2008). In support of an important role for adipose tissue 
angiogenesis, increased production of pro-angiogenic factors, in particular 
VEGF, by adipose tissue improves whole body metabolism in high fat diet-fed 
mice (Michailidou et al., 2012) (Sung et al., 2013) (Wree et al., 2012). Thus, 
investigating the mechanisms that regulate adipose tissue angiogenesis could 
lead to better understanding of adipose tissue function and potentially reveal new 
therapeutic strategies.  
Research on complex processes, such as tissue vascularization, can benefit 
from in vitro models that mimic important features of the process. In the area of 
angiogenesis, significant information has been derived from the aorta ring assay, 
in which aortic rings dissected from rat or mouse thoracic aortas generate 
outgrowths of branching microvessels (Aplin, Fogel, Zorzi, & Nicosia, 2008) 
(Baker et al., 2012). The formation of sprouts can be visualized by light 
microscopy of live cultures, and branching microvessels are composed of the 
same cell types that operate in vivo. The formation of aortic ring sprouts is 
regulated by endogenous and exogenously added pro- and anti-angiogenic 
factors. Thus, this assay has been extremely valuable in dissecting the basic 
mechanisms of angiogenesis.  
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Here we present an adaptation of the aorta ring assay, which we have used to 
assess the angiogenic capacity of adipose tissue from mice and humans 
(Gealekman et al., 2008) (Gealekman et al., 2012) (Gealekman et al., 2011). We 
have found that angiogenic capacity of adipose tissue in vitro reflects the 
physiological conditions of the donor. For example, adipose tissue angiogenesis, 
but not that of aorta, is enhanced in ob/ob hyperphagic mice, and in response to 
stimuli that increase adipose tissue growth, such as thiazolidinediones 
(Gealekman et al., 2008). Angiogenic capacity also differs among human 
adipose tissue depots and correlates with insulin sensitivity (Gealekman et al., 
2011). Thus, this assay can be used to dissect endogenous factors that regulate 
adipose tissue angiogenesis under different physiological conditions.  
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Materials 
Medium, instruments, and culture dishes  
• Matrigelä Basement Membrane Matrix, Growth Factor Reduced, Phenol 
Red-free, *LDEV-Free (BD Biosciences, San Jose, CA, catalog # 356231). 
Matrigel comes in bottles of 10 ml. To avoid freeze–thaw cycles and 
contamination, it is dispensed into 1 ml aliquots and stored at 20°C.  
• EBM-2 medium supplemented with EGM-2 MV (Lonza, Basel, 
Switzerland, BulletKit, CC-3202)  
• Dulbecco’s phosphate-buffered saline (DPBS) (Life Technologies Corp- 
Gibco®, Carlsbad, CA, catalog # 14190)  
• Dispase (BD Biosciences, San Jose, CA, catalog # 354235) enzyme is 
used for proteolysis of Matrigel. Aliquot dispase in 1.5 ml tubes and store 
at 20°C. Try to avoid multiple freeze–thaw cycle.  
• 50 mM EDTA  
• Trypsin-Versene (Lonza, Basel, Switzerland, catalog # 17-161E)  
• Formaldehyde (Ted Pella, Inc., Redding, CA, catalog #18505)  
• Hoechst 33258, pentahydrate (Life Technologies Corp, Carlsbad, CA, 
catalog # 947743)  
• Triton X-100 (Sigma-Aldrich, St. Louis, MO, catalog # T-9284)  
• BSA (Sigma-Aldrich, St. Louis, MO, catalog # A3059)  
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• 96-well flat bottom multiwell plates (BD FalconTM, Franklin Lakes, NJ, 
catalog # 353072)  
• 35 mm glass-bottom culture dishes (MatTek Corporation, Ashland, MA, 
catalog # P35G-1.5-14-C) 
• Very fine point forceps (VWR International, Radnor, PA, catalog #  
25607-856)  
• Micro Surgery Scissors (IntegraTM-Miltex®, York, PA, catalog # 17-2150) 
• Sterile pipettes, tips, and conical tubes  
• Three 100 mm x 20 mm petri dishes  
• Round bladed disposable scalpels (FEATHER® Safety Razor Co. Ltd, 
Osaka, Japan, catalog # 2975#10)  
Adipose tissue samples  
Sample collection of adipose tissue from mice or human subjects requires 
IACUC and IRB approval from the institution at which the procedure will be 
performed. In preliminary studies, only the epididymal adipose depot of mice was 
competent to form angiogenic sprouts in vitro, for reasons that are currently 
under investigation. Thus, all of our studies have been carried out with male mice 
on a C56BL/6 background, or on genetic variants such as the ob/ob mouse. For 
this assay, epididymal adipose tissue is dissected and processed for embedding 
as described in detail below.  
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This assay has also been used to measure angiogenesis from human adipose 
tissue. Explants from both subcutaneous and visceral adipose tissue depots 
develop capillary sprouts (Gealekman et al., 2011). However, differences in the 
extent of angiogenic growth have been seen between visceral and subcutaneous 
adipose tissue. Thus, the exact source of each adipose tissue sample (including 
morphometric and metabolic characteristics of human subjects and the exact 
location from which the adipose tissue sample is extracted) should be carefully 
tracked and kept as consistent as possible between subjects within a study. An 
additional factor that may affect the outcome of this assay is the time between 
the excision of adipose tissue from the patient and the embedding of the tissue 
pieces into Matrigel. Both the conditions in which adipose tissue samples are 
stored and the time between excision and embedding should be optimized and, 
at very least, kept consistent between the subjects being compared. For optimal 
results we recommend collecting adipose tissue pieces that do not exceed 1 g 
and storing them at room temperature in EGM-2 MV-supplemented EBM-2 
medium. The time between excision of the adipose tissue from human subject 
and its embedding into Matrigel should be minimized, and in our laboratory is 
routinely under 3 h.	 
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Methods 
Sample preparation  
Before starting  
• Protocol should be performed in a Class II Biocabinet.  
• Wear personal protective garment including the use of lab coat, double  
gloves, facial barrier protection, hair net, etc. Follow Human Tissue  
Handling Guidelines from your institution.  
• Instruments for handling tissue should be previously sterilized.  
• Remove aliquots of Matrigel from 20°C and place on ice to bring it to  
4°C. Use 2.5 ml of Matrigel for 60 wells of a 96-well-multiwell plate.  
Collection of mouse adipose tissue  
• Male C57Bl/6 mice from 9 to 23 weeks of age, fed either normal chow or 
high-fat diet.  
• Mice are sacrificed according to institutional protocols.  
• Epididymal fat pads are harvested by dissection using iris scissors 
according to the proximity to the epididymis and vesicular gland, taking 
care not to include the internal spermatic artery/vein and caput  
epididymis.  
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• After harvesting, adipose tissue is placed into 50 ml conical tubes 
containing 25 ml of EGM-2 MV-supplemented EBM-2 medium in which it 
is stored until embedding.  
Collection of human adipose tissue  
• Tissue is obtained following IRB protocols. In our studies, human adipose 
tissue has been obtained from needle biopsies, bariatric surgery, or 
panniculectomy procedures.  
• Tissue is cut into ~1 g fragments, from which large vessels and obvious 
connective tissue are removed using iris scissors.  
• After harvesting, adipose tissue is placed into 50 ml conical tubes 
containing 25 ml of EGM-2 MV-supplemented EBM-2 medium in which it 
is stored until embedding.  
Embedding procedure  
1. Label 3 100 cm petri dishes as #1, 2, and 3.  
2. Pipette 25 ml of EGM-2MV-supplemented EBM-2 medium in plate  
#1 and #3. Put 15 ml of medium in plate #2.  
3. Using forceps, transfer tissue from 50 ml conical tube into plate #1 and  
wash it by gently moving it around the plate.  
4. Using forceps and scalpel, cut the tissue into strips (Figure Ap.1). Use the  
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forceps to hold the piece and the scalpel to make the cuts, always moving 
in one direction (no upward or downward movement). Rinse the strip with 
a gentle mix in the medium on the plate. Move the tissue strips to plate #2.  
5. In plate #2, cut the strips into small slices. Maintain the size of pieces 
constant. As a guide for size, you can place millimeter paper underneath 
plate #2. Each piece should not be greater than 1 mm
3
. Once cut, move 
the piece to plate #3. Cut approximately 75–80 slices per tissue sample.  
6. Obtain a small tray and fill with ice. Put 96-well plate over ice. Maintain the 
plate in ice during the following steps.  
7. Dispense 40 µl of Matrigel into wells to be used. Do not use the wells 
around the perimeter of the plate. Keep Matrigel on ice at all times.  
8. Using the forceps, place one piece of adipose tissue per well.  
9. After embedding, take plate out of ice. Make sure each explant is in the  
middle of the well. Use forceps if accommodation is needed.  
10. Incubate at 37°C in 5% CO2 for 30 min.  
11. Add 200 µl of EGM-2 MV-supplemented EBM-2 medium per well.  
Make sure to fill all wells in the plate, including the wells around the 
perimeter of the plate, which do not contain adipose tissue explants. Wells 
at the perimeter of the plate tend to evaporate faster and placing explants 
only in the wells located in the middle of the plate allows for maintenance 
of a constant level of medium in all wells containing the explants.  
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12. Incubate at 37°C in 5% CO2.100µl of the medium should be replaced 
every other day. 
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Figure Ap. 1 Embedding procedure. 
(A) Adipose tissue samples placed in a 100 cm petri dish containing 25 ml of EGM-2 MV 
medium. The millimeter (mm) paper placed under the petri dish is used as a size 
reference. (B) Sample of adipose tissue in plate #2 containing 15 ml of EGM-2 MV 
medium. The scalpel and forceps are used to hold the fat and cut it into strips. (C) Piece 
of fat strip cut from the adipose tissue sample. Using the millimeter paper reference, the 
fat strip is aligned in order to cut the appropriate size of each slice (explant). (D) For the 
first cut, it is easier to start at one of the ends of the adipose tissue strip. The forceps are 
used to hold the fat while the scalpel is used to cut the slice. (E) The explant is aligned 
with one of the quadrants in the millimeter paper to verify adequate size. (F) The rest of 
the strip is cut into slices. The adipose tissue is held by forceps and the cut is done by the 
scalpel. While handling the forceps, avoid pulling or stretching the fat, since it may damage 
the tissue. (G) Individual slices cut to appropriate size and verified with the millimeter 
paper. (H) Display of workstation in the biocabinet before starting the embedding 
procedure. Explants were transferred to plate #3, containing 25 ml of EGM-2 MV medium. 
96-multiwell plate is kept in a tray filled with ice for the embedding steps. (I) Embedding 
step. After the Matrigel is dispensed, forceps are used to place the explants, one per well. 
The explant is positioned at the center of the well.  
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Quantification of angiogenic potential  
The mount of capillary growth can be evaluated using several approaches. Here 
we describe three independent strategies to quantify angiogenic potential, which 
we have successfully applied to both mouse and human samples. We 
recommend using at least two independent methods so correlation analysis can 
be performed to validate reproducibility of the data obtained.  
Counting of capillary sprouts  
A capillary sprout is defined as a branching structure of at least three cells 
connected to each other in a linear manner (Figure Ap.2 A, B). This structure is 
qualitatively different from other cell types that can also emerge from the explant, 
but which grow in a disorganized manner and typically adhere to the surface of 
the plate (Figure Ap.2 C, D). To detect capillary sprouts, imaging under sufficient 
magnification under phase contrast is required. In our laboratory we use a Zeiss 
Axiovert equipped with a 10 objective. Phase contrast images of embedded 
explants and emerging capillary sprouts from mouse adipose tissue at day 14 are 
shown in Figure Ap.2 E, and in Figure Ap.2 F, the structures that would be 
considered to be sprouts are delineated in red. As new sprouts emerge, they 
become interconnected and grow into the three-dimensional volume of the 
Matrigel; thus, counting should be performed early during the growth period. 
Sprouts begin to emerge after 4–5 days post-embedding of mouse epididymal fat 
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explants, and we quantify the number of sprouts per explant at day 7 and day 14 
post-embedding. Because the definition of a sprout is somewhat subjective, it is 
necessary to have more than one individual perform the counting, and that the 
individuals performing the counting be blinded as to the experimental condition of 
the sample.  
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Figure Ap. 2 Cells emerging from mouse adipose tissue explant. 
(A, B) Capillary sprout emerging from embedded mouse explant, displaying 
characteristic linear branching structure. (C, D) Focus set to the surface of the well, 
where fibroblastic adherent cells can be seen emerging from the explant, observed at a 
different optical plane of the image. (E) Phase contrast image of the explant and the 
capillary sprouts 14 days post-embedding. (F) Structures shown in red highlight 
formations that can be considered to be sprouts.  
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Because of the variability in the number of sprouts emerging from each explant, 
at least 25 explants must be analyzed for each experimental condition. The 
results are expressed as the average number of sprouts per explant. When 
studying mouse epididymal fat, there is a linear correlation between the number 
of explants that develop sprouts and the average number of sprouts per explant 
(Figure Ap.3). Thus, the percent of explants that display sprouting is an 
alternative way to quantify angiogenic potential.  
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Figure Ap. 3 Linear correlation between the number of explants sprouting and the 
quantity of sprouts per explant from mouse adipose tissue. 
Capillary sprouting was quantified in a study of 36 mice fed normal or high-fat diet for 3–
30 weeks. 25–30 explants from each mouse were embedded. The percent of the 
embedded explants for each mouse displaying sprouts after 14 days of culture is plotted 
on the x-axis. The mean number of sprouts per explant (i.e., sum of sprouts in all 
explants/total number of explants embedded) is plotted on the y-axis. Linear regression 
was calculated using PRISM software.  
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Counting can also be performed on human explants, which form well defined 
capillaries with tight junctions defining primitive lumens (Figure Ap.4). Human 
explants develop many more sprouts compared to mouse (Figure Ap.5). After 11 
days, the sprouts become highly branched and expand into the three-
dimensional volume of the Matrigel, making counting more complex. Thus, 
counting of human sprouts is best done at days 5–7 post-embedding.  
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Figure Ap. 4 Electron micrograph of capillary sprouts from a human adipose tissue 
explant. 
Arrows identify tight junctions. n, nucleus. 
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Figure Ap. 5 Capillary sprouting from human adipose tissue. 
A human explant from subcutaneous adipose tissue at days 3 (A, E), 5 (B, F) 7 (C, G), 
and 11 (D, H) post-embedding. Capillary sprouting begins to be observed at day 5. After 
day 11, the growth is highly increased (I, J), making difficult to identify all sprout formation. 
 
 
208 
 
Digital analysis of growth area  
The capillary growth can be further analyzed by measuring the area of sprouting 
in each well. In our laboratory, we have used a Zeiss Axio Observer Z1 
microscope equipped with an automated stage. Brightfield images of each well of 
a 96-well plate are acquired using a 2.5 objective and captured using an Andor 
Clara E interline CCD camera. The stage position, illumination and acquisition 
setting are controlled by Micro-manager open source microscopy software 
(Edelstein, Amodaj, Hoover, Vale, & Stuurman, 2010) using a multiwell plate 
plugin developed by Karl Bellve and Ben Czech 
(http://valelab.ucsf.edu/$MM/MMwiki/index.php/ Well_Plate_Plugin). The plugin 
is designed to handle standard SBS well plates from 24, 96, 384, and 1536 wells. 
The plugin will calculate the correct X, Y, and Z coordinate for each well position, 
and for any number of positions within each well. Imaging can then iterate 
through each well, starting at the first well. The plugin will move the stage down 
or up each column, until the last row, before moving to the next column and 
reversing direction. The zigzag path chosen for moving the stage is the fastest 
path on a Zeiss AxioObserver Z1. The starting well, or the ending well, can be 
selected to only work on a sub region. For our experiments, each well of a 96-
well plate containing an explant is divided into four quadrants, with a 50 CCD 
pixel overlap. Five optical sections spaced at 150 mm are collected for each 
quadrant, and a montage of the quadrants is then generated for further analysis.  
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For further analysis, the composite image is imported into Fiji, an image 
processing package, which is a distribution of ImageJ, Java, Java 3D, and 
several plugins organized into a coherent menu structure (Schindelin et al., 
2012). For calculation of the growth area, areas of explant and capillary sprout 
growth are delineated. Various parameters can then be extracted, including the 
area occupied by explant and sprouts (Figure Ap.6) as follows:  
To measure areas in the image files:  
1. Open Fiji  
2. Open image to be analyzed  
3. Visually examine in which plane the explant is more in focus. Use it for  
selecting the area of the explant.  
4. In the tools menu, select “Freehand selections”  
5. Select the area of the explant:  
1. Highlight the borders of the explant with the cursor, keeping pressed the 
left button on the mouse. If the button is released, the area selected will be 
automatically closed.  
6. Edit>Selection>Add to Manager. Automatically, the selected area is added 
to ROI Manager. Keep the ROI Manager window open. ROI will allow you 
to select the area of growth in the same image and measure a series of 
parameters, including the area measurements.  
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7. Go back to the image and select the area of growth. Make sure to 
examine every plane. You can move around each plane while making the 
selection, so all the growth is included.  
8. After selecting the area of growth, press “Add (t)” in the ROI Manager 
window.  
9. In the ROI Manager window, select both areas  
1. “Shift”+“¯” if needed  
10. Press “Measure” in the ROI Manager window. A “Results” window will 
appear. It contains different kinds of measurements, including area of the 
explant and growth.  
1. Item #1 is the area of the explant  
2. Item #2 is the area of the growth  
3. It is very important to maintain the order of measurements. First the  
explant, then the area of growth. 
11. In the Results window, go to File>Save as  
1. Suggestion: Save results file with the well name (A2, B2, etc.) and 
a short identification of the sample. Keep consistency in naming, in 
case a program is developed to help in analysis.  
(Examples: A2_Control_Day7.txt, B7_Sample1_Day7.txt)  
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12. In the ROI Manager window, select “More>>,” Save 
1. Save ROI file as a .zip. This will allow you to save both explant and 
growth area as .roi files. Suggestion: Name the .zip file with the well 
name (A2, B2, etc.) and a short identification of the sample. Keep 
consistency in naming, in case a program is developed to help in 
analysis. (Examples: A2_Control_Day7.zip, B7_Sample1_Day7. 
zip)  
13. To open image files that were already measured  
1. Open Fiji  
2. Open desired image  
3. File>Open>Select file>Open “.zip” file  
4. In the ROI Manager window, select both areas  
5. “Shift”+“¯” if needed  
6. Mark “Show All”  
7. Both selected areas should appear in the active image  
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Figure Ap. 6 Digital Analysis of capillary growth area. 
An example of montages generated from bright field images of quadrants of a single well 
from a 96-well-multiwell plate containing an explant from human omental adipose tissue. 
The region of the explant (A), and of capillary growth at day 7 (B), and day 11 (C) post-
embedding is delineated. The areas are calculated for the selected regions highlighted in 
red. (D) Calculated areas of 34 explants from the same tissue sample growing in the same 
96-well-multiwell plotted in a before–after format, revealing linear growth in all embedded 
explants over the culture period. (E) Scatter plot displaying the means and standard 
deviation of the values obtained for each explant at each time point, and values obtained 
after subtracting the area of the initial explant. Paired Student’s t-test between time points 
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reveals highly significant differences, which can be used to compare angiogenic potential 
among different donors.  
Immunofluorescence analysis of explants  
Adipose tissue explants can also be analyzed by immunofluorescence, with the 
exception that embedding must be done on coverslips or glass-bottom culture 
dishes. In our laboratory we have used 35 mm glass-bottom culture dishes 
(MatTek Corporation). The use of glass-bottom culture dishes allows for 
examination of stained samples at higher magnifications. The protocol used for 
visualizing human Von Willebrand factor is as follows:  
1. Dispense 100 µl of Matrigel to cover the bottom of each dish and embed 
explants and maintain in culture as described above.  
2. On the desired day, wash samples three times in DPBS by gently 
aspirating medium from the side of the dish and using 3 ml of DPBS for 
each wash.  
3. Prepare fresh 4% formaldehyde solution by diluting the supplied 16% 
solution in DPBS at 1:3 ratio. Make sure to use chemical hood with proper 
ventilation at all times while handling formaldehyde.  
4. Inside of chemical hood, gently aspirate DPBS from the dishes with 
samples and add 1 ml of freshly prepared 4% formaldehyde solution into 
each dish. Incubate for 15 min at room temperature with very gentle 
shaking.  
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5. Gently remove 4% formaldehyde from the dish and wash again three 
times in DPBS, gently shaking for 5 min in each wash step.  
6. Prepare permeabilizing solution by supplementing DPBS with 0.5% Triton 
X-100 and 1% BSA.  
7. Permeabilize and block non-specific antibody attachment by incubating in 
0.5% Triton X-100 1% BSA in DPBS for 60 min with gentle shaking. Use 2 
ml of the solution per each well.  
8. Remove solution and replace with primary antibody, in this case anti- 
human polyclonal rabbit Von Willebrand factor (Dako, catalog # A0082), 
diluted 1:100 in permeabilizing solution. Use at least 1 ml of antibody 
solution for each dish. Incubate overnight at 5°C with gentle shaking.  
9. Remove primary antibody, and wash three times with DPBS, gently 
shaking for 5 min between each wash step.  
10. Incubate for 1 h with secondary antibodies diluted in permeabilizing 
solution. The secondary antibody we have used is Alexa Fluor 488 
(Invitrogen; Molecular probes, catalog # 11008, dilution 1:500).  
11. Wash three times with DPBS, gently shaking for 5 min between each 
wash step.  
12. Perform nuclear counter staining by incubating for 5 min with Hoechst 
33258, pentahydrate diluted 1:5000 in DPBS.  
13. Wash in DPBS three times.  
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Isolated cell analysis  
After completing manual counting and digital assessments of capillary growth, 
cells comprising capillary sprouts can be harvested from the Matrigel for further 
analysis by western blotting, FACS, etc. To quantitatively recover the cells from 
each well, the following procedure is used:  
Before starting  
• Dispase is used for proteolysis of Matrigel. Dispase should be aliquoted in 
1.5 ml volume vials and stored at 20 °C. Avoid multiple freeze–thaw 
cycles. Before use, dispase is thawed at 37°C. 
• Most of the capillary cells grow in Matrigel, but some cells (e.g., fibro- 
blasts) attach to the bottom of the plate. Trypsin-Versene is used for 
detaching cells that remain adherent to the well after the dispase 
treatment.  
• Materials and tools used, including jeweler’s forceps and scissors, should 
be sterile.  
1. Carefully, remove the medium by aspirating it from the wells. Be careful 
not to aspirate Matrigel or explants. 
2. Rinse twice with 200 µl of sterile DPBS. Discard DPBS.  
Caution: In case of human tissue, discard medium and DPBS 
according to your institution’s safety regulations.  
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3. Add 50 µl of dispase to each well. Incubate at 37°C for 1.5–2 h. Make sure 
that all cells are detached and floating in the digested Matrigel by looking 
under the microscope after incubation.  
4. Prepare a 1:1 mixture of Trypsin-Versene and 50 mM EDTA.  
5. Add 50 µl of the Trypsin-Versene/EDTA mixture to each well to stop 
dispase digestion and dislodge adherent cells. Gently mix by pipetting  
up and down. Incubate at 37°C for 10 min.  
6. Use forceps to remove remaining explant from wells. Discard the  
explants in biomedical waste.  
7. Add 50 µl of DPBS to each well. Mix by pipetting up and down.  
8. Transfer the cell suspension from all wells to a 15 ml conical tube. Fill  
with EGM-2 MV-supplemented EBM-2 medium to achieve a final  
volume of 10 ml.  
9. Centrifuge the tube containing the cells at 200xg for 10 min at room  
temperature.  
10. Make sure the cells are pelleted down. Aspirate the supernatant and  
resuspend the pellet in 1 ml of fresh EGM-2 MV-supplemented  
EBM-2 medium.  
11. Obtain cell concentration and viability. For this purpose, the Cellometer 
Auto T4 Cell Counter and Software was used (Nexcelom Bioscience).  
12. Resuspend cells for further use.  
217 
 
Method limitations  
1. There is significant variation between each individual explant, so 
quantitative analysis requires at least 25 explants per condition.  
2. The capillary sprouts are defined by morphological criteria, so changes in 
the cellular composition, cell shape or cell motility could affect the result.  
3. The Matrigel is relatively impermeable and thus penetration by large 
molecules such as nucleic acids, or viruses that could be used to 
interrogate the properties of the growing cells is difficult.  
4. Immunostaining is complicated by non-specific attachment of antibodies  
to Matrigel, and therefore successful results depend on the availability of 
high affinity antibodies and molecules expressed at relatively high levels.  
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